<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" dtd-version="1.3" xml:lang="EN" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//ACS//DTD ACS Journal DTD v1.02 20061031//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName ACSJournal-v102.dtd?><?SourceDTD.Version 1.02?><?ConverterInfo.XSLTName acs2nlmx2.xsl?><?ConverterInfo.Version 1?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Med Chem</journal-id><journal-id journal-id-type="iso-abbrev">J Med Chem</journal-id><journal-id journal-id-type="publisher-id">jm</journal-id><journal-id journal-id-type="coden">jmcmar</journal-id><journal-title-group><journal-title>Journal of Medicinal Chemistry</journal-title></journal-title-group><issn pub-type="ppub">0022-2623</issn><issn pub-type="epub">1520-4804</issn><publisher><publisher-name>American Chemical Society</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmcid">11320645</article-id><article-id pub-id-type="pmid">39078366</article-id>
<article-id pub-id-type="doi">10.1021/acs.jmedchem.4c01095</article-id><article-categories><subj-group><subject>Article</subject></subj-group></article-categories><title-group><article-title>Genomic Discovery
and Structure&#x02013;Activity Exploration
of a Novel Family of Enzyme-Activated Covalent Cyclin-Dependent Kinase
Inhibitors</article-title></title-group><contrib-group><contrib contrib-type="author" id="ath1"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-6803-304X</contrib-id><name><surname>Davison</surname><given-names>Jack R.</given-names></name><xref rid="notes-17" ref-type="notes">&#x025cb;&#x025cb;</xref><xref rid="aff1" ref-type="aff">&#x02020;</xref></contrib><contrib contrib-type="author" id="ath2"><name><surname>Hadjithomas</surname><given-names>Michalis</given-names></name><xref rid="notes-17" ref-type="notes">&#x025cb;&#x025cb;</xref><xref rid="aff1" ref-type="aff">&#x02020;</xref></contrib><contrib contrib-type="author" id="ath3"><name><surname>Romeril</surname><given-names>Stuart P.</given-names></name><xref rid="notes-17" ref-type="notes">&#x025cb;&#x025cb;</xref><xref rid="aff1" ref-type="aff">&#x02020;</xref></contrib><contrib contrib-type="author" id="ath4"><name><surname>Choi</surname><given-names>Yoon Jong</given-names></name><xref rid="notes-17" ref-type="notes">&#x025cb;&#x025cb;</xref><xref rid="aff1" ref-type="aff">&#x02020;</xref></contrib><contrib contrib-type="author" id="ath5"><name><surname>Bentley</surname><given-names>Keith W.</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref></contrib><contrib contrib-type="author" id="ath6"><name><surname>Biggins</surname><given-names>John B.</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref><xref rid="notes-2" ref-type="notes">&#x000a7;</xref></contrib><contrib contrib-type="author" id="ath7"><name><surname>Chacko</surname><given-names>Nadia</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref></contrib><contrib contrib-type="author" id="ath8"><name><surname>Castaldi</surname><given-names>M. Paola</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref><xref rid="notes-3" ref-type="notes">&#x02225;</xref></contrib><contrib contrib-type="author" id="ath9"><name><surname>Chan</surname><given-names>Lawrence K.</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref></contrib><contrib contrib-type="author" id="ath10"><name><surname>Cumming</surname><given-names>Jared N.</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref><xref rid="notes-3" ref-type="notes">&#x02225;</xref></contrib><contrib contrib-type="author" id="ath11"><name><surname>Downes</surname><given-names>Thomas D.</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref></contrib><contrib contrib-type="author" id="ath12"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0009-0007-1487-8542</contrib-id><name><surname>Eisenhauer</surname><given-names>Eric L.</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref><xref rid="notes-4" ref-type="notes">&#x022a5;</xref></contrib><contrib contrib-type="author" id="ath13"><name><surname>Fei</surname><given-names>Fan</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref><xref rid="notes-5" ref-type="notes">#</xref></contrib><contrib contrib-type="author" id="ath14"><name><surname>Fontaine</surname><given-names>Benjamin M.</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref></contrib><contrib contrib-type="author" id="ath15"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-8857-250X</contrib-id><name><surname>Endalur Gopinarayanan</surname><given-names>Venkatesh</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref><xref rid="notes-6" ref-type="notes">&#x02207;</xref></contrib><contrib contrib-type="author" id="ath16"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0009-0008-0655-094X</contrib-id><name><surname>Gurnani</surname><given-names>Srishti</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref></contrib><contrib contrib-type="author" id="ath17"><name><surname>Hecht</surname><given-names>Audrey</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref></contrib><contrib contrib-type="author" id="ath18"><name><surname>Hosford</surname><given-names>Christopher J.</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref></contrib><contrib contrib-type="author" id="ath19"><name><surname>Ibrahim</surname><given-names>Ashraf</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref><xref rid="notes-5" ref-type="notes">#</xref></contrib><contrib contrib-type="author" id="ath20"><name><surname>Jagels</surname><given-names>Annika</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref></contrib><contrib contrib-type="author" id="ath21"><name><surname>Joubran</surname><given-names>Camil</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref><xref rid="notes-7" ref-type="notes">&#x025cb;</xref></contrib><contrib contrib-type="author" id="ath22"><name><surname>Kim</surname><given-names>Ji-Nu</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref><xref rid="notes-8" ref-type="notes">&#x025c6;</xref></contrib><contrib contrib-type="author" id="ath23"><name><surname>Lisher</surname><given-names>John P.</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref></contrib><contrib contrib-type="author" id="ath24"><name><surname>Liu</surname><given-names>Daniel D.</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref></contrib><contrib contrib-type="author" id="ath25"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-3111-6527</contrib-id><name><surname>Lyles</surname><given-names>James T.</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref><xref rid="notes-9" ref-type="notes">&#x000b6;</xref></contrib><contrib contrib-type="author" id="ath26"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0009-0005-8823-1966</contrib-id><name><surname>Mannara</surname><given-names>Matteo N.</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref><xref rid="notes-10" ref-type="notes">&#x02020;&#x02020;</xref></contrib><contrib contrib-type="author" id="ath27"><name><surname>Murray</surname><given-names>Gordon J.</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref><xref rid="notes-11" ref-type="notes">&#x02021;&#x02021;</xref></contrib><contrib contrib-type="author" id="ath28"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0009-0008-5666-4531</contrib-id><name><surname>Musial</surname><given-names>Emilia</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref></contrib><contrib contrib-type="author" id="ath29"><name><surname>Niu</surname><given-names>Mengyao</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref></contrib><contrib contrib-type="author" id="ath30"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-5964-0171</contrib-id><name><surname>Olivares-Amaya</surname><given-names>Roberto</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref></contrib><contrib contrib-type="author" id="ath31"><name><surname>Percuoco</surname><given-names>Marielle</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref></contrib><contrib contrib-type="author" id="ath32"><name><surname>Saalau</surname><given-names>Susanne</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref></contrib><contrib contrib-type="author" id="ath33"><name><surname>Sharpe</surname><given-names>Kristen</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref></contrib><contrib contrib-type="author" id="ath34"><name><surname>Sheahan</surname><given-names>Anjali V.</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref><xref rid="notes-12" ref-type="notes">&#x000a7;&#x000a7;</xref></contrib><contrib contrib-type="author" id="ath35"><name><surname>Thevakumaran</surname><given-names>Neroshan</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref><xref rid="notes-13" ref-type="notes">&#x02225;&#x02225;</xref></contrib><contrib contrib-type="author" id="ath36"><name><surname>Thompson</surname><given-names>James E.</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref></contrib><contrib contrib-type="author" id="ath37"><name><surname>Thompson</surname><given-names>Dawn A.</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref><xref rid="notes-14" ref-type="notes">&#x022a5;&#x022a5;</xref></contrib><contrib contrib-type="author" id="ath38"><name><surname>Wiest</surname><given-names>Aric</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref><xref rid="notes-15" ref-type="notes">##</xref></contrib><contrib contrib-type="author" id="ath39"><name><surname>Wyka</surname><given-names>Stephen A.</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref></contrib><contrib contrib-type="author" id="ath40"><name><surname>Yano</surname><given-names>Jason</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref><xref rid="notes-16" ref-type="notes">&#x02207;&#x02207;</xref></contrib><contrib contrib-type="author" corresp="yes" id="ath41"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-2195-364X</contrib-id><name><surname>Verdine</surname><given-names>Gregory L.</given-names></name><xref rid="cor1" ref-type="other">*</xref><xref rid="aff1" ref-type="aff">&#x02020;</xref><xref rid="aff2" ref-type="aff">&#x02021;</xref></contrib><aff id="aff1"><label>&#x02020;</label><institution>LifeMine
Therapeutics</institution>, 30 Acorn Park Drive, Cambridge, Massachusetts 02140, <country>United States</country></aff><aff id="aff2"><label>&#x02021;</label>Departments
of Chemistry and Chemical Biology, and Stem Cell and Regenerative
Biology, <institution>Harvard University and Harvard
Medical School</institution>, 12 Oxford Street, Cambridge, Massachusetts 02138, <country>United States</country></aff></contrib-group><author-notes><corresp id="cor1"><label>*</label>Email: <email>gregory_verdine@harvard.edu</email>.</corresp></author-notes><pub-date pub-type="epub"><day>30</day><month>07</month><year>2024</year></pub-date><pub-date pub-type="collection"><day>08</day><month>08</month><year>2024</year></pub-date><volume>67</volume><issue>15</issue><fpage>13147</fpage><lpage>13173</lpage><history><date date-type="received"><day>08</day><month>05</month><year>2024</year></date><date date-type="accepted"><day>18</day><month>07</month><year>2024</year></date><date date-type="rev-recd"><day>03</day><month>07</month><year>2024</year></date></history><permissions><copyright-statement>&#x000a9; 2024 The Authors. Published by American Chemical Society</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>The Authors</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>Permits non-commercial access and re-use, provided that author attribution and integrity are maintained; but does not permit creation of adaptations or other derivative works (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">https://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>).</license-p></license></permissions><abstract><p content-type="toc-graphic"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jm4c01095_0018" id="ab-tgr1"/></p><p>Fungi have historically been the source of numerous important
medicinal
compounds, but full exploitation of their genetic potential for drug
development has been hampered in traditional discovery paradigms.
Here we describe a radically different approach, top-down drug discovery
(TD<sup>3</sup>), starting with a massive digital search through a
database of over 100,000 fully genomicized fungi to identify loci
encoding molecules with a predetermined human target. We exemplify
TD<sup>3</sup> by the selection of cyclin-dependent kinases (CDKs)
as targets and the discovery of two molecules, <bold>1</bold> and <bold>2</bold>, which inhibit therapeutically important human CDKs. <bold>1</bold> and <bold>2</bold> exhibit a remarkable mechanism, forming
a site-selective covalent bond to the CDK active site Lys. We explored
the structure&#x02013;activity relationship via semi- and total synthesis,
generating an analog, <bold>43</bold>, with improved kinase selectivity,
bioavailability, and efficacy. This work highlights the power of TD<sup>3</sup> to identify mechanistically and structurally novel molecules
for the development of new medicines.</p></abstract><custom-meta-group><custom-meta><meta-name>document-id-old-9</meta-name><meta-value>jm4c01095</meta-value></custom-meta><custom-meta><meta-name>document-id-new-14</meta-name><meta-value>jm4c01095</meta-value></custom-meta><custom-meta><meta-name>ccc-price</meta-name><meta-value/></custom-meta></custom-meta-group></article-meta><notes id="spn1"><title>Special Issue</title><p>Published
as part of <italic>Journal of Medicinal Chemistry</italic><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/page/virtual-collections.html?journal=jmcmar&#x00026;ref=feature">virtual special issue</ext-link> &#x0201c;Natural Products Driven
Medicinal Chemistry&#x0201d;.</p></notes></front><body><sec id="sec1"><title>Introduction</title><p>Several of the most impactful medicines
known to humankind are
the products of small molecule evolution in fungi. Lovastatin was
the first drug approved by the FDA to lower cholesterol by blocking
sterol biogenesis,<sup><xref ref-type="bibr" rid="ref1">1</xref></sup> and is the direct progenitor
to the entire family of statin drugs that are among the most widely
prescribed medicines in the US, with over 800 million prescriptions
filled annually to 40 million patients.<sup><xref ref-type="bibr" rid="ref2">2</xref></sup> Cyclosporin enabled routine and widespread organ transplantation
in humans by suppressing T cell mediated rejection of the donor-derived
organs.<sup><xref ref-type="bibr" rid="ref3">3</xref></sup> Cyclosporin also served as an
invaluable tool for elucidation of many fundamental aspects of T cell
biology, while revealing a powerful new modality for drug action,
launching the field of molecules known as molecular glues.<sup><xref ref-type="bibr" rid="ref4">4</xref></sup> Lovastatin and cyclosporin exemplify the potential
of genetically encoded small molecules (GEMs), otherwise known as
natural products, to provide mechanistically and structurally novel
medicines that have saved and extended millions of lives.</p><p>In
the predominant paradigm for small molecule drug discovery,
a clinical molecule is elaborated through an iterative optimization
process that typically requires the synthesis and characterization
of thousands of fully synthetic compounds. In contrast to this bottom-up
approach, lovastatin and cyclosporin represent an appealing alternative
paradigm, which we term top-down drug discovery (TD<sup>3</sup>),
where a new lead molecule emerges fully fledged from a discovery program
as a clinical candidate. Both lovastatin and cyclosporin achieved
FDA approval with no further elaboration; importantly, they also served
as an advanced starting point for focused semisynthetic optimization
that subsequently yielded next-gen FDA-approved drugs with improved
clinical properties.<sup><xref ref-type="bibr" rid="ref5">5</xref></sup> Penicillin, a drug
that has saved millions of lives, is the most famous example of a
fungal GEM discovered in the TD<sup>3</sup> paradigm that was life-cycle-managed,
in this case to overcome emergent bacterial drug resistance.<sup><xref ref-type="bibr" rid="ref6">6</xref></sup> Mycophenolic acid is yet another prominent example
of a clinically administered drug discovered from fungi by this approach,
and subsequently life-cycle-managed by semisynthesis (CellCept).<sup><xref ref-type="bibr" rid="ref7">7</xref></sup></p><p>Notwithstanding the obvious appeal of TD<sup>3</sup> from fungi,
broader deployment of this strategy has been hampered by the numerous
difficulties encountered during activity-guided isolation of fungal
GEMs.<sup><xref ref-type="bibr" rid="ref8">8</xref></sup> These molecules are often potent
and target-specific, but are typically present in vanishingly small
quantities and in complex mixtures comprising hundreds to thousands
of contaminating GEMs, many of which exhibit diverse biological activities
that confound cell-based screens.<sup><xref ref-type="bibr" rid="ref9">9</xref></sup> Having
successfully carried out a large-scale genome-mining operation in
bacteria that led to the discovery of new members of the FK506/rapamycin
class of GEMs,<sup><xref ref-type="bibr" rid="ref10">10</xref></sup> it occurred to us that
exploitation of advances in fungal genomics, bioengineering, and multiomics
might also accelerate, simplify and render more predictable the scalable
discovery of GEMs from fungi. In both bacteria and fungi, the genes
encoding GEM biosynthesis are often colocated within the genome in
biosynthetic gene clusters (BGCs), each comprising a cassette of coordinately
regulated genes that evolve and act together to perform context-dependent
production of their self-encoded GEM.<sup><xref ref-type="bibr" rid="ref11">11</xref></sup> Many fungal GEMs have evolved to provide a competitive advantage
over other fungi, and this creates the need for self-protection of
fungi from their own GEMs.<sup><xref ref-type="bibr" rid="ref12">12</xref></sup> Such protective
genes typically reside within the BGC, as resistance mechanisms are
coevolved with, and mechanistically tailored to, individual GEMs.
Many BGCs, for example, contain one or more genes encoding GEM-specific
transmembrane pumps that export their cognate GEM from the producing
fungus.<sup><xref ref-type="bibr" rid="ref13">13</xref></sup> However, most relevant to the
field of drug discovery, a small but important subset of BGCs contain
a gene embedded within their evolutionarily conserved boundaries that
encodes a copy of the molecular target of the encoded GEM, which we
refer to as an embedded target gene (ETaG). For example, colocalized
within the lovastatin BGC can be found a copy of the HMG-CoA reductase
gene, the target of lovastatin that, when inhibited in humans, is
responsible for its cholesterol-lowering effect.<sup><xref ref-type="bibr" rid="ref14">14</xref></sup> Typically, fungi hosting BGCs using this method of self-resistance
encode two copies of the target gene: an ancestral copy that remains
susceptible to inhibition, and a second ETaG copy that has acquired
GEM-resistant mutations while maintaining the capacity for functional
complementation; for example, the protein encoded by the HMG-CoA reductase
ETaG is active enzymatically but resistant to inhibition by lovastatin.</p><p>Fungi and humans share many genes that can be considered evolutionarily
conserved, and often perform the same or a related function in both
organisms.<sup><xref ref-type="bibr" rid="ref15">15</xref></sup> These orthologs typically
exhibit moderate overall sequence identity, but active site amino
acid residues can be conserved almost identically.<sup><xref ref-type="bibr" rid="ref16">16</xref></sup> However, it is exactly these functionally important and
highly conserved regions that comprise important drug binding sites.
While fungal GEMs can be assumed to have evolved to compete with organisms
encountered in their native environments, such as other fungi, bacteria,
or plants, there is considerable potential for cross-kingdom binding
to homologous human proteins at conserved active sites. In this context,
an ETaG can be viewed as an avatar for a relevant human therapeutic
target, enabling a digital search through genomic space to identify
BGCs that encode novel GEMs with important clinical properties.<sup><xref ref-type="bibr" rid="ref17">17</xref></sup> These concepts suggested to us the possibility
of broadly enabling an ETaG-based platform for more rapid, scalable,
and targeted implementation of TD<sup>3</sup> in fungi than has previously
been available, by (1) assembling a massive database of phylogenetically
diverse, comprehensively annotated fungal genomes; (2) selecting a
disease-relevant human protein; (3) performing genomic search to query
the database for BGCs having an ETaG avatar of the preselected human
target; (4) using multiomic methods to monitor BGC-related RNA expression
and metabolite production under a variety of conditions; (5) identifying
the fully elaborated GEM product of the BGC; then (6) performing minor
structural optimization if necessary to develop the GEM as a drug.</p><p>By applying our integrated TD<sup>3</sup> platform we report the
use of ETaG-based search to identify a BGC that encodes two inhibitors
of human cyclin-dependent kinases (CDKs): compounds <bold>1</bold> and <bold>2</bold>, respectively roseopurpurins D and C. The roseopurpurins
were originally isolated from the fungi <italic>Aspergillus spp.</italic>(<xref ref-type="bibr" rid="ref18">18</xref>,<xref ref-type="bibr" rid="ref19">19</xref>) and <italic>Penicillium roseopurpureum</italic>(<xref ref-type="bibr" rid="ref20">20</xref>) and shown to exhibit selective cytotoxicity
toward cancer cell lines,<sup><xref ref-type="bibr" rid="ref20">20</xref></sup> though the
target responsible for the activity of these GEMs was not identified
in that earlier work. We recently disclosed that <bold>1</bold> and <bold>2</bold> are novel CDK-inhibitors, with potential utility in the
treatment of CDK-dependent cancers.<sup><xref ref-type="bibr" rid="ref21">21</xref></sup> Subsequent
to our disclosure, the target identification of <bold>1</bold> and <bold>2</bold> was replicated independently in a publication that describes
the CDK-active properties of the roseopurpurins and delineates the
encoding BGC, designated as <italic>rosA</italic>&#x02013;<italic>rosK</italic>.<sup><xref ref-type="bibr" rid="ref22">22</xref></sup> Here we provide a fully detailed account
of our genomic deorphanization of these kinase-inhibitor GEMs, comprehensive
elucidation of the biosynthetic pathway, characterization of their
extraordinary covalent kinase engagement mechanism, an initial structure&#x02013;activity
exploration by semisynthetic and synthetic modification, and preliminary
in cellulo and in vivo characterization.</p></sec><sec id="sec2"><title>Results and Discussion</title><sec id="sec2.1"><title>Computational Discovery of a BGC Family with a CDK ETaG</title><p>With a goal to discover novel CDK inhibitors, we applied our TD<sup>3</sup> platform to identify CDK ETaGs in our proprietary database
of over 100,000 annotated fungal genomes (LifeBase). After gathering
all candidate BGCs having a CDK ETaG, we performed comparative genome
analyses to identify the consensus gene set comprising each family
of BGCs, and established that the candidate ETaG was embedded within
the biosynthetic cluster.</p><p>We identified a candidate BGC family
with a putative CDK ETaG and a polyketide synthase core (<xref rid="notes-1" ref-type="notes">Supporting Table 1</xref>), consisting of 900 members
in 173 species distributed across four taxonomic classes of ascomycete
fungi, representing close to 1% of all fungi within in our collection
(<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig">1</xref></xref>). During
the preparation of this manuscript, two alleles of this same BGC family
(<italic>ros</italic>) were described in another publication.<sup><xref ref-type="bibr" rid="ref22">22</xref></sup> Of the 900 <italic>ros</italic> BGC alleles
identified in our database, 98.9% contain the candidate ETaG. Furthermore,
we observed 70 distinct BGC variants, each having a unique gene order
and orientation. The presence of the putative ETaG in most members
of this BGC family, despite the substantial degree of gene rearrangement,
strongly suggested functional association of the ETaG with the <italic>ros</italic> BGC.</p><fig id="fig1" position="float"><label>Figure 1</label><caption><p>Gene content and taxonomic distribution of a representative <italic>ros</italic> BGC. (A) The <italic>ros</italic> BGC has 11 genes,
including a polyketide synthase core (<italic>rosJ</italic>) and a
putative ETaG homologous to human CDKs (<italic>rosG</italic>). (B)
Shown are 4 of the 70 distinct alleles of the <italic>ros B</italic>GC discovered in diverse taxonomic classes (indicated on the left)
within LifeBase. Though the order and orientation of genes differ,
the consensus genes are maintained, including the ETaG (red), consistent
with functional essentiality.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jm4c01095_0001" id="gr6" position="float"/></fig><p>A commonly observed characteristic of ETaGs is
that they represent
an extra copy of a housekeeping gene.<sup><xref ref-type="bibr" rid="ref13">13</xref></sup> Indeed, phylogenetic analysis comparing a CDK ETaG from a LifeBase
strain of <italic>Preussia flanaganii</italic> with
CDK proteins from <italic>Saccharomyces cerevisiae</italic> (yeast), and <italic>Homo sapiens</italic> (human)
revealed that the ETaG is most closely related to fungal housekeeping
Pho85 protein, which in turn is most closely related to human CDK5
(<xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig">2</xref></xref>). An important
feature of CDKs is that they are central to cellular processes in
both fungi and humans, with conserved evolutionary, structural, and
functional relationships between subgroups. The CDK family is greatly
expanded (radiated) in humans, which presents an opportunity to optimize
a single fungal GEM scaffold to inhibit evolutionarily divergent human
kinases. We anticipated that identifying the GEM encoded by this BGC
might provide a starting point for the development of novel inhibitors
of human CDK2, an attractive target for drug development<sup><xref ref-type="bibr" rid="ref23">23</xref></sup> and a close sequence homologue of CDK5.</p><fig id="fig2" position="float"><label>Figure 2</label><caption><p>Phylogenetic
comparison of the candidate <italic>ros</italic> BGC
ETaG protein (red) from <italic>P. flanaganii</italic> with yeast and human CDK protein isoforms. Note that the ETaG (red)
is a second copy of and is most closely related to the corresponding
housekeeping Pho85 (blue).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jm4c01095_0002" id="gr7" position="float"/></fig><p>ETaGs may provide self-resistance via the acquisition
of mutations
that reduce or abolish the binding of an inhibitor, but that maintain
normal enzymatic function.<sup><xref ref-type="bibr" rid="ref12">12</xref></sup> We thus performed
residue conservation analysis comparing 100 diverse housekeeping Pho85
proteins (selected as having a single <italic>pho85</italic> gene
copy and lacking the <italic>ros</italic> BGC) and the sequences of
38 diverse Pho85 ETaGs, to identify statistically significant sequence
variations. Using this approach, we identified 8 residues that consistently
differed between the housekeeping protein set and the ETaG protein
set, and where the most abundant residue was present in more than
50% of each set of sequences (<xref rid="tbl1" ref-type="other">Table <xref rid="tbl1" ref-type="other">1</xref></xref>). Three of these potential resistance mutations were
colocalized within the ATP binding pocket, as judged from the structure
of the yeast Pho85-Pho80 CDK-Cyclin complex (PDB ID <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="PDB" xlink:href="2PMI">2PMI</ext-link>, <xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref>). As resistance mutations
are most likely to interfere directly with drug binding, these observations
suggest that the GEM encoded by the <italic>ros</italic> BGC is an
active site (orthosteric) inhibitor that competes directly with ATP.
One of the putative resistance mutations occurs at the so-called gatekeeper
residue; gatekeeper mutations in human kinases are a known, frequent
escape mechanism that confers clinical resistance to FDA-approved
kinase inhibitors.<sup><xref ref-type="bibr" rid="ref24">24</xref></sup> Here, the gatekeeper
Phe in Pho85 is replaced by Ser in the ETaG. In the ATP binding pocket,
human CDK2 has identical residues with the fungal housekeeping Pho85
in two out of three mutation sites, including the gatekeeper Phe,
which led us to hypothesize that human CDK2, similarly to fungal housekeeping
Pho85, would be susceptible to the GEM produced by this BGC.</p><fig id="fig3" position="float"><label>Figure 3</label><caption><p>Residue conservation
analysis identified three putative resistance
mutations in the active site of the CDK ETaG (<xref rid="tbl1" ref-type="other">Table <xref rid="tbl1" ref-type="other">1</xref></xref>), suggesting that the product of the <italic>ros</italic> BGC is an active site, ATP-competitive inhibitor of
CDKs. Mutations are mapped onto the structure of the yeast Pho85-Pho80
CDK-Cyclin complex (PDB ID <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="PDB" xlink:href="2PMI">2PMI</ext-link>).<sup><xref ref-type="bibr" rid="ref25">25</xref></sup></p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jm4c01095_0003" id="gr8" position="float"/></fig><table-wrap id="tbl1" position="float"><label>Table 1</label><caption><title>Conserved ETaG Mutant Residues<xref rid="t1fn1" ref-type="table-fn">a</xref></title></caption><table frame="hsides" rules="groups" border="0"><colgroup><col align="left"/><col align="left"/><col align="left"/><col align="char" char="."/><col align="left"/></colgroup><thead><tr><th style="border:none;" align="center">&#x000a0;</th><th colspan="2" align="center">predominant
residue (abundance)<hr/></th><th style="border:none;" align="center" char=".">&#x000a0;</th><th style="border:none;" align="center">&#x000a0;</th></tr><tr><th style="border:none;" align="center">position<xref rid="t1fn2" ref-type="table-fn">b</xref></th><th style="border:none;" align="center">Pho85</th><th style="border:none;" align="center">ETaG</th><th style="border:none;" align="center" char=".">distance to ATP-&#x003b3;-S/&#x000c5;</th><th style="border:none;" align="center">human CDK2<xref rid="t1fn3" ref-type="table-fn">c</xref></th></tr></thead><tbody><tr><td style="border:none;" align="left"><bold>66</bold></td><td style="border:none;" align="left"><bold>Val (92%)</bold></td><td style="border:none;" align="left"><bold>Leu (93%)</bold></td><td style="border:none;" align="char" char="."><bold>4.9</bold></td><td style="border:none;" align="left"><bold>64 Val</bold></td></tr><tr><td style="border:none;" align="left">69</td><td style="border:none;" align="left">His (66%)</td><td style="border:none;" align="left">Tyr (53%)</td><td style="border:none;" align="char" char=".">8.8</td><td style="border:none;" align="left">67 Leu</td></tr><tr><td style="border:none;" align="left">79</td><td style="border:none;" align="left">Met (57%)</td><td style="border:none;" align="left">Ile (56%)</td><td style="border:none;" align="char" char=".">12.4</td><td style="border:none;" align="left">77 Tyr</td></tr><tr><td style="border:none;" align="left"><bold>82</bold></td><td style="border:none;" align="left"><bold>Phe (87%)</bold></td><td style="border:none;" align="left"><bold>Ser (88%)</bold></td><td style="border:none;" align="char" char="."><bold>4.4</bold></td><td style="border:none;" align="left"><bold>80 Phe</bold></td></tr><tr><td style="border:none;" align="left">123</td><td style="border:none;" align="left">Phe (54%)</td><td style="border:none;" align="left">Tyr (52%)</td><td style="border:none;" align="char" char=".">17.3</td><td style="border:none;" align="left">117 Phe</td></tr><tr><td style="border:none;" align="left">129</td><td style="border:none;" align="left">Val (58%)</td><td style="border:none;" align="left">Ile (55%)</td><td style="border:none;" align="char" char=".">14.6</td><td style="border:none;" align="left">123 Val</td></tr><tr><td style="border:none;" align="left"><bold>150</bold></td><td style="border:none;" align="left"><bold>Gly (58%)</bold></td><td style="border:none;" align="left"><bold>Ala (58%)</bold></td><td style="border:none;" align="char" char="."><bold>7.9</bold></td><td style="border:none;" align="left"><bold>144 Ala</bold></td></tr><tr><td style="border:none;" align="left">176</td><td style="border:none;" align="left">Ala (64%)</td><td style="border:none;" align="left">Pro (57%)</td><td style="border:none;" align="char" char=".">17.8</td><td style="border:none;" align="left">170 Ala</td></tr></tbody></table><table-wrap-foot><fn id="t1fn1"><label>a</label><p>Residue conservation analysis between
housekeeping Pho85 and ETaG proteins identified 8 candidate resistance
mutations that differ between housekeeping (Pho85) and ETaG sets,
and are more than 50% conserved in each set. Three of these residues
(bold) are within 8 &#x000c5; of the active site (PDB ID <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="PDB" xlink:href="2PMI">2PMI</ext-link>)<sup><xref ref-type="bibr" rid="ref25">25</xref></sup> and are proposed here to be determinants of GEM resistance
in the ETaG.</p></fn><fn id="t1fn2"><label>b</label><p>Positions are
in reference to yeast
Pho85 (Uniprot ID P17157).</p></fn><fn id="t1fn3"><label>c</label><p>Human CDK2 (Uniprot ID P24941).</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec2.2"><title>Identification of GEMs <bold>1</bold> and <bold>2</bold> as
CDK Inhibitors</title><p>To induce high-level expression of the GEM
encoded by the <italic>ros</italic> BGC, we replaced the promoter
of the <italic>rosH</italic> transcription factor with a strong constitutive
promoter in a LifeBase strain <italic>Mycophilomyces sp.</italic>,
with the expectation that overproduction of this transcription factor
would coordinately up-regulate all the biosynthetic genes in the <italic>ros</italic> BGC. By screening extract fractions from these engineered
overproducer strains in an enzyme assay utilizing fungal Pho85 and
human CDK5/p25, we identified and purified to homogeneity two CDK-inhibitory
products, <bold>1</bold> and <bold>2</bold>, of the candidate BGC.
Detailed nuclear magnetic resonance (NMR) analysis (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.4c01095/suppl_file/jm4c01095_si_001.pdf">Supporting Tables 2 and 3</ext-link>) identified <bold>1</bold> and <bold>2</bold> as a diastereomeric pair of tricyclic polyketides containing
a vinylogous anhydride, previously isolated and structurally characterized
as roseopurpurins D and C, respectively.</p><p>To confirm our functional
analysis of <italic>rosG</italic> as a cluster-specific ETaG, and
our genomic prediction of the resistance-determining residues of the
ETaG, we expressed and purified the wild-type Pho85 protein ortholog
of <italic>Mycophilomyces sp.</italic> alongside a chimeric variant
incorporating the putative resistance-determining residues (Val66Leu,
Phe82Ser, and Gly150Ala) in <italic>Escherichia coli</italic>. In vitro functional assays of both proteins, wild-type and chimeric
variant, in the presence of <bold>2</bold> revealed that the three
conserved active site residues from the ETaG were sufficient to confer
resistance to Pho85 against <bold>2</bold> at greater than 50 mM concentration
(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.4c01095/suppl_file/jm4c01095_si_001.pdf">Supporting Figure 1</ext-link>). This result validated
our TD<sup>3</sup> platform as a means to identify both GEMs and their
molecular target through genomic search, as well as provided key mechanistic
insights into binding mode and resistance in silico.</p><p>Having
established the product of the <italic>ros</italic> gene
cluster in an engineered strain of <italic>Mycophilomyces sp.</italic>, we returned to the LifeBase strain collection to see whether we
could identify, by targeted metabolite screening, a high-producing
wild-type strain. We selected a set of 83 fungal strains containing
the <italic>ros</italic> cluster, so as to reasonably represent the
full phylogenetic diversity of the 900 total strains in which this
cluster is present. Each strain was fermented on a panel of seven
media conditions and harvested at day 7 and 14. Samples were subjected
to gene expression analysis by RNAseq and detection of roseopurpurin
production by targeted liquid chromatography with tandem mass spectrometry
(LC-MS/MS) (<xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig">4</xref></xref>). Fifteen strains were identified with increased cluster gene expression
and accumulation of <bold>1</bold> and <bold>2</bold>, as compared
to the promoter-engineered strain of <italic>Mycophilomyces sp.</italic> In general, the highest expressing and producing strains were observed
within two phylogenetic groups, the genus <italic>Penicillium</italic>, and the family Lasiosphaeriaceae. We selected strains of <italic>Penicillium sp.</italic> (sect. <italic>Excilicaulis</italic>, <italic>Penicillium restrictum</italic> clade, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.4c01095/suppl_file/jm4c01095_si_001.pdf">Supporting Figure 2</ext-link>)<sup><xref ref-type="bibr" rid="ref26">26</xref></sup> for GEM
production, on the basis of their favorable properties for growth
and handling.</p><fig id="fig4" position="float"><label>Figure 4</label><caption><p>Heatmap of the sum of LC-MS/MS response from targeted
detection
of <bold>1</bold> and <bold>2</bold> (green) and the average expression
of <italic>ros</italic> cluster genes (purple), as determined by quantitative
RNAseq, in fermentations of LifeBase strains containing the <italic>ros</italic> BGC. Plotted values are the maximum observed in fermentations
on 7 different media conditions at days 7 and 14. The heatmap is organized
by multilocus phylogenetic analysis of 100 fungal housekeeping proteins.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jm4c01095_0004" id="gr9" position="float"/></fig></sec><sec id="sec2.3"><title>Biosynthetic Pathway of <bold>1</bold> and <bold>2</bold></title><p>To fully understand the biosynthetic pathway of <bold>1</bold> and <bold>2</bold>, single-gene knockout experiments were conducted on each
of the 11 genes of the <italic>ros</italic> BGC in the wild-type production
strain (<italic>Penicillium sp.</italic>) discussed above. Biosynthetic
intermediates that uniquely accumulated in each knockout strain were
characterized by LC-MS/MS analysis (<xref rid="sch1" ref-type="scheme">Scheme <xref rid="sch1" ref-type="scheme">1</xref></xref>). Seven of the <italic>ros</italic> genes
(<italic>rosABCDFJK</italic>) were found to be essential for the biosynthesis
of <bold>2</bold>, while deletions of the four remaining <italic>ros</italic> genes (<italic>rosEGHI</italic>) led to similar or reduced production
levels of <bold>2</bold>, suggesting that they play a supporting role.
Disruption of <italic>rosE</italic> significantly reduced both molecule
production and BGC transcription, effects similar to those seen upon
targeted deletion of the transcription factor <italic>rosH</italic>, suggesting that <italic>rosE</italic> also serves a role in transcriptional
activation, despite its lack of sequence or structural similarity
to any known transcription factor (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.4c01095/suppl_file/jm4c01095_si_001.pdf">Supporting Figure 3</ext-link>).</p><fig id="sch1" position="float"><label>Scheme 1</label><caption><title>Biosynthetic Pathway of <bold>1</bold> and <bold>2</bold></title><p id="s1fn1">(A) Biosynthetic pathway
of <bold>1</bold> and <bold>2</bold>, showing nonenzymatic degradation
pathway
of <bold>2</bold> to <bold>9</bold> by hydrolysis and spontaneous
decarboxylation at C11a to form <bold>10</bold> (gray arrows). (B)
Heatmap of LC-MS/MS response for biosynthetic intermediates of <bold>2</bold> accumulated in single-gene KO strains of <italic>Penicillium
sp.</italic></p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jm4c01095_0011" id="gr1" position="float"/></fig><p>The structures of intermediates <bold>3</bold> and <bold>5</bold> (<xref rid="sch1" ref-type="scheme">Scheme <xref rid="sch1" ref-type="scheme">1</xref></xref>) were confirmed
by comparison to reference standards prepared by chemical synthesis
(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.4c01095/suppl_file/jm4c01095_si_001.pdf">Supporting Figure 4</ext-link>). The early steps
of the biosynthetic pathway of <bold>2</bold>, up to formation of <bold>5</bold>, are similar to other recently characterized fungal depsidone
biosynthetic systems as well as previous proposals for the biosynthesis
of <bold>2</bold>.<sup><xref ref-type="bibr" rid="ref27">27</xref></sup> However, our observations
have more clearly delineated several late-stage steps in the pathway,
involving three genes responsible for oxidation, reduction and methylation
that are proposed to convert <bold>5</bold> to <bold>1</bold>, via
roseopurpurin G <bold>6</bold>. The hydroxylation of <bold>5</bold> by RosA was confirmed after heterologous expression of the encoding
gene in <italic>S. cerevisiae</italic>, however we did
not observe further oxidation to putative intermediate <bold>7</bold> in this system (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.4c01095/suppl_file/jm4c01095_si_001.pdf">Supporting Figure 5</ext-link>).
Disruption of <italic>rosF</italic>, encoding an <italic>O</italic>-methyltransferase, led to accumulation of <bold>8</bold>, which
was isolated and its structure was confirmed by NMR. While previous
studies have proposed a different biosynthetic pathway, one in which <bold>6</bold> is formed by elimination of water from <bold>8</bold>,<sup><xref ref-type="bibr" rid="ref22">22</xref></sup> we did not observe such an elimination reaction
during purification. In our extensively characterized pathway, <bold>6</bold> is not a shunt artifact but a bona fide biosynthetic intermediate.</p><p>The final gene in the biosynthesis encodes RosD, which is a unique
protein in fungal biosynthesis having no significant sequence identity
to any functionally characterized enzyme (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.4c01095/suppl_file/jm4c01095_si_001.pdf">Supporting Table 1</ext-link>). RosD does however have a conserved domain belonging
to the vicinal oxygen chelating (VOC) superfamily, which has been
associated with highly diverse functions in other proteins.<sup><xref ref-type="bibr" rid="ref28">28</xref></sup> RosD has been suggested to catalyze the hydrolysis
of <bold>2</bold> to aculeatusquinone C as a detoxification mechanism,<sup><xref ref-type="bibr" rid="ref22">22</xref></sup> but the comprehensive analysis here demonstrates
unambiguously that <italic>rosD</italic> encodes a C7 hydroxyl epimerase
that interconverts <bold>1</bold> and <bold>2</bold> to the equilibrium
mixture of &#x0223c;30/70% <bold>1</bold>/<bold>2.</bold> Consistent
with this role, disruption of <italic>rosD</italic> resulted in accumulation
of <bold>1</bold>, without production of <bold>2</bold>. The purified
RosD protein, generated by heterologous expression in <italic>E. coli</italic>, enabled reconstitution of the epimerization
reaction in vitro, affording rapid conversion of <bold>1</bold> to
the equilibrium <bold>1</bold>/<bold>2</bold> mixture (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.4c01095/suppl_file/jm4c01095_si_001.pdf">Supporting Figure 5</ext-link>). In these reconstitution
reactions, we also observed two new products by LC-MS/MS, these being
consistent with hydrolytic ring-opening of the vinylogous anhydride
in <bold>2</bold> to form the known compound roseopurpurin A <bold>9</bold>, which undergoes spontaneous decarboxylation to form aculeatusquinone
C <bold>10</bold> (<xref rid="sch1" ref-type="scheme">Scheme <xref rid="sch1" ref-type="scheme">1</xref></xref>). Interestingly, the corresponding products of hydrolytic
ring-opening and decarboxylation from <bold>1</bold> were not observed
in significant quantities under reaction conditions, consistent with
our general observation that the vinylogous anhydride in <bold>2</bold> is more reactive than that in <bold>1</bold>. Degradants <bold>9</bold> and <bold>10</bold> were formed at the same rate under conditions
in which the RosD enzyme was omitted, with all other conditions being
held constant. To further establish the nonenzymatic nature of this
pathway, <bold>2</bold> was dissolved in a mixture of acetonitrile
and water with a mild base (NaHCO<sub>3</sub>), resulting in formation
of <bold>9</bold> and <bold>10</bold>. Because intermediates such
as <bold>6</bold> in the biosynthetic pathway can also undergo nonenzymatic
hydrolysis and decarboxylation, or methanolysis to produce methyl
esters, we propose that a number of the aculeatusquinones and roseopurpurins
derived from intermediates in the <italic>ros</italic> biosynthetic
pathway similarly result from shunt pathways and are not evolved products
of the <italic>ros</italic> BGC (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.4c01095/suppl_file/jm4c01095_si_001.pdf">Supporting Figure 6</ext-link>).</p></sec><sec id="sec2.4"><title>Characterization of Mechanism of Action of <bold>1</bold> and <bold>2</bold> on Human CDK2</title><p>Our initial characterization of the
interaction of <bold>1</bold> with the <italic>Aspergillus
nidulans</italic> CDK Pho85 (PhoA) revealed the site-selective
formation of a covalent 1:1 adduct, with the inhibitor being linked
to the active site Lys residue that engages the &#x003b1;- and &#x003b2;-phosphate
moieties of ATP. Peptide mapping by mass spectrometry identified a
single 348 Da mass shift of the Lys38-containing peptide, along with
a missed tryptic cleavage site following this residue, consistent
with site-specific modification by <bold>1</bold> (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.4c01095/suppl_file/jm4c01095_si_001.pdf">Supporting Figure 7</ext-link>). This residue is highly conserved in
the vast majority of enzymatically active protein kinases, including
all CDKs, and mutation to any other residue is known to abolish kinase
activity.<sup><xref ref-type="bibr" rid="ref29">29</xref></sup> The kinase activity of CDK
enzymes is strongly stimulated in vitro and in vivo by complexation
with a cognate cyclin, and this is fundamental to the biological role
of CDK/cyclin complexes exerting exquisite regulatory control over
cell cycle progression. The preliminary observations of covalent inhibition
by the fungal CDK employed the enzyme in the absence of its cyclin,
and yet robust covalent conjugation of <bold>1</bold> and <bold>2</bold> was observed. In our mechanistic and structural studies of the human
CDKs, we deemed it essential to use only the physiologically active
form of the enzyme, namely its fully phosphorylated complex with the
cognate cyclin.</p><p>In enzyme activity assays with human CDK2/cyclin
E, we observed time-dependence in the IC<sub>50</sub> for inhibition
by <bold>2</bold>, behavior that can be ascribed to covalent inhibition.
We therefore employed a full battery of kinetic assays (<xref rid="fig5" ref-type="fig">Figure <xref rid="fig5" ref-type="fig">5</xref></xref>) to characterize the potency
of <bold>2</bold> with respect to the relevant covalent inactivation
parameters,<sup><xref ref-type="bibr" rid="ref30">30</xref></sup> the reversible equilibrium
dissociation constant (<italic>K</italic><sub>I</sub>) and the maximal
rate of inactivation (<italic>k</italic><sub>inact</sub>). In these
assays, <bold>2</bold> exhibited rapid enzyme inactivation, with a <italic>k</italic><sub>inact</sub> of 0.04 s<sup>&#x02013;1</sup>. The preinactivation
binding equilibrium was of moderate strength, with a <italic>K</italic><sub>I</sub> of 1.9 &#x003bc;M, while the ratio (<italic>k</italic><sub>inact</sub>/ <italic>K</italic><sub>I</sub>), generally used
as a gauge of potency for covalent inhibitors, was determined to be
23, which is comparable to FDA-approved covalent kinase inhibitors
such as afatinib and dacomitinib.<sup><xref ref-type="bibr" rid="ref31">31</xref></sup> To
further elucidate the mechanism of action, we performed intact mass
spectrometry analysis of CDK2/cyclin E incubated with <bold>2</bold>, confirming formation of a 1:1 covalent adduct (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.4c01095/suppl_file/jm4c01095_si_001.pdf">Supporting Figure 7</ext-link>).</p><fig id="fig5" position="float"><label>Figure 5</label><caption><p>Kinase activity assays utilizing the CDK2/cyclin
E kinase complex
to characterize covalent binding interactions with <bold>2</bold>.
(A) Enzyme inhibition by <bold>2</bold> exhibited time-dependence
of the IC<sub>50</sub>, here plotted in relative units (RU). (B) CDK2/cyclin
E activity as a function of preincubation time was fit to determine
the <italic>k</italic><sub>obs</sub> rate constants which are plotted
as a function of <bold>2</bold> concentration. Mean <italic>k</italic><sub>obs</sub> reported &#x000b1; SEM. These data were fit to determine <italic>K</italic><sub>I</sub> (the apparent inhibitor affinity), <italic>k</italic><sub>inact</sub> (the maximal inactivation rate), and the
ratio <italic>k</italic><sub>inact</sub>/<italic>K</italic><sub>I</sub> (potency).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jm4c01095_0005" id="gr10" position="float"/></fig><p>The binding interactions and inhibitory mechanism
of <bold>2</bold> with the CDK2/cyclin E protein complex were elucidated
at the molecular
level by X-ray crystallography (<xref rid="fig6" ref-type="fig">Figure <xref rid="fig6" ref-type="fig">6</xref></xref>A). As expected, the reaction product of <bold>2</bold> with CDK2/cyclin E was located in the ATP binding site, with the
phenolic ring engaging the kinase active site hinge region in a prototypical
manner; specifically, the C3 phenol forms a hydrogen bond with the
backbone of hinge residues Glu81 and Leu83. The central 7-membered
ring has undergone ring-opening, and electron density clearly shows
that the catalytic lysine (Lys33) is within covalent bonding distance
to the carbonyl moiety of the original vinylogous anhydride (<xref rid="fig6" ref-type="fig">Figure <xref rid="fig6" ref-type="fig">6</xref></xref>B). The nonaromatic
ring is rotated away, with the C8 carbonyl forming a hydrogen bond
to Gln131 on the periphery of the active site.</p><fig id="fig6" position="float"><label>Figure 6</label><caption><p>(A) Co-crystal structure
of CDK2/cyclin E in complex with <bold>2</bold> (PDB ID <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="PDB" xlink:href="9BJB">9BJB</ext-link>). (B) Active site
of CDK2 with bound <bold>2</bold>, showing H-bonding
interactions from C3-OH to the kinase hinge; electron density map
of <bold>2</bold> overlaid in mesh (2fo-fc contoured at 1 sigma) demonstrates
covalent attachment to Lys33. (C) Binding of amide analog XC208 <bold>51</bold> (PDB ID <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="PDB" xlink:href="9BJC">9BJC</ext-link>) without covalent interaction, demonstrating a prereaction complex.
(D) 2D map of binding site interactions between CDK2 and <bold>2</bold>, showing covalent (solid line) and H-bonding (dotted lines) positions.
(E) Structure of CDK2/cyclin A with ATP bound showing similar interactions
to <bold>2</bold> and <bold>51</bold> at the hinge and catalytic Lys33
(PDB ID <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="PDB" xlink:href="4EOQ">4EOQ</ext-link>).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jm4c01095_0006" id="gr11" position="float"/></fig><p>The structure depicted in <xref rid="fig6" ref-type="fig">Figure <xref rid="fig6" ref-type="fig">6</xref></xref>B clearly represents that of a postreaction
complex;
in order to determine the binding mode of the compound prior to the
covalent reaction, we used the known isostructural amide derivative <bold>51</bold>(<xref ref-type="bibr" rid="ref18">18</xref>) (XC208) as a nonelectrophilic
crystallographic probe. In enzyme activity assays, compound <bold>51</bold> showed reversible binding to CDK2/cyclin E, with an IC<sub>50</sub> of 3 &#x003bc;M. The cocrystal structure of <bold>51</bold> bound to CDK2/cyclin E (<xref rid="fig6" ref-type="fig">Figure <xref rid="fig6" ref-type="fig">6</xref></xref>C) revealed similar contacts at the kinase hinge region
compared to the postreaction complex of <bold>2</bold>, but importantly
no covalent bond was evident to Lys33, confirming that this structure
approximates the prereaction binding mode for this series of compounds.</p><p>H-bonding interactions are observed between residues Asp86, Lys89,
Gln131 and substituents at C8 and the chiral position C7 (<xref rid="fig6" ref-type="fig">Figure <xref rid="fig6" ref-type="fig">6</xref></xref>D), highlighting
the importance of the chiral groups distant from the covalent reaction
center in defining the optimal binding pose for nucleophilic attack
(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.4c01095/suppl_file/jm4c01095_si_001.pdf">Supporting Figure 8</ext-link>). The binding mode
of <bold>2</bold> is very similar to that observed for the kinase
substrate ATP (<xref rid="fig6" ref-type="fig">Figure <xref rid="fig6" ref-type="fig">6</xref></xref>E), which forms interactions from the hinge region to the nucleobase
and from the catalytic Lys33 to the &#x003b1; and &#x003b2; phosphates,
suggesting that the structure and binding mode of <bold>2</bold> is
primed for potent inhibition of CDK2.</p><p>To evaluate the biological
activity of <bold>2</bold> in cellulo,
we explored whether a durable irreversible response could be achieved
in cells with just a short exposure for 4 h followed by washout (<xref rid="fig7" ref-type="fig">Figure <xref rid="fig7" ref-type="fig">7</xref></xref>). A <italic>CCNE1</italic> amplified ovarian cancer cell line (OVCAR-3), reported as a CDK2
dependent cell line by DepMap,<sup><xref ref-type="bibr" rid="ref32">32</xref></sup> was treated
in culture with a range of concentrations of <bold>2</bold> for 4
h and subsequently washed out and assessed at 120 h. After the transient
4 h exposure, <bold>2</bold> maintained full potency for 120 h (IC<sub>50</sub> = 0.64 &#x003bc;M) comparable to conditions when cells were
treated constantly with inhibitor for the entire 120 h, IC<sub>50</sub> = 1 &#x003bc;M.</p><fig id="fig7" position="float"><label>Figure 7</label><caption><p>(A) % Inhibition of pRbT821 dose response of <bold>2</bold> in
OVCAR-3 cells. Potency of <bold>2</bold> with transient 4 h exposure
was similar to constant treatment. Mean IC<sub>50</sub> reported &#x000b1;
SEM (B) % growth inhibition dose response measured by Cell Titer-Glo
in OVCAR-3 cells. Potency of <bold>2</bold> with transient 4h exposure
was similar to constant treatment. Mean IC<sub>50</sub> reported &#x000b1;
SEM.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jm4c01095_0007" id="gr12" position="float"/></fig><p>In a parallel experiment we evaluated the cellular
impact of treatment
with <bold>2</bold> on an extensively characterized direct CDK2 substrate,
Retinoblastoma protein (Rb), wherein CDK2 inhibition is known to result
in reduced phosphorylation of Rb (pRb) and consequential antigrowth
activity in OVCAR-3 cells.<sup><xref ref-type="bibr" rid="ref33">33</xref></sup> Treatment
with <bold>2</bold> resulted in inhibition of pRb (IC<sub>50</sub> = 1.1 &#x003bc;M) with equipotency to the antigrowth activity IC<sub>50</sub> = 1.0 &#x003bc;M (<xref rid="fig7" ref-type="fig">Figure <xref rid="fig7" ref-type="fig">7</xref></xref>). Furthermore, pRb inhibition was sustained with only
a short exposure of 4 h and washout (IC<sub>50</sub> = 0.95 &#x003bc;M)
with equipotency to that of cells treated constantly for 18 h. In
summary, the cellular mechanistic and phenotypic responses in living
cells are fully sustained after just transient exposure and washout,
corroborating with the irreversible nature of the catalytic inhibition.</p><p>Taken together, the time-dependent inhibition, intact mass spectrometry,
crystallographic evidence and cellular washout clearly demonstrated
a covalent mechanism of action via the key catalytic lysine residue
of human CDK2.</p></sec><sec id="sec2.5"><title>Synthetic Chemistry</title><p>Compounds <bold>1</bold> and <bold>2</bold> have been evolved to target fungal CDKs for covalent inactivation,
while our primary interest lies in selective inhibition of human CDK2.
With a <italic>K</italic><sub>i</sub> in the low micromolar range,
and as described below, low selectivity within the CDK family and
modest oral bioavailability (12% in rats), it became clear that optimization
by medicinal chemistry would be desirable. Our TD<sup>3</sup> lead-optimization
strategy focused on making structure&#x02013;activity explorations
using three synthetic approaches executed in parallel: (1) a total
synthesis campaign to execute the first total synthesis of <bold>1</bold> and <bold>2</bold>, gaining broad control over chemical matter in
this series; (2) a campaign to a relevant series of analogs probing
various aspects of structure&#x02013;activity relationships; and (3)
semisynthetic modification starting from <bold>2</bold> produced by
fungal fermentation. With respect to fully synthetic approaches, the
compactness of this scaffold (<italic>M</italic><sub>W</sub> = 348
Da) is attractive, but the structure poses a formidable synthetic
challenge, due to the three contiguous chiral centers (C5a, C6 and
C7), a quaternary chiral center, a reactive and water-sensitive vinylogous
anhydride warhead, and an oxidatively dearomatized moiety with the
potential to rearomatize.</p><p>The hydrolysis of <bold>2</bold> (<xref rid="sch1" ref-type="scheme">Scheme <xref rid="sch1" ref-type="scheme">1</xref></xref>) served as an inspiration
for our synthetic strategy, featuring a late-stage dehydration to
form the central 7-member ring. Disconnecting into a suitably protected
orsellinic acid derivative and a nonaromatic ring bearing the stereochemical
complexity, we reasoned that an epoxide coupling approach would set
the desired relative stereochemistry. Our initial experiments coupling
known compound <bold>14</bold> with the racemic epoxide of a protected
benzoquinone delivered a trans intermediate <bold>15</bold>, which
was methylated to form <bold>16</bold> (<xref rid="sch2" ref-type="scheme">Scheme <xref rid="sch2" ref-type="scheme">2</xref></xref>). Relative stereochemistry was confirmed
by NOE NMR experiments. Epoxidation to <bold>17</bold>, followed by
substrate-controlled stereoselective reduction afforded intermediate <bold>18</bold> with the desired relative stereochemistry at C7 (highlighted
blue). We had planned to induce the rearrangement of the epoxide to
the vinylogous carboxylic acid in preparation for dehydrative ring
closure to form <bold>2</bold> but were unable to effect the transformation.
Instead, we opted for a stepwise approach by first reducing the epoxide
to intermediate <bold>19</bold> then reoxidation; this was successful,
but overoxidized to intermediate <bold>20</bold> ablating the C7 stereocenter.
Regioselective reduction was achieved using zinc with ammonium chloride,
however this delivered exclusively the undesired stereochemistry at
C7 (<bold>21</bold>, highlighted red). Debenzylation to <bold>22</bold> occurred smoothly, and our key dehydrative ring closure was achieved
with TFAA to afford racemic mixture <bold>23</bold>, which was resolved
by chiral supercritical fluid chromatography (SFC) to afford each
enantiomer (<bold>1</bold> and <bold>24</bold>) in 99% e.e. The desired
enantiomer was identified by comparison of chiral analytical SFC retention
times to fermented samples of <bold>1</bold>.</p><fig id="sch2" position="float"><label>Scheme 2</label><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jm4c01095_0012" id="gr2" position="float"/></fig><p>To complete the synthesis of <bold>2</bold>,
we leveraged our unique
insight into the biosynthetic pathway (<xref rid="sch1" ref-type="scheme">Scheme <xref rid="sch1" ref-type="scheme">1</xref></xref>), specifically that the enzyme RosD would
catalyze the transformation of <bold>1</bold> to <bold>2</bold> by
epimerization of the C7 hydroxyl. Synthetic <bold>1</bold> was treated
with the RosD epimerase which resulted in a 70% conversion, but only
11% isolated yield of <bold>2</bold> due to the small scale and the
requirement for HPLC to separate the unreacted starting material.
Under the same conditions, the racemic mixture <bold>23</bold> shows
diminished conversion (30%), and the chirally purified diastereomer <bold>24</bold> showed no conversion to <bold>25</bold>. These results
provide further evidence that epimerization of the C7 hydroxyl is
an enzymatically driven process catalyzed by RosD, and that the enzyme
is stereospecific for (<italic>S</italic>)-stereochemistry at C5a.
The analytical data for synthetic <bold>1</bold> and <bold>2</bold> matched the data for samples prepared by fermentation, which confirmed
that we have completed the total synthesis of two GEMs.</p><p>During
the synthetic sequence above we observed that ring opening
of the racemic epoxide afforded an unexpected 2:1 mixture of trans
(<bold>15a</bold> and <bold>15b</bold>) and cis (<bold>15c</bold> and <bold>15d</bold>) products (<xref rid="sch3" ref-type="scheme">Scheme <xref rid="sch3" ref-type="scheme">3</xref></xref>). We deduced that the cis product was formed by epimerization
of the stereocenter &#x003b1; to the carbonyl of the initially formed
trans product under the basic reaction conditions (i.e., <bold>15a</bold> &#x02192; <bold>15c</bold> and <bold>15b</bold> &#x02192; <bold>15d</bold>), and furthermore that <bold>15d</bold> had the configuration corresponding
to the epimerized C6 quaternary center (5a<italic>S</italic>,6<italic>R</italic>; highlighted blue). The cis product was isolated as a
racemic mixture of <bold>15c</bold> and <bold>15d</bold> and using
the same synthetic sequence as above elaborated to racemic mixture <bold>26</bold> and then resolved by chiral SFC. Leveraging the equilibrating
nature of the epimerase the (5a<italic>S</italic>,6<italic>R</italic>,7<italic>S</italic>)<italic>-</italic>enantiomer <bold>27</bold> was treated with RosD, which resulted in 35% conversion by LC&#x02013;MS
and 6% isolated yield of the C7 epimer <bold>28</bold>, requiring
SFC purification to remove the starting material. The relative stereochemistry
at C5a, C6 and C7 of <bold>27</bold> and <bold>28</bold> were confirmed
by NOESY data (see <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.4c01095/suppl_file/jm4c01095_si_003.zip">Supporting Information</ext-link>). The (5a<italic>R</italic>,6<italic>S</italic>,7<italic>R)-</italic>enantiomer <bold>29</bold> was isolated but showed no conversion
with the RosD epimerase.</p><fig id="sch3" position="float"><label>Scheme 3</label><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jm4c01095_0013" id="gr3" position="float"/></fig><p>In parallel to the total synthesis approach,
we undertook a systematic
simplification of the molecule, especially with respect to stereochemistry.
We used the same disconnection strategy, but substituted into the
synthesis a simplified nonaromatic ring, which expedited the synthesis
and avoided the late-stage redox challenges discussed above. The &#x003b2;-diketone <bold>30</bold> was methylated to form <bold>31</bold> and protected with
a benzoyl group in <bold>32</bold>, then brominated with NBS. The
resulting &#x003b1;-bromo ketone <bold>33</bold> was alkylated with
an orsellinic acid derivative <bold>34</bold> (<xref rid="sch4" ref-type="scheme">Scheme <xref rid="sch4" ref-type="scheme">4</xref></xref>). The resulting intermediate <bold>35</bold> was cyclized using TFAA to afford racemic <bold>36</bold>. The unsubstituted
intermediate <bold>36a</bold> (R<sub>6</sub> = H) was resolved to <bold>37</bold> using chiral SFC then deprotected to afford <bold>38</bold>. The simplified intermediate <bold>36b</bold> (R<sub>6</sub> = Me)
was oxidized using Davis reagent to install the C7 OH, then deprotected
and resolved using chiral SFC to afford <bold>39</bold> and subsequent
RosD-catalyzed epimerization afforded <bold>40</bold>.</p><fig id="sch4" position="float"><label>Scheme 4</label><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jm4c01095_0014" id="gr4" position="float"/></fig><p>Utilizing high-producing
strains of <italic>Penicillium sp</italic>., identified from our fungal
collection (<xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig">4</xref></xref>), we performed medium-scale static flask
fermentations at up to 45 L batch size to isolate <bold>2</bold>,
which formed the basis for a semisynthesis campaign. Derivatives <bold>41</bold>&#x02013;<bold>50</bold> were prepared in 1&#x02013;4 steps
(<xref rid="sch5" ref-type="scheme">Scheme <xref rid="sch5" ref-type="scheme">5</xref></xref>). Direct
halogenation was effective, but silyl protection of the phenol was
employed to enable palladium-catalyzed coupling and derivatization
of the C7 OH. The structures of <bold>2</bold> and the chlorinated
derivative <bold>43</bold> were confirmed by single crystal X-ray
analysis (see <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.4c01095/suppl_file/jm4c01095_si_001.pdf">Supporting Information</ext-link>).</p><fig id="sch5" position="float"><label>Scheme 5</label><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jm4c01095_0015" id="gr5" position="float"/></fig></sec><sec id="sec2.6"><title>Lead Optimization and SAR</title><p>We were intrigued by the
observation that <bold>2</bold> shows 25-fold enhanced biochemical
inhibition of CDK2/cyclin E relative to the coisolated GEM <bold>1</bold>, despite only a single difference between the two compounds, specifically
the configuration at the C7 stereocenter. To ascertain the impact
of the stereochemical configuration on the activity, we characterized
our panel of stereoisomer analogs (<xref rid="tbl2" ref-type="other">Table <xref rid="tbl2" ref-type="other">2</xref></xref>). To confirm biological activity we tested
compounds in parallel in live cells employing NanoBRET alongside in
vitro enzyme assays; these data corroborated each other well. Compound <bold>2</bold> showed 21-fold greater biochemical inhibition than its C6
epimer <bold>28</bold>, and for the epimerized scaffold the C7 diastereomer <bold>28</bold> was superior to <bold>27</bold>, showing the same trend
as <bold>2</bold> and <bold>1</bold>. Compounds <bold>24</bold> and <bold>29</bold> (enantiomers of <bold>1</bold> and <bold>27</bold>, respectively)
lost significant activity against CDK2/cyclin E, and displayed noncovalent
binding properties. The C6/C7-simplified analog set was also profiled,
however complete removal of substituents at C6 and C7 (compound <bold>38</bold>) led to substantial loss of activity on CDK2/cyclin E,
which was partially restored upon reintroduction of both a methyl
group at C6 and hydroxyl at C7 (<bold>39</bold>). Epimerization at
C7 in <bold>40</bold> provided a further boost to activity, achieving
a similar level of cellular inhibition to <bold>1</bold>, but still
6-fold lower than <bold>2</bold>.</p><table-wrap id="tbl2" position="float"><label>Table 2</label><caption><title>SAR of the Stereoisomers of <bold>2</bold> and Simplified Analogs<xref rid="t2fn1" ref-type="table-fn">a</xref></title></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jm4c01095_0016" id="fx1" position="float"/><table frame="hsides" rules="groups" border="0"><colgroup><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/></colgroup><thead><tr><th style="border:none;" align="center">&#x000a0;</th><th style="border:none;" align="center">&#x000a0;</th><th style="border:none;" align="center">&#x000a0;</th><th style="border:none;" align="center">&#x000a0;</th><th style="border:none;" align="center">&#x000a0;</th><th style="border:none;" align="center">&#x000a0;</th><th colspan="3" align="center">enzyme
assay (<italic>k</italic><sub>inact</sub>/<italic>K</italic><sub>I</sub>&#x000a0;&#x000d7;&#x000a0;10<sup>&#x02013;3</sup>/s<sup>&#x02013;1</sup>&#x000a0;&#x003bc;M<sup>&#x02013;1</sup>)<hr/></th><th colspan="3" align="center">NanoBRET
(EC<sub>50</sub>, &#x003bc;M)<hr/></th></tr><tr><th style="border:none;" align="center">compound</th><th style="border:none;" align="center">5a</th><th style="border:none;" align="center">R<sub>6</sub></th><th style="border:none;" align="center">R<sub>6</sub>&#x02032;</th><th style="border:none;" align="center">R<sub>7</sub></th><th style="border:none;" align="center">R<sub>7</sub>&#x02032;</th><th style="border:none;" align="center">CDK2</th><th style="border:none;" align="center">CDK1</th><th style="border:none;" align="center">CDK7</th><th style="border:none;" align="center">CDK2</th><th style="border:none;" align="center">CDK1</th><th style="border:none;" align="center">CDK7</th></tr></thead><tbody><tr><td style="border:none;" align="left"><bold>1</bold> (5aS,6S,7R)</td><td style="border:none;" align="left">(<italic>S</italic>)</td><td style="border:none;" align="left">Me</td><td style="border:none;" align="left">OMe</td><td style="border:none;" align="left">H</td><td style="border:none;" align="left">OH</td><td style="border:none;" align="left">0.92</td><td style="border:none;" align="left">0.018</td><td style="border:none;" align="left">0.18</td><td style="border:none;" align="left">0.90</td><td style="border:none;" align="left">2.89</td><td style="border:none;" align="left">5.36</td></tr><tr><td style="border:none;" align="left"><bold>2</bold> (5aS,6S,7S)</td><td style="border:none;" align="left">(<italic>S</italic>)</td><td style="border:none;" align="left">Me</td><td style="border:none;" align="left">OMe</td><td style="border:none;" align="left">OH</td><td style="border:none;" align="left">H</td><td style="border:none;" align="left">23</td><td style="border:none;" align="left">1.1</td><td style="border:none;" align="left">9</td><td style="border:none;" align="left">0.14</td><td style="border:none;" align="left">0.61</td><td style="border:none;" align="left">0.30</td></tr><tr><td style="border:none;" align="left"><bold>24</bold> (5a<italic>R</italic>,6<italic>R</italic>,7<italic>S)</italic></td><td style="border:none;" align="left">(<italic>R</italic>)</td><td style="border:none;" align="left">OMe</td><td style="border:none;" align="left">Me</td><td style="border:none;" align="left">OH</td><td style="border:none;" align="left">H</td><td style="border:none;" align="left">rev (70&#x000a0;&#x003bc;M)</td><td style="border:none;" align="left">rev (&#x0003e;100&#x000a0;&#x003bc;M)</td><td style="border:none;" align="left">rev</td><td style="border:none;" align="left">&#x0003e;33</td><td style="border:none;" align="left">&#x0003e;33</td><td style="border:none;" align="left">&#x0003e;33</td></tr><tr><td style="border:none;" align="left"><bold>27</bold> (5a<italic>S</italic>,6<italic>R</italic>,7S<italic>)</italic></td><td style="border:none;" align="left">(<italic>S</italic>)</td><td style="border:none;" align="left">OMe</td><td style="border:none;" align="left">Me</td><td style="border:none;" align="left">OH</td><td style="border:none;" align="left">H</td><td style="border:none;" align="left">1.1</td><td style="border:none;" align="left">0.11</td><td style="border:none;" align="left">0.08</td><td style="border:none;" align="left">0.33</td><td style="border:none;" align="left">1.6</td><td style="border:none;" align="left">4.0</td></tr><tr><td style="border:none;" align="left"><bold>28</bold> (5aS,6<italic>R</italic>,7<italic>R)</italic></td><td style="border:none;" align="left">(<italic>S</italic>)</td><td style="border:none;" align="left">OMe</td><td style="border:none;" align="left">Me</td><td style="border:none;" align="left">H</td><td style="border:none;" align="left">OH</td><td style="border:none;" align="left">0.16</td><td style="border:none;" align="left">0.012</td><td style="border:none;" align="left">0.007</td><td style="border:none;" align="left">3.0</td><td style="border:none;" align="left">8.0</td><td style="border:none;" align="left">11.6</td></tr><tr><td style="border:none;" align="left"><bold>29</bold> (5a<italic>R</italic>,6<italic>S</italic>,7<italic>R)</italic></td><td style="border:none;" align="left">(<italic>R</italic>)</td><td style="border:none;" align="left">Me</td><td style="border:none;" align="left">OMe</td><td style="border:none;" align="left">H</td><td style="border:none;" align="left">OH</td><td style="border:none;" align="left">rev (9&#x000a0;&#x003bc;M)</td><td style="border:none;" align="left">rev (19&#x000a0;&#x003bc;M)</td><td style="border:none;" align="left">rev</td><td style="border:none;" align="left">22</td><td style="border:none;" align="left">&#x0003e;33</td><td style="border:none;" align="left">&#x0003e;33</td></tr><tr><td style="border:none;" align="left"><bold>38</bold></td><td style="border:none;" align="left">(<italic>S</italic>)</td><td style="border:none;" align="left">H</td><td style="border:none;" align="left">H</td><td style="border:none;" align="left">H</td><td style="border:none;" align="left">H</td><td style="border:none;" align="left">0.0002</td><td style="border:none;" align="left">&#x000a0;</td><td style="border:none;" align="left">&#x000a0;</td><td style="border:none;" align="left">26.6</td><td style="border:none;" align="left">&#x000a0;</td><td style="border:none;" align="left">&#x000a0;</td></tr><tr><td style="border:none;" align="left"><bold>39</bold></td><td style="border:none;" align="left">(<italic>S</italic>)</td><td style="border:none;" align="left">H</td><td style="border:none;" align="left">Me</td><td style="border:none;" align="left">H</td><td style="border:none;" align="left">OH</td><td style="border:none;" align="left">0.14</td><td style="border:none;" align="left">&#x000a0;</td><td style="border:none;" align="left">0.01</td><td style="border:none;" align="left">1.62</td><td style="border:none;" align="left">16.35</td><td style="border:none;" align="left">30.2</td></tr><tr><td style="border:none;" align="left"><bold>40</bold></td><td style="border:none;" align="left">(<italic>S</italic>)</td><td style="border:none;" align="left">H</td><td style="border:none;" align="left">Me</td><td style="border:none;" align="left">OH</td><td style="border:none;" align="left">H</td><td style="border:none;" align="left">0.10</td><td style="border:none;" align="left">0.0057</td><td style="border:none;" align="left">0.01</td><td style="border:none;" align="left">0.87</td><td style="border:none;" align="left">35</td><td style="border:none;" align="left">55.5</td></tr></tbody></table><table-wrap-foot><fn id="t2fn1"><label>a</label><p>Stereochemistry indicated for stereoisomers
of <bold>2</bold>. Rev = Reversible. Enzyme and NanoBRET activity
assays were assessed on the active CDK/cyclin holoenzyme as follows:
CDK2/cyclin E1, CDK1/cyclin B1, CDK7/cyclin H/MAT1. Mean values calculated
from at least two independent replicates for enzyme assays and NanoBRET;
exception: NanoBRET compounds 24 and 38 were run <italic>n</italic> = 1 and inactive.</p></fn></table-wrap-foot></table-wrap><p>In aggregate, these observations suggest that both
the presence
of substituents and the natural stereochemical configuration are crucial
for the covalent inhibition of human CDK2/cyclin E, likely determining
the proximity and orientation of the vinylogous anhydride to the catalytic
lysine. Furthermore, the range of activities across the chemical series
demonstrates that this unusual motif is not an indiscriminate electrophile,
but rather a tunable warhead.</p><p>The CDK inhibitory profiles on
the semisynthetic derivatives of <bold>2</bold> are shown in <xref rid="tbl3" ref-type="other">Table <xref rid="tbl3" ref-type="other">3</xref></xref>. The C7 OH tolerated
diverse functionality, such as acetyl,
glycine, methylcarbamate and a linked biotin moiety, but there was
a universal loss of activity. The R<sub>2</sub> position was also
synthetically tractable, and we were able to establish an SAR trend
according to size across compounds <bold>41</bold>&#x02013;<bold>45</bold>. The smaller R<sub>2</sub> substituents are more active: biochemically
H &#x0003e; F, Me, Cl &#x0003e; Br &#x0226b; Et; and in the NanoBRET cellular
context
H, <italic>F</italic> &#x0003e; Cl &#x0003e; Me &#x0003e; Br &#x0226b; Et. It is also
worthy
of note that larger substituents R<sub>2</sub> = Cl (<bold>43</bold>) and Br (<bold>44</bold>) show increased selectivity for CDK2 over
CDK7 relative to smaller substituents H and F (<bold>2</bold> and <bold>41</bold>, respectively).</p><table-wrap id="tbl3" position="float"><label>Table 3</label><caption><title>SAR of Semisynthetic Analogs<xref rid="t3fn1" ref-type="table-fn">a</xref></title></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jm4c01095_0017" id="fx2" position="float"/><table frame="hsides" rules="groups" border="0"><colgroup><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/></colgroup><thead><tr><th style="border:none;" align="center">&#x000a0;</th><th style="border:none;" align="center">&#x000a0;</th><th style="border:none;" align="center">&#x000a0;</th><th colspan="3" align="center">enzyme
assay (<italic>k</italic><sub>inact</sub>/<italic>K</italic><sub>I</sub>&#x000a0;&#x000d7;&#x000a0;10<sup>&#x02013;3</sup>/s<sup>&#x02013;1</sup>&#x003bc;M<sup>&#x02013;1</sup>)<hr/></th><th colspan="3" align="center">NanoBRET
(EC<sub>50</sub>, &#x003bc;M)<hr/></th></tr><tr><th style="border:none;" align="center">compound</th><th style="border:none;" align="center">R<sub>2</sub></th><th style="border:none;" align="center">R<sub>7</sub></th><th style="border:none;" align="center">CDK2</th><th style="border:none;" align="center">CDK1</th><th style="border:none;" align="center">CDK7</th><th style="border:none;" align="center">CDK2</th><th style="border:none;" align="center">CDK1</th><th style="border:none;" align="center">CDK7</th></tr></thead><tbody><tr><td style="border:none;" align="left"><bold>2</bold></td><td style="border:none;" align="left">H</td><td style="border:none;" align="left">OH</td><td style="border:none;" align="left">23</td><td style="border:none;" align="left">1.1</td><td style="border:none;" align="left">9</td><td style="border:none;" align="left">0.14</td><td style="border:none;" align="left">0.61</td><td style="border:none;" align="left">0.3</td></tr><tr><td style="border:none;" align="left"><bold>41</bold></td><td style="border:none;" align="left">F</td><td style="border:none;" align="left">OH</td><td style="border:none;" align="left">5.9</td><td style="border:none;" align="left">0.044</td><td style="border:none;" align="left">0.71</td><td style="border:none;" align="left">0.13</td><td style="border:none;" align="left">0.57</td><td style="border:none;" align="left">0.35</td></tr><tr><td style="border:none;" align="left"><bold>42</bold></td><td style="border:none;" align="left">Me</td><td style="border:none;" align="left">OH</td><td style="border:none;" align="left">2.7</td><td style="border:none;" align="left">0.23</td><td style="border:none;" align="left">0.3</td><td style="border:none;" align="left">0.99</td><td style="border:none;" align="left">5.25</td><td style="border:none;" align="left">5.76</td></tr><tr><td style="border:none;" align="left"><bold>43</bold> (XC219)</td><td style="border:none;" align="left">Cl</td><td style="border:none;" align="left">OH</td><td style="border:none;" align="left">5.8</td><td style="border:none;" align="left">0.35</td><td style="border:none;" align="left">0.21</td><td style="border:none;" align="left">0.23</td><td style="border:none;" align="left">1.0</td><td style="border:none;" align="left">3.4</td></tr><tr><td style="border:none;" align="left"><bold>44</bold></td><td style="border:none;" align="left">Br</td><td style="border:none;" align="left">OH</td><td style="border:none;" align="left">1.0</td><td style="border:none;" align="left">0.14</td><td style="border:none;" align="left">0.05</td><td style="border:none;" align="left">0.7</td><td style="border:none;" align="left">4.9</td><td style="border:none;" align="left">12.2</td></tr><tr><td style="border:none;" align="left"><bold>45</bold></td><td style="border:none;" align="left">Et</td><td style="border:none;" align="left">OH</td><td style="border:none;" align="left">0.025</td><td style="border:none;" align="left">0.012</td><td style="border:none;" align="left">0.005</td><td style="border:none;" align="left">&#x0003e;33</td><td style="border:none;" align="left">&#x0003e;33</td><td style="border:none;" align="left">&#x0003e;33</td></tr><tr><td style="border:none;" align="left"><bold>47</bold></td><td style="border:none;" align="left">H</td><td style="border:none;" align="left">OAc</td><td style="border:none;" align="left">3.18</td><td style="border:none;" align="left">0.17</td><td style="border:none;" align="left">1.1</td><td style="border:none;" align="left">1.5</td><td style="border:none;" align="left">4.3</td><td style="border:none;" align="left">1.6</td></tr><tr><td style="border:none;" align="left"><bold>48</bold></td><td style="border:none;" align="left">H</td><td style="border:none;" align="left">OC(O)OMe</td><td style="border:none;" align="left">0.5</td><td style="border:none;" align="left">0.059</td><td style="border:none;" align="left">0.31</td><td style="border:none;" align="left">6.1</td><td style="border:none;" align="left">17.7</td><td style="border:none;" align="left">6.3</td></tr><tr><td style="border:none;" align="left"><bold>49</bold></td><td style="border:none;" align="left">H</td><td style="border:none;" align="left">OGly</td><td style="border:none;" align="left">3.9</td><td style="border:none;" align="left">0.28</td><td style="border:none;" align="left">5.6</td><td style="border:none;" align="left">1.4</td><td style="border:none;" align="left">6.5</td><td style="border:none;" align="left">1.8</td></tr><tr><td style="border:none;" align="left"><bold>50</bold></td><td style="border:none;" align="left">H</td><td style="border:none;" align="left">OC(O)(CH<sub>2</sub>)<sub>2</sub>&#x02013;PEG<sub>4</sub>-biotin</td><td style="border:none;" align="left">0.28</td><td style="border:none;" align="left">0.077</td><td style="border:none;" align="left">&#x000a0;</td><td style="border:none;" align="left">&#x000a0;</td><td style="border:none;" align="left">&#x000a0;</td><td style="border:none;" align="left">&#x000a0;</td></tr><tr><td style="border:none;" align="left"><bold>51</bold> (XC208)</td><td style="border:none;" align="left">H</td><td style="border:none;" align="left">OH</td><td style="border:none;" align="left">rev (3&#x000a0;&#x003bc;M)</td><td style="border:none;" align="left">rev (7&#x000a0;&#x003bc;M)</td><td style="border:none;" align="left">rev (9&#x000a0;&#x003bc;M)</td><td style="border:none;" align="left">&#x0003e;33</td><td style="border:none;" align="left">&#x0003e;33</td><td style="border:none;" align="left">&#x0003e;33</td></tr></tbody></table><table-wrap-foot><fn id="t3fn1"><label>a</label><p>Rev = Reversible. Enzyme and NanoBRET
activity assays were assessed on the active CDK/cyclin holoenzyme
as follows: CDK2/cyclin E1, CDK1/cyclin B1, CDK7/cyclin H/MAT1. Mean
values calculated from at least two independent replicates for enzyme
assays and NanoBRET.</p></fn></table-wrap-foot></table-wrap><p>The chlorinated analog <bold>43</bold> (LifeMine code
XC219) was
selected for additional profiling as it retained potent biochemical
and cellular inhibition of CDK2 while demonstrating improved selectivity
against CDK7. We acquired an X-ray crystal structure of <bold>43</bold> in complex with CDK2/cyclin E, which showed that its binding mode
matches that of <bold>2</bold>, with the C3 phenol binding the hinge
and formation of a covalent bond from C11 to Lys33 (<xref rid="fig8" ref-type="fig">Figure <xref rid="fig8" ref-type="fig">8</xref></xref>). The R<sub>2</sub> vector
projects toward Val64 of CDK2, which rotates to accommodate the Cl
atom of <bold>43</bold>. There is a point-change of the corresponding
residue to Ile75 in CDK7, and we propose that the larger residue cannot
accommodate the R<sub>2</sub> = Cl, affording selectivity for CDK2
over CDK7.</p><fig id="fig8" position="float"><label>Figure 8</label><caption><p>(A) Cocrystal structure of CDK2/cyclin E with <bold>2.</bold> (B)
Cocrystal structure of CDK2/cyclin E with XC219 <bold>43</bold> (PDB
ID <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="PDB" xlink:href="9BJD">9BJD</ext-link>) showing
the same binding pose as <bold>2</bold> with rotation of Val64 to
accommodate the larger R<sub>2</sub> = Cl substituent.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jm4c01095_0008" id="gr13" position="float"/></fig></sec><sec id="sec2.7"><title>Selectivity across the Kinome and Proteome</title><p>The vinylogous
anhydride of <bold>2</bold> reacts with the active site lysine of
CDK2 (Lys33) to form a covalent bond. This residue is highly conserved
within the protein kinase family, which raises the question of the
selectivity of <bold>2</bold> not only for CDKs but for the entire
kinome.<sup><xref ref-type="bibr" rid="ref34">34</xref></sup> Furthermore, the vinylogous anhydride
of <bold>2</bold> clearly shows conditional reactivity with CDKs,
but its electrophilic nature could give rise to off-target reactivity.
To assess the selectivity of <bold>2</bold> across the human kinome,
we tested <bold>2</bold> in a competitive Kinobead pull-down assay.<sup><xref ref-type="bibr" rid="ref35">35</xref></sup> The assay revealed remarkably high overall selectivity,
with the primary human targets of <bold>2</bold> being the CMGC family
of proline-directed serine/threonine kinases (<xref rid="fig9" ref-type="fig">Figure <xref rid="fig9" ref-type="fig">9</xref></xref>A), which contains 21 CDK family members.
A small number of additional kinase targets were identified in the
CK1, CAMK, and TKL classes. A broader competitive chemoproteomic screen
using the biotinylated probe <bold>50</bold> in lysates treated with
25 &#x003bc;M of <bold>2</bold> detected no additional nonkinase targets
(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.4c01095/suppl_file/jm4c01095_si_001.pdf">Supporting Figure 9</ext-link>).</p><fig id="fig9" position="float"><label>Figure 9</label><caption><p>Kinome binding profile
of <bold>2</bold> and analogs using the
Kinobead assay. (A) Profile of GEM <bold>2</bold> (2 &#x003bc;M) compared
to (B) chlorinated analog <bold>43</bold> (2 &#x003bc;M) with improved
CDK2 selectivity; (C) acetylated analog <bold>47</bold> (2 &#x003bc;M)
with alternate selectivity in the CAMK group; (D) analog <bold>38</bold> (50 &#x003bc;M) with alternate specificity in the CK1 group. Kinases
with engagement &#x0003e;50% are labeled, kinase classes that show differentiation
between analogs of <bold>2</bold> are highlighted.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jm4c01095_0009" id="gr14" position="float"/></fig><p>We also performed an analogous Kinobead experiment
in <italic>S. cerevisiae</italic> lysate to profile
the fungal kinase
targets of <bold>2</bold>, revealing potent (EC<sub>50</sub> = 31
nM) and selective engagement of yeast PHO85, consistent with the genomic
target prediction based on the fungal Pho85 ETaG in the <italic>ros</italic> BGC. Compound <bold>2</bold> engaged yeast PHO85 as the top ranking
target out of 81 detected kinases in the cell lysate, demonstrating
&#x0003e;100-fold higher potency relative to nearly all other detected
kinases,
including fungal CDK orthologs CDC28, KIN28, and SGV1 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.4c01095/suppl_file/jm4c01095_si_001.pdf">Supporting Figure 10</ext-link>).</p><p>We profiled a diverse
selection of synthetic analogs in the human
Kinobead assay (<xref rid="fig9" ref-type="fig">Figure <xref rid="fig9" ref-type="fig">9</xref></xref>B&#x02013;D). The improved selectivity of <bold>43</bold> versus <bold>2</bold> was recapitulated in the Kinobead assay, and extended to
the larger CDK family CDK5, 7, 12, and 13, and importantly the kinome
in general. The transcriptional regulators CDK7, 12, and 13 are known
to have a narrow therapeutic window, while reduced inhibition of CDK5
offers more favorable neurological safety.<sup><xref ref-type="bibr" rid="ref36">36</xref></sup> Beyond the CDK family we also noted improved selectivity on kinases
such as MAP3K11 and CSKN1E. The C7 acetylated analog <bold>47</bold> led to a slight shift of activity favoring the CMGC kinase CLK2,
and the CAMK kinase AURKC. The simplified analog <bold>38</bold> showed
barely detectable CDK2 activity but was highly selective for a therapeutically
valued target, CK1 kinase CSNK1A1,<sup><xref ref-type="bibr" rid="ref37">37</xref></sup> albeit
with weak activity.</p></sec><sec id="sec2.8"><title>Pharmacokinetics</title><p>The in vivo pharmacokinetic profiles
of <bold>2</bold> and <bold>43</bold> are reported in <xref rid="tbl4" ref-type="other">Table <xref rid="tbl4" ref-type="other">4</xref></xref>. <bold>2</bold> shows high
clearance and low oral bioavailability in mouse and rat. In contrast, <bold>43</bold> shows low clearance and good oral bioavailability in both
rodent species. Here, a single atom change afforded a significant
improvement in the PK profile, and we attribute this to the improved
microsomal stability observed in vitro.</p><table-wrap id="tbl4" position="float"><label>Table 4</label><caption><title>Pharmacokinetic and Select In Vitro
ADME Parameters of Compounds <bold>2</bold> and <bold>43</bold></title></caption><table frame="hsides" rules="groups" border="0"><colgroup><col align="left"/><col align="left"/><col align="left"/></colgroup><thead><tr><th style="border:none;" align="center">&#x000a0;</th><th style="border:none;" align="center">Cpd <bold>2</bold></th><th style="border:none;" align="center">Cpd <bold>43</bold></th></tr></thead><tbody><tr><td colspan="3" align="center">Mouse PK</td></tr><tr><td style="border:none;" align="left">IV
dose (mg/kg)</td><td style="border:none;" align="left">0.94</td><td style="border:none;" align="left">0.81</td></tr><tr><td style="border:none;" align="left">AUC (ng&#x000b7;h/mL)</td><td style="border:none;" align="left">93</td><td style="border:none;" align="left">1263</td></tr><tr><td style="border:none;" align="left">Cl (mL/min/kg)</td><td style="border:none;" align="left">176</td><td style="border:none;" align="left">13.1</td></tr><tr><td style="border:none;" align="left"><italic>V</italic><sub>ss</sub> (L/kg)</td><td style="border:none;" align="left">6.3</td><td style="border:none;" align="left">1.6</td></tr><tr><td style="border:none;" align="left"><italic>t</italic><sub>1/2</sub> (h)</td><td style="border:none;" align="left">0.6</td><td style="border:none;" align="left">5.2</td></tr><tr><td style="border:none;" align="left">oral dose (mg/kg)</td><td style="border:none;" align="left">2.79</td><td style="border:none;" align="left">2.42</td></tr><tr><td style="border:none;" align="left">AUC (ng&#x000b7;h/mL)</td><td style="border:none;" align="left">42</td><td style="border:none;" align="left">2058</td></tr><tr><td style="border:none;" align="left">F (%)</td><td style="border:none;" align="left">12</td><td style="border:none;" align="left">54</td></tr><tr><td colspan="3" align="center">Rat PK</td></tr><tr><td style="border:none;" align="left">IV dose (mg/kg)</td><td style="border:none;" align="left">0.89</td><td style="border:none;" align="left">0.83</td></tr><tr><td style="border:none;" align="left">AUC (ng&#x000b7;h/mL)</td><td style="border:none;" align="left">229</td><td style="border:none;" align="left">1288</td></tr><tr><td style="border:none;" align="left">Cl (mL/min/kg)</td><td style="border:none;" align="left">68</td><td style="border:none;" align="left">11</td></tr><tr><td style="border:none;" align="left"><italic>V</italic><sub>ss</sub> (L/kg)</td><td style="border:none;" align="left">29.5</td><td style="border:none;" align="left">2.0</td></tr><tr><td style="border:none;" align="left"><italic>t</italic><sub>1/2</sub> (h)</td><td style="border:none;" align="left">9.0</td><td style="border:none;" align="left">3.1</td></tr><tr><td style="border:none;" align="left">oral dose (mg/kg)</td><td style="border:none;" align="left">2.73</td><td style="border:none;" align="left">2.55</td></tr><tr><td style="border:none;" align="left">AUC (ng&#x000b7;h/mL)</td><td style="border:none;" align="left">227</td><td style="border:none;" align="left">2261</td></tr><tr><td style="border:none;" align="left"><italic>F</italic> (%)</td><td style="border:none;" align="left">25</td><td style="border:none;" align="left">58</td></tr><tr><td colspan="3" align="center">Microsomal Stability</td></tr><tr><td style="border:none;" align="left">mouse <italic>t</italic><sub>1/2</sub> (min)</td><td style="border:none;" align="left">18.2</td><td style="border:none;" align="left">65.2</td></tr><tr><td style="border:none;" align="left">rat <italic>t</italic><sub>1/2</sub> (min)</td><td style="border:none;" align="left">41.0</td><td style="border:none;" align="left">148</td></tr></tbody></table></table-wrap><p>Brain and plasma exposures were evaluated over a 24
h period in
mice administered with a single dose of either <bold>2</bold> or <bold>43</bold>, at 30 mpk. Interestingly, <bold>2</bold> showed exceptionally
high levels of brain exposure (AUC blood-to-plasma ratio of 0.68),
and <bold>43</bold> significantly reduced brain exposures (AUC b/p
ratio = 0.0003).</p><p>High-dose intraperitoneal (i.p.) mouse PK was
conducted to determine
tolerability. Although animals treated with a single 50 mpk dose of <bold>2</bold> presented with acute body weight loss within 3 days, animals
treated with <bold>43</bold> tolerated 7 days of daily dosing at 100
mpk with no adverse observations noted. We attributed the improved
tolerability to the improved selectivity profile.</p></sec><sec id="sec2.9"><title>In Vivo Efficacy</title><p>Given the favorable selectivity, PK
and tolerability profiles, <bold>43</bold> was advanced to an efficacy
study to evaluate this novel mechanism of CDK2 inhibition in a gastric
patient derived xenotransplant (PDX) model. We selected a rapidly
proliferating PDX, CRT00292 gastric mouse model harboring a high CCNE1
amplification (CN = 12), which is a predictive biomarker of response
to CDK2 inhibition. Animals with established subcutaneous tumor fragments
were dosed daily i.p. for 14 days, resulting in tumor growth inhibition
(TGI) measured relative to the vehicle control over the duration of
the study (<xref rid="fig10" ref-type="fig">Figure <xref rid="fig10" ref-type="fig">10</xref></xref>). At 14 days <bold>43</bold> showed 44 and 80% TGI at 30 and 100
mpk, respectively, demonstrating a dose-dependent response and a remarkable
level of TGI at the high dose in this aggressive PDX model.</p><fig id="fig10" position="float"><label>Figure 10</label><caption><p>Antitumor
growth activity in a CCNE amplified (CN = 12) gastric
PDX model CRT00292. NOG mice were inoculated subcutaneously with tumor
fragments and randomized (<italic>n</italic> = 7/group) when tumors
reached an average of 150&#x02013;200 mm<sup>3</sup>. Animals were
dosed daily with XC219 <bold>43</bold> (30 and 100 mpk &#x000d7; 14d,
i.p.). In the highest dose group 3 animals were moribund or withdrawn
from treatment. One-way ANOVA, Dunnett&#x02019;s multiple comparison
test was performed reporting statistical significance of 100 mpk group, <italic>p</italic> value = 0.0079.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jm4c01095_0010" id="gr15" position="float"/></fig></sec></sec><sec id="sec3"><title>Conclusions</title><p>In this work, we have employed ETaG-based
genomic search across
a comprehensively sequenced and functionally annotated collection
of over 100,000 diverse wild-type fungi (LifeBase) to identify an
inhibitor of a preselected human target family, cyclin-dependent kinases.
To our knowledge, this represents the first example in which a fungal
GEM inhibiting a human protein of therapeutic interest was discovered
first by a targeted search in genomic space.<sup><xref ref-type="bibr" rid="ref21">21</xref></sup> In other words, our TD<sup>3</sup> discovery paradigm starts with
a human target, progresses to the discovery of genes encoding a fungal
GEM predicted to engage that human target, and then progresses further
to the isolation and characterization of the GEM. This is in reversed
order compared to the historical paradigm of &#x0201c;natural product&#x0201d;
drug discovery, in which a GEM was first isolated and in some cases
its target identified, but only in relatively rare instances was the
producing organism sequenced and the genetic origins of the GEM characterized.
The historical emphasis on searching through chemical space has led
to a situation in which many GEMs in the literature have been isolated,
structurally characterized and reported to possess biological activity
in human cells, but the target(s) responsible for that activity has
not been elucidated. Genomic search for BGCs using the presence of
a colocated ETaG offers a powerful means to deorphanize the targets
of such GEMs. The present work exemplifies the use of genomic search
for GEM deorphanization&#x02014;<bold>1</bold> and <bold>2</bold> had
been isolated decades ago and shown to possess antiproliferative activity
in cultured human cells, but their molecular target(s) had not been
identified. Here we found that, as predicted by the presence of the
CDK-homologous <italic>rosG</italic> ETaG in the <italic>ros</italic> BGC, <bold>1</bold> and <bold>2</bold> indeed encode inhibitors
of both fungal and human CDK enzymes. In work to be reported elsewhere,
we have undertaken a systematic deorphanization of known GEMs and
are developing AI-based methods to correlate BGC and GEM structure.</p><p>The ability to search in genomic space for therapeutics that engage
a predetermined human target offers substantial advantages over searching
for GEMs through chemical space using activity-based fractionation.
As demonstrated in this study, up-front knowledge of the genes encoding
a GEM enables the transcriptional activity of the cluster to be monitored
as a function of growth conditions, allowing for GEM production to
be maximized prior to initiation of isolation. The functions of the
genes within the BGC can provide important insights into the chemical
structure of the GEM that aid in isolation based on MS/MS fragmentation,
for example analysis of the <italic>ros</italic> BGC suggested a heavily
oxidized orsellinic acid derivative with a methylated heteroatom.
Furthermore, enzymes encoded within the BGC can be used as reagents
in a hybrid bio/chemo-catalytic synthesis to aid downstream preparation
of the GEM and analogs for SAR. Of the roughly 100,000 genomicized
strains in LifeBase, 900 bore a colocated assemblage of the <italic>ros</italic> genes, though the order of genes within the cluster
was not conserved. Targeted profiling of a subset of these strains
for the transcriptional activity of the <italic>ros</italic> genes
under various growth conditions enabled us efficiently to identify
a wild-type fungal strain that natively overproduces <bold>1</bold> and <bold>2</bold>.</p><p>Fungal proteins exhibit a high degree
of structural relatedness
to their functionally related human counterparts, with sequence and
structural conservation being especially high in enzyme active sites
and surfaces that engage in protein&#x02013;protein interactions. This
relatedness leads to species crossover, whereby a GEM evolved in fungi
to target fungal proteins engages the corresponding human protein.
Given the high relatedness of the fungal CDK Pho85 to human CDKs,
it comes as no surprise that <bold>1</bold> and <bold>2</bold> engage
human CDKs. Species crossover is however complicated by homologue
radiation; whereas there are 6 CDKs in fungi, the need for more specialized
orchestration of cell cycle related mechanisms in humans versus fungi
has resulted in radiation to 21 CDK homologues in humans. For radiated
human targets, sequence comparisons alone are unlikely to be predictive
of human homologue selectivity for a fungal-derived GEM, because interactions
with a drug are determined by a handful of amino acid residues on
the target, whereas phylogenetic analysis encompasses the entire protein
sequence. In the case of <bold>1</bold> and <bold>2</bold>, human
homologue selectivity is further complicated by the covalent inhibition
mechanism of these GEMs, with contributions from both noncovalent
binding (<italic>K</italic><sub>I</sub>) and the kinetics of covalent
bond formation (<italic>k</italic><sub>inact</sub>). Thus, while <bold>1</bold> and <bold>2</bold> show marked selectivity for human CDKs
over other protein kinases, selectivity among the human CDK homologues
is poorly predicted by phylogenetic distance (compare <xref rid="fig9" ref-type="fig">Figures <xref rid="fig9" ref-type="fig">9</xref></xref>A and <xref rid="fig2" ref-type="fig">2</xref>). To emphasize this point for proteins of therapeutic importance, <bold>1</bold> and <bold>2</bold> show little activity on CDK4 and CDK6
but have robust activity on CDK1 and CDK2, though the former are only
marginally more distant from Pho85 than the latter. However, in the
context of fungal kinases <bold>1</bold> and <bold>2</bold> show exquisite
selectivity for Pho85 versus the other 5 endogenous CDK homologues.</p><p>The structural features in kinase inhibitors that give rise to
selectivity can be subtle and difficult to predict. That is indeed
so in the case of <bold>1</bold> and <bold>2</bold>, for which the
kinetics of covalent bond formation make a major contribution to selectivity.
The aromatic ring of <bold>1</bold> and <bold>2</bold> slots into
the active site in a manner consistent with other orthosteric kinase
inhibitors, with the phenolic hydroxyl engaging the hinge region (<xref rid="fig6" ref-type="fig">Figure <xref rid="fig6" ref-type="fig">6</xref></xref>B). We were able
to gain insight into the binding interaction that precedes covalent
bond formation using the analog <bold>51</bold>, in which the vinylogous
anhydride of <bold>2</bold> is replaced by an amide-NH, rendering
the analog inert. The structure of CDK2/cyclin E bound to <bold>51</bold> (<xref rid="fig6" ref-type="fig">Figure <xref rid="fig6" ref-type="fig">6</xref></xref>C) shows
the molecule optimally positioned in the active site for nucleophilic
attack by Lys33. GEMs <bold>1</bold> and <bold>2</bold> are selective
by many orders of magnitude for Lys33 over other lysines in CDK2 as
well as lysines in other proteins, which in combination with the optimal
binding pose demonstrates that covalent bond formation with Lys33
is enzyme-activated, most likely by a combination of orbital steering
and enzyme-assisted lysine desolvation. Nearly all protein kinases
possess a lysine residue in the same position as Lys33 in CDK2, and
yet <bold>1</bold> and <bold>2</bold> are far from promiscuous kinase
inhibitors.</p><p>The origins of kinase selectivity in <bold>1</bold> and <bold>2</bold> are likely to derive from the substituents and
stereochemistry of
the GEMs, especially at the junction with the 7-membered ring (C5a)
and the adjacent C6. Both of these critical positions are, interestingly,
remote from the hinge-interacting region. The stereocenter at C7 may
be less important for selectivity, as <bold>1</bold> and <bold>2</bold> are stereoisomeric at this position, yet exhibit nearly identical
kinase selectivity. Our SAR studies provided further insights into
the role of these positions in determining selectivity. For example,
at equal concentrations the enantiomer of <bold>1</bold> is devoid
of kinase inhibitory activity when <bold>1</bold> and <bold>2</bold> show nearly complete inhibition. Analog <bold>38</bold>, stripped
of stereochemistry and substituents at C6 and C7, was drastically
reduced in CDK-inhibitory activity but had undergone reprogramming
to target a completely different kinase, CSNK1A1 (<xref rid="fig9" ref-type="fig">Figure <xref rid="fig9" ref-type="fig">9</xref></xref>D). This observation suggests
that a systematic SAR exploration of the tricyclic scaffold in <bold>1</bold> and <bold>2</bold> is warranted, as it is likely to yield
a family of novel Lys-targeting covalent kinase inhibitors, possibly
with high brain penetration. Finally, semisynthetic chloro-substitution
at C2 provided an analog with improved selectivity for CDK2 compared
to <bold>1</bold> and <bold>2</bold>, retaining good CDK2 activity
but reducing activity against several other CDKs (e.g., CDK7) and
against other protein kinases (e.g., MAP3K11) (compare <xref rid="fig9" ref-type="fig">Figure <xref rid="fig9" ref-type="fig">9</xref></xref>A,B).</p><p>A recent report
confirming our discovery that <bold>2</bold> targets
CDKs failed to observe a covalent binding mode, despite presentation
of a ligand-protein cocrystal structure (PDB ID <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="PDB" xlink:href="8OY2">8OY2</ext-link>).<sup><xref ref-type="bibr" rid="ref22">22</xref></sup> In our previous disclosure and as further elaborated here
we provide multiple lines of evidence, from intact mass spectrometry
to rigorous enzymological characterization and high-resolution structural
information, all confirming that <bold>1</bold> and <bold>2</bold> are irreversible covalent inhibitors that modify the active site
Lys residue (Lys33 in CDK2) of their kinase targets. The discrepancy
is most likely attributable to the fact that noncovalent binding was
reported from CDK2 in the absence of its obligate cyclin partner,
whereas this study utilized the relevant physiologic form of CDK2
in complex with its cognate cyclin E. Cyclins are essential binding
partners required to activate CDKs both in vitro and in vivo and,
since ATP interacts differently with these enzymes in the presence
and absence of the cyclin,<sup><xref ref-type="bibr" rid="ref38">38</xref></sup> it is straightforward
to imagine that the CDK would interact differently with inhibitors
that also bind the ATP site.</p><p>The molecule series reported here
has many interesting and promising
properties that differentiate them radically from existing orthosteric
kinase inhibitors. First, they have a rigid tricyclic ring system
devoid of nitrogen atoms, as opposed to the nitrogen-rich beads-on-a-string
structure of most human-designed kinase inhibitors. This difference
may underlie the high brain exposure seen with <bold>2</bold>, as
brain penetration in small molecule drugs is typically counter-associated
with rotatable bonds.<sup><xref ref-type="bibr" rid="ref39">39</xref></sup> Brain penetration
is a highly desirable feature of cancer drugs in general but even
more so in those being used to treat breast cancer, as metastasis
to the brain is commonly observed and is often aggressively lethal
in patients taking nonbrain-penetrant precision medicines.<sup><xref ref-type="bibr" rid="ref40">40</xref></sup> Second, this family of molecules possess highly
conditional enzyme-activated Lys-specific warheads, an attribute that
humans have found difficult to design but fungi have produced via
evolutionary selection. In cancer drugs that covalently attach to
Cys residues, mutational escape by genetic alteration of the Cys residue
is common, because there is strong selective pressure favoring such
mutation and little selective pressure against it.<sup><xref ref-type="bibr" rid="ref41">41</xref></sup> Similar mutational escape would be ineffective for molecules
of the <bold>1</bold>/<bold>2</bold> scaffold class, because the Lys
residue is essential for the catalytic activity of the kinase targets,
hence there is strong selective pressure against its loss. While the
most promising molecules presented here will require further optimization
to increase potency and to improve the modest &#x0223c;5-fold CDK2
versus CDK1 selectivity, the work detailed here provides substantial
enablement for that optimization campaign. Beyond CDKs, we expect
that this pharmacologically privileged scaffold will find broader
utility in the important and burgeoning field of kinase inhibition.</p><p>In a future publication, we will report the results of a comprehensive
genomic search detailing all BGCs in the LifeBase collection of over
100k fungal genomes having an ETaG predictive of the fungal and human
target of the encoded GEMs. Given the speed of retrieval and the structural
and mechanistic novelty of fungal GEMs, we expect that the TD<sup>3</sup> paradigm of drug discovery will make an increasingly visible
contribution to the transformative medicines of the future.</p></sec><sec id="sec4"><title>Experimental Section</title><sec id="sec4.1"><title>CDK Activity Assay</title><p>Kinase inhibition experiments were
performed using recombinant and commercial-available (Carna Biosciences,
ProQinase) cyclin-dependent kinases utilizing previously published
fluorescence-based kinase probes.<sup><xref ref-type="bibr" rid="ref42">42</xref></sup> First,
a 12-point dose curve of each compound was serially diluted in DMSO
in 96-well V-bottom plates (Costar #3357) from a 10 mM DMSO stock,
and 1 &#x003bc;L transferred to 384 well black flat bottom plates (Corning
#3575). For each CDK, a 5&#x000d7; solution of ATP and the corresponding
fluorogenic peptide substrate (AssayQuant Technologies, Inc.) were
prepared in Kinase Assay Buffer (50 mM HEPES, 10 mM MgCl2, 0.01% <italic>n</italic>-octyl &#x003b2;-<sc>d</sc> glucopyranoside (NOG), 50 &#x003bc;M
TCEP, pH 7.5) and 5 &#x003bc;L added to each well so the final concentrations
of ATP and peptide substrate were 1&#x000d7; <italic>K</italic><sub>m</sub> and 10 &#x003bc;M, respectively. Finally, a 1.2&#x000d7; solution of
CDK enzyme in Kinase Assay Buffer was prepared and added using the
instrument syringe of the ClarioStar 2 (BMG LabTech) to a final volume
of 25 &#x003bc;L. Final concentrations of enzyme and ATP were 2 nM and
25 &#x003bc;M for CDK2/cyclin E1, 4 nM and 25 &#x003bc;M for CDK1/cyclin
B1 and 20 nM and 50 &#x003bc;M for CDK7/cyclin H/MAT1. Once added, the
fluorescent signal (Ex 360 nm, Em 485 nm, Gain 1800) was measured
continuously over a 60 min period to produce a time course curve.</p><p>For compounds with fast <italic>k</italic><sub>inact</sub> kinetic
assays were performed by monitoring phosphorylation of a fluorescence-based
kinase probe (AQT0297, AssayQuant) by CDK2/cyclin E1 (Carna Biosciences)
using a stopped flow fluorescence spectrometer (SX-20, Applied Photophysics).
Two solutions were prepared for the runs: Solution A: ATP (50 &#x003bc;M)
and AQT0297 (10 &#x003bc;M) with varied concentrations of inhibitor
in a modified Kinase Assay Buffer (50 mM HEPES pH 7.5, 10 mM MgCl2,
0.01% <italic>n</italic>-octyl &#x003b2;-<sc>d</sc> glucopyranoside,
50 &#x003bc;M TCEP, 4% DMSO), and Solution B: CDK2/cyclin E1 (35 nM)
in the modified Kinase Assay Buffer were prepared. Each solution was
used to fill one syringe of the stopped flow system. Each analyte
concentration was flushed 5 times using the drive function followed
by three acquisitions with 0.5 s intervals (excitation 360 nm, PMT
filter 435 nm, voltage 520 V), and data was exported from the instrument
for fitting.</p><p>For time-dependent inhibitors, the time course
was fitted using
the following equation to determine the pseudo-first-order rate constant, <italic>k</italic><sub>obs</sub> for each inhibitor concentration<disp-formula id="ueq1"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jm4c01095_m001" position="anchor"/></disp-formula>where <italic>V</italic> is the initial rate
of fluorescence change; <italic>k</italic><sub>obs</sub> is the rate
constant for the progression of the rate from <italic>V</italic> to
zero; <italic>t</italic> is time; FI is fluorescence intensity and
BF is background fluorescence. Fitted <italic>k</italic><sub>obs</sub> were plotted against compound concentrations [I] to determine if
covalent inactivation shows either single-step or two-step inactivation
kinetics. For single-step inactivation kinetics, a linear fit of the
plot determines the <italic>k</italic><sub><italic>inact</italic></sub>/<italic>K</italic><sub>I</sub> value for the tested compound. For
two-step inactivation, the data was fitted using the following equation
to determine <italic>K</italic><sub>I</sub> and <italic>k</italic><sub>inact</sub> for each compound against the tested CDK enzyme,
and <italic>k</italic><sub>inact</sub>/<italic>K</italic><sub>I</sub> was calculated from those determined values.<disp-formula id="ueq2"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jm4c01095_m002" position="anchor"/></disp-formula></p><p>For reversible inhibitors, the slope
of the time course was determined
for each well through the ClarioStar analysis software (MARS, BMG
Labtech). Slopes values (<italic>S</italic>) were normalized against
positive (<italic>P</italic>, 100% inhibited) and negative (<italic>N</italic>, 0% inhibited) control wells using the following equation,
plotted against compound concentrations, and fitted to a four-parameter
nonlinear curve model shown below to determine the IC<sub>50</sub> value.<disp-formula id="ueq3"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jm4c01095_m003" position="anchor"/></disp-formula><disp-formula id="ueq4"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jm4c01095_m004" position="anchor"/></disp-formula></p></sec><sec id="sec4.2"><title>NanoLuc Bioluminescence Resonance Energy Transfer (NanoBRET)
Assay for Target Engagement</title><p>HEK293 cells were cotransfected
with CDK2-NanoLuc Fusion Vector (CDK2: NV2781) and CCNE1 Expression
Vector (CCNE1: NV2781); CDK1-NanoLuc Fusion Vector (CDK1: NV2701)
and CCNB1 Expression Vector (CCNB1: NV2601); or CDK7-NanoLuc Fusion
Vector (CDK7: NV2851) (Promega, Madison, WI) and Expression Vectors
CCNH1 and MNAT1 (GenScript, Piscataway, NJ). Cells were seeded at
20,000 cells/well in 96-well plates in DMEM media supplemented with
10% FBS. The compounds were serially diluted from a 10 mM DMSO stock
and tested at a top concentration of 33 &#x003bc;M with 3-fold dilution
in a 10-point dose curve. Cells were incubated for 2 h at 37 &#x000b0;C
5% CO<sub>2</sub> and performed per manufacturer&#x02019;s specifications
(Promega, Madison, WI). Tracer #9 (K-9; N2631) and Tracer #10 (K-10;
N2641) were added in appropriate wells. NanoBRET NanoGlo Substrate
and Extracellular NanoLuc Inhibitor were added, and donor (450 nm)
and acceptor (610 nm) emission were measured within 10 min on a ClarioStar
2. Mean corrected milliBRET units (mBU) was calculated as follows<disp-formula id="ueq5"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jm4c01095_m005" position="anchor"/></disp-formula></p></sec><sec id="sec4.3"><title>Cell Proliferation Assay</title><p>Ovarian cancer cell line,
OVCAR-3 cells were seeded at 3000 cells/well in 96-well plates in
RPMI media supplemented with 20% FBS + 10 &#x003bc;g/mL insulin for
24 h at 37 &#x000b0;C 5% CO<sub>2</sub>. The compounds were serially
diluted from a 10 mM DMSO stock and tested at a top concentration
of 33 &#x003bc;M with 3-fold dilution in an 8-point dose curve. Cells
were incubated for 5 days at 37 &#x000b0;C 5% CO<sub>2</sub>. For the
washout conditions, the same method was applied except media containing
DMSO or compound was removed after 4 h of treatment, then washed 2&#x000d7;
with 1&#x000d7; PBS and replaced with complete media without compound.</p><p>To determine the relative growth upon treatment, CellTiter-Glo
2.0 Viability Assay (Promega, Madison, WI) was performed per manufacturer&#x02019;s
specifications and luminescence was read on the ClarioSTAR1 with a
gain of 3100. Mean GI<sub>50</sub> values were determined using a
four-parameter fit determined by GraphPad Prism software.</p></sec><sec id="sec4.3.1"><title>pRb T821/826 AlphaLISA Assay</title><p>Phosphorylation of RbT821/826
was measured in OVCAR-3 cells using the Multiplex Surefire Ultra Phospho
Thr821/826/Total Rb Assay Kit MPSU-PTRB-N500 according to manufacturer&#x02019;s
specifications (Revvity, Waltham, MA). Cells were seeded at 25,000
cells/well in a 96 well plate in serum-free DMEM for 24&#x02013;30
h at 37 &#x000b0;C 5% CO<sub>2</sub>. Media was replaced the following
day with complete DMEM containing 20% FBS+ 10 &#x003bc;g/mL insulin
and treated for 18 h with either DMSO or compounds. The compounds
were serially diluted from a 10 mM DMSO stock and tested at a top
concentration of 10 &#x003bc;M with 3-fold dilution, to obtain a 9-pt
dose curve for pRb levels on an EnVision plate reader (PerkinElmer).
For the washout conditions, the same method was applied except media
containing DMSO or compound was removed after 4 h of treatment, then
washed 2&#x000d7; with 1&#x000d7; PBS and replaced with complete media without
compound. Data were processed with GraphPad Prism using a four-parameter
fit to calculate mean IC<sub>50</sub>.</p></sec><sec id="sec4.3.2"><title>In Vivo Pharmacology and Pharmacokinetics</title><p>Female NOG
mice were purchased from Taconic and implanted at 10&#x02013;16 weeks
old. Animals were housed for a minimum 3-day acclimation period for
all nonanesthesia-based procedures. Animals were housed in individual
HEPA ventilated cages (Innocage IVC, Innovive). Fluorescent lighting
was maintained on a 12-h cycle. Temperature and humidity were monitored,
recorded daily, and maintained at 68&#x02013;74 &#x000b0;F (20&#x02013;23
&#x000b0;C) and 30&#x02013;70% humidity, respectively. 2920X.10 18% soy
irradiated rodent feed (Teklad) was provided and available ad libitum.
Acidified water (pH 2.5&#x02013;3) (Aquavive, Innovive) was provided
and available ad libitum. female NOG mice were implanted with CRT_STAD_00292
tumor fragments subcutaneously into the right rear flank. The mice
were anesthetized using isoflurane induction. Animals were shaved
and surgically prepped using 70% isopropyl alcohol. A small incision
was made to the lower right rear flank of the mouse. A subcutaneous
space was created using gentle blunt dissection. A tumor fragment
was inserted into the subcutaneous pocket and a wound clip was applied
to seal the incision. Analgesic was administered. Tumor volumes were
recorded twice weekly using digital calipers. The length (<italic>L</italic>) and the width (<italic>W</italic>) of the tumors were
measured and tumor volumes were automatically calculated using the
following formula: 0.5 &#x000d7; <italic>L</italic> &#x000d7; <italic>W</italic>2. When tumors reached an average of 170 mm<sup>3</sup>, ranging
from 111&#x02013;262 mm<sup>3</sup>, 35 animals were randomized into
the respective treatment groups and dosed within 24 h. Body weights
were measured 2 times weekly following randomization and throughout
treatment. Animals were dosed at 30 or 100 mpk daily, q.d. for 14
days and monitored until animals reached a tumor volume of 1500 mm<sup>3</sup>, or humane end point, whichever occurred first. BW of the
mouse Body weight changes were calculated based on the first day of
treatment.</p><p>Percent inhibition was calculated as follows<disp-formula id="ueq6"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jm4c01095_m006" position="anchor"/></disp-formula><italic>T<sub>t</sub></italic> = mean tumor
volume of treated at time <italic>t</italic>, <italic>T</italic><sub>0</sub> = mean tumor volume of treated at time 0, <italic>C<sub>t</sub></italic> = mean tumor volume of control at time <italic>t</italic> and <italic>C</italic><sub>0</sub> = mean tumor volume of control
at time 0. One-way ANOVA, Dunnett&#x02019;s multiple comparison test
was performed.</p><p>Pharmacokinetic Assessment was conducted in Laboratory
Animal studies
following Institutional Animal Care and Use Committee Care, Welfare
for laboratory animals used including male Sprague&#x02013;Dawley rat,
male CD-1 mice following single intravenous and/or oral administration.
Blood samples were collected in EDTA collection tubes for plasma protein
precipitation followed by LC/MS/MS analysis. PK profile parameters
were analyzed by noncompartmental methods (WinNonlin Professional,
version 4.1).</p></sec><sec id="sec4.3.3"><title>Chemistry</title><sec id="sec4.3.3.1"><title>General Methods</title><p>All commercially available materials
were used as received without further purification. Air or moisture
sensitive reactions were carried out under an atmosphere of nitrogen.
Flash chromatography was conducted on Biotage instruments with the
silica gel cartridges and elution gradients indicated. Chiral SFC
was conducted on a Waters UPC2 or Agilent 1260 instrument using column
and elution system indicated. Reverse phase HPLC was conducted on
an ISCO instrument with Sunfire column unless otherwise specified.
NMR spectra were recorded on a Bruker 400 or 500 MHz spectrometer.
Chemical shifts (&#x003b4;) are quoted in parts per million (ppm) referenced
to the solvent peak. Coupling constants (<italic>J</italic>) are reported
in hertz (Hz). LC&#x02013;MS were recorded on Agilent instrument with
C18 column eluting with acetonitrile/water gradient with 0.1% formic
acid. All tested compounds were determined to be &#x02265;95% pure
by LC&#x02013;MS or analytical HPLC.</p></sec><sec id="sec4.3.3.2"><title>General Procedure for the Epimerase Reaction</title><p>To a 40
mL vial was added substrate (10 mg) as a solution in DMSO (0.29 mL),
aqueous epimerase enzyme solution (0.29 mL 400 &#x003bc;M) and TRIS
buffer (28.1 mL, 50 mM, pH 9.0). The vial was shaken for 90 min at
30 &#x000b0;C then 30 mL acetonitrile was added and the reaction filtered.
The resulting mixture was concentrated in vacuo and purified by reverse
phase HPLC to afford epimerized material.</p><sec id="sec4.3.3.3"><title>6,9-Dimethyl-1,4-dioxaspiro[4.5]deca-6,9-dien-8-one (<bold>12</bold>)</title><p>To a solution of PhI(OAc)<sub>2</sub> (131.8 g, 409.3
mmol, 4 equiv) in hexane (500 mL) was added 2,5-dimethylphenol (12.5
g, 102 mmol, 1 equiv) and ethylene glycol (82.6 g, 1.33 mol, 74.4
mL, 13 equiv) at 0 &#x000b0;C. The mixture was stirred at 25 &#x000b0;C
for 16 h. The reaction mixture was diluted with H<sub>2</sub>O (500
mL) and extracted with EtOAc (3 &#x000d7; 500 mL). The combined organic
phase was washed with brine (3 &#x000d7; 500 mL), dried with anhydrous
Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated in vacuum.
The residue was purified by flash chromatography (0&#x02013;10% EtOAc
in petroleum ether, 220 g column) to afford 6,9-dimethyl-1,4-dioxaspiro[4.5]deca-6,9-dien-8-one
(<bold>12</bold>) (18 g, 47% yield) as a yellow oil. LC&#x02013;MS <italic>m</italic>/<italic>z</italic> = 181.0 [M + H]<sup>+.</sup></p></sec><sec id="sec4.3.3.4"><title>1,4-Dimethyl-7-oxaspiro[bicyclo[4.1.0]heptane-2,2&#x02032;-[1,3]dioxolan]-3-en-5-one
(<bold>13</bold>)</title><p>To a solution of 6,9-dimethyl-1,4-dioxaspiro[4.5]deca-6,9-dien-8-one
(<bold>12</bold>) (10 g, 55.5 mmol, 1 equiv) in MeOH (200 mL) was
added H<sub>2</sub>O<sub>2</sub> (30% w/w, 23.6 g, 208 mmol, 20 mL,
3.75 equiv) and Na<sub>2</sub>CO<sub>3</sub> (1 M, 111 mL, 2 equiv)
at 0 &#x000b0;C. The mixture was degassed, purged with N<sub>2</sub> 3
times and stirred at 25 &#x000b0;C for 5 h. The reaction mixture was
quenched by the addition of aqueous Na<sub>2</sub>SO<sub>3</sub> (30
mL) at 0 &#x000b0;C, and then the reaction mixture was diluted with H<sub>2</sub>O (500 mL) and extracted with EtOAc (3 &#x000d7; 500 mL). The
combined organic phase was washed with brine (3 &#x000d7; 200 mL), dried
with anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated
in vacuum. The residue was purified by flash chromatography (0&#x02013;5%
EtOAc in petroleum ether, 80 g column) to afford 1,4-dimethyl-7-oxaspiro[bicyclo[4.1.0]heptane-2,2&#x02032;-[1,3]dioxolan]-3-en-5-one
(<bold>13</bold>) (2.3 g, 10% yield) as a yellow oil. LC&#x02013;MS <italic>m</italic>/<italic>z</italic> = 196.9 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) &#x003b4; 6.07 (ddd, <italic>J</italic> = 1.5, 3.6, 5.2 Hz, 1 H), 4.22&#x02013;4.14 (m, 1 H), 4.08 (brdd, <italic>J</italic> = 2.8, 6.5 Hz, 2 H), 4.03&#x02013;3.96 (m, 1 H), 3.28&#x02013;3.20
(m, 1 H), 1.76&#x02013;1.70 (m, 3 H), 1.45&#x02013;1.38 (m, 3 H).</p></sec><sec id="sec4.3.3.5"><title><italic>rac</italic>-Benzyl 2-(((6<italic>R</italic>,7<italic>R</italic>)-6-Hydroxy-6,9-dimethyl-8-oxo-1,4-dioxaspiro[4.5]dec-9-en-7-yl)oxy)-4-((4-methoxybenzyl)oxy)-3,6-dimethylbenzoate
(<bold>15</bold>)</title><p>A mixture of 1,4-dimethyl-7-oxaspiro[bicyclo[4.1.0]heptane-2,2&#x02032;-[1,3]dioxolan]-3-en-5-one
(<bold>13</bold>) (4.2 g, 1 equiv, 21 mmol) and benzyl 2-hydroxy-4-((4-methoxybenzyl)oxy)-3,6-dimethylbenzoate
(<bold>14</bold>) (25 g, 3 equiv, 64 mmol), NaOH (2.6 g, 3 equiv,
64 mmol) in ACN (400 mL) was degassed and purged with N<sub>2</sub> 3 times, and then the mixture was stirred at 65 &#x000b0;C for 72 h
under N<sub>2</sub> atmosphere. The reaction mixture was filtered
and concentrated under reduced pressure to give a residue. The residue
was purified by flash chromatography (1&#x02013;25% EtOAc in petroleum
ether) to afford <italic>rac</italic>-benzyl 2-(((6<italic>R</italic>,7<italic>R</italic>)-6-hydroxy-6,9-dimethyl-8-oxo-1,4-dioxaspiro[4.5]dec-9-en-7-yl)oxy)-4-((4-methoxybenzyl)oxy)-3,6-dimethylbenzoate
(<bold>15</bold>) (2.5 g, 20%) as a white solid. <sup>1</sup>H NMR
(400 MHz, CDCl<sub>3</sub>) &#x003b4; 7.47&#x02013;7.40 (m, 2H), 7.40&#x02013;7.31
(m, 5H), 6.92 (d, <italic>J</italic> = 8.8 Hz, 2H), 6.47 (s, 1H),
6.31 (d, <italic>J</italic> = 1.3 Hz, 1H), 5.41&#x02013;5.35 (m, 1H),
5.31&#x02013;5.25 (m, 1H), 5.03 (s, 1H), 4.97 (s, 2H), 4.91 (s, 1H),
4.31&#x02013;4.26 (m, 1H), 4.25&#x02013;4.16 (m, 1H), 4.12&#x02013;4.01
(m, 2H), 3.83 (s, 3H), 2.17 (s, 3H), 2.11 (s, 3H), 1.86 (d, <italic>J</italic> = 1.5 Hz, 3H), 1.31 (s, 3H).</p></sec><sec id="s0068"><title><italic>rac</italic>-Benzyl 2-(((6<italic>S</italic>,7<italic>R</italic>)-6-Hydroxy-6,9-dimethyl-8-oxo-1,4-dioxaspiro[4.5]dec-9-en-7-yl)oxy)-4-((4-methoxybenzyl)oxy)-3,6-dimethylbenzoate
(<bold>15c</bold> and <bold>15d</bold>)</title><p>Also isolated from
the above purification was the title compound (1.5 g, 12%) as a white
solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) &#x003b4; 7.47&#x02013;7.41
(m, 2H), 7.39&#x02013;7.29 (m, 5H), 6.92 (d, <italic>J</italic> = 8.5
Hz, 2H), 6.52 (s, 1H), 6.38 (s, 1H), 5.38&#x02013;5.27 (m, 2H), 5.02&#x02013;4.89
(m, 2H), 4.39 (s, 1H), 4.21&#x02013;4.02 (m, 4H), 3.83 (s, 3H), 3.64
(s, 1H), 2.23 (s, 3H), 2.02 (s, 3H), 1.84 (s, 3H), 1.29 (s, 3H).</p></sec><sec id="sec4.3.3.6"><title><italic>rac</italic>-Benzyl 4-Hydroxy-2-(((1<italic>R</italic>,6<italic>R</italic>)-6-methoxy-3,6-dimethyl-2,5-dioxocyclohex-3-en-1-yl)oxy)-3,6-dimethylbenzoate
(<bold>16</bold>)</title><p>Twelve batches of the following experiment
were conducted then combined before purification. To a solution of <italic>rac</italic>-benzyl 2-(((6<italic>R</italic>,7<italic>R</italic>)-6-hydroxy-6,9-dimethyl-8-oxo-1,4-dioxaspiro[4.5]dec-9-en-7-yl)oxy)-4-((4-methoxybenzyl)oxy)-3,6-dimethylbenzoate
(<bold>15</bold>) (500 mg, 1 equiv, 0.85 mmol) in THF (18 mL) was
added NaH (60% dispersion in mineral oil, 0.17 g, 5 equiv, 4.25 mmol)
at 0 &#x000b0;C for 50 min under N<sub>2</sub> atmosphere, then added
methyl trifluoromethanesulfonate (348 mg, 2.5 equiv, 2.12 mmol). The
mixture was stirred at 0 &#x000b0;C for 1 h under N<sub>2</sub> atmosphere.
The combined reaction mixture was poured into water (18 mL) and then
extracted with EtOAc (3 &#x000d7; 25 mL). The combined organic layers
were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated
under reduced pressure to give a residue. The residue was purified
by flash chromatography (1&#x02013;25% EtOAc in petroleum ether) to
afford <italic>rac</italic>-benzyl 2-(((6<italic>R</italic>,7<italic>R</italic>)-6-methoxy-6,9-dimethyl-8-oxo-1,4-dioxaspiro[4.5]dec-9-en-7-yl)oxy)-4-((4-methoxybenzyl)oxy)-3,6-dimethylbenzoate
(3.6 g, 58% yield) as a white solid. LC&#x02013;MS <italic>m</italic>/<italic>z</italic> = 603.3 [M + H]<sup>+</sup>. <sup>1</sup>H NMR
(400 MHz, CDCl<sub>3</sub>) &#x003b4; 7.49&#x02013;7.40 (m, 2H), 7.39&#x02013;7.29
(m, 5H), 6.92 (d, <italic>J</italic> = 8.6 Hz, 2H), 6.47 (s, 1H),
6.22 (d, <italic>J</italic> = 1.3 Hz, 1H), 5.39&#x02013;5.32 (m, 1H),
5.30&#x02013;5.21 (m, 2H), 4.98 (s, 2H), 4.26&#x02013;4.19 (m, 1H),
4.17&#x02013;4.07 (m, 2H), 4.05&#x02013;3.97 (m, 1H), 3.88&#x02013;3.78
(m, 3H), 3.55&#x02013;3.48 (m, 3H), 2.27 (s, 3H), 2.19 (s, 3H), 1.77
(d, <italic>J</italic> = 1.4 Hz, 3H), 1.57 (s, 2H), 1.55 (s, 3H).</p><p>To a solution of <italic>rac</italic>-benzyl 2-(((6<italic>R</italic>,7<italic>R</italic>)-6-methoxy-6,9-dimethyl-8-oxo-1,4-dioxaspiro[4.5]dec-9-en-7-yl)oxy)-4-((4-methoxybenzyl)oxy)-3,6-dimethylbenzoate
(4 g, 1 equiv, 7 mmol) in 1,3-dimethoxybenzene (18.34 g, 20 equiv,
0.13 mol) was added dropwise a mixture of 1,3-dimethoxybenzene (18.34
g, 20 equiv, 0.13 mol) and formic acid (305 mg, 4 mL, 1 equiv, 7 mmol).
The mixture was stirred at 25 &#x000b0;C for 16 h. The residue was purified
by flash chromatography (0&#x02013;10% EtOAc in petroleum ether, 40
g column) to afford <italic>rac</italic>-benzyl 4-hydroxy-2-(((1<italic>R</italic>,6<italic>R</italic>)-6-methoxy-3,6-dimethyl-2,5-dioxocyclohex-3-en-1-yl)oxy)-3,6-dimethylbenzoate
(<bold>16</bold>) (5.65 g, 62% yield) as a yellow solid. LC&#x02013;MS <italic>m</italic>/<italic>z</italic> = 439.0 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, THF-<italic>d</italic><sub>8</sub>) &#x003b4; 8.64&#x02013;8.55
(m, 1H), 7.32&#x02013;7.25 (m, 2H), 7.22&#x02013;7.10 (m, 3H), 6.47
(d, <italic>J</italic> = 1.5 Hz, 1H), 6.23 (s, 1H), 5.13&#x02013;5.07
(m, 1H), 5.02&#x02013;4.96 (m, 1H), 4.60 (s, 1H), 2.94 (s, 3H), 1.96
(s, 3H), 1.87 (s, 3H), 1.84&#x02013;1.82 (m, 3H), 1.61 (br s, 14H),
1.37&#x02013;1.29 (m, 4H).</p></sec><sec id="sec4.3.3.7"><title><italic>rac</italic>-Benzyl 4-Hydroxy-2-(((3<italic>R</italic>,4<italic>R</italic>)-4-methoxy-1,4-dimethyl-2,5-dioxo-7-oxabicyclo[4.1.0]heptan-3-yl)oxy)-3,6-dimethylbenzoate
(<bold>17</bold>)</title><p>To a solution of <italic>rac</italic>-benzyl
4-hydroxy-2-(((1<italic>R</italic>,6<italic>R</italic>)-6-methoxy-3,6-dimethyl-2,5-dioxocyclohex-3-en-1-yl)oxy)-3,6-dimethylbenzoate
(<bold>16</bold>) (1.5 g, 3.42 mmol, 1 equiv) in H<sub>2</sub>O<sub>2</sub> (30% w/w, 776 mg, 6.84 mmol, 0.65 mL, 2 equiv) and MeOH (40
mL) was added Na<sub>2</sub>CO<sub>3</sub> (1 M, 13.68 mL, 4 equiv).
The mixture was stirred at 25 &#x000b0;C for 10 min. The reaction mixture
was quenched by the addition of Na<sub>2</sub>SO<sub>3</sub> (30 mL)
and extracted with EtOAc (3 &#x000d7; 20 mL). The combined organic layers
were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated
under reduced pressure to give a residue. The residue was purified
by flash chromatography (1&#x02013;50% EtOAc in petroleum ether) to
afford <italic>rac</italic>-benzyl 4-hydroxy-2-(((3<italic>R</italic>,4<italic>R</italic>)-4-methoxy-1,4-dimethyl-2,5-dioxo-7-oxabicyclo[4.1.0]heptan-3-yl)oxy)-3,6-dimethylbenzoate
(<bold>17</bold>) (600 mg, 33% yield) as a white solid. LC&#x02013;MS <italic>m</italic>/<italic>z</italic> = 455.1 [M + H]<sup>+</sup>.</p></sec><sec id="sec4.3.3.8"><title><italic>rac</italic>-Benzyl 4-Hydroxy-2-(((3<italic>R</italic>,4<italic>S</italic>,5<italic>R</italic>)-5-hydroxy-4-methoxy-1,4-dimethyl-2-oxo-7-oxabicyclo[4.1.0]heptan-3-yl)oxy)-3,6-dimethylbenzoate
(<bold>18</bold>)</title><p>To a solution of <italic>rac</italic>-benzyl
4-hydroxy-2-(((3<italic>R</italic>,4<italic>R</italic>)-4-methoxy-1,4-dimethyl-2,5-dioxo-7-oxabicyclo[4.1.0]heptan-3-yl)oxy)-3,6-dimethylbenzoate
(<bold>17</bold>) (0.6 g, 1.32 mmol, 1 equiv) in toluene (20 mL) was
added Ti(i-PrO)<sub>4</sub> (1.13 g, 3.96 mmol, 1.17 mL, 3.0 equiv)
and 2-trimethylsilylethanol (0.63 g, 5.28 mmol, 4.0 equiv). The mixture
was stirred at 110 &#x000b0;C for 10 h. The reaction mixture was quenched
by the addition of H<sub>2</sub>O (25 mL), diluted with EtOAc (2 &#x000d7;
35 mL). The combined organic layers were concentrated under reduced
pressure to give a residue. The residue was purified by flash chromatography
(1&#x02013;50% EtOAc in petroleum ether) to afford <italic>rac</italic>-benzyl 4-hydroxy-2-(((3<italic>R</italic>,4<italic>S</italic>,5<italic>R</italic>)-5-hydroxy-4-methoxy-1,4-dimethyl-2-oxo-7-oxabicyclo[4.1.0]heptan-3-yl)oxy)-3,6-dimethylbenzoate
(<bold>18</bold>) (300 mg, 50% yield) as a white solid. LC&#x02013;MS <italic>m</italic>/<italic>z</italic> = 457.0 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<italic>d</italic><sub>6</sub>) &#x003b4; 9.72
(s, 1H), 7.50&#x02013;7.34 (m, 5H), 6.40 (s, 1H), 5.89 (d, <italic>J</italic> = 5.7 Hz, 1H), 5.24&#x02013;5.04 (m, 3H), 4.26 (d, <italic>J</italic> = 5.7 Hz, 1H), 3.01 (s, 3H), 2.06 (s, 3H), 1.99 (s, 3H),
1.39 (s, 3H), 1.02 (s, 3H).</p></sec><sec id="sec4.3.3.9"><title><italic>rac</italic>-Benzyl 2-(((1<italic>R</italic>,2<italic>S</italic>,3<italic>R</italic>)-3,4-Dihydroxy-2-methoxy-2,5-dimethyl-6-oxocyclohexyl)oxy)-4-hydroxy-3,6-dimethylbenzoate
(<bold>19</bold>)</title><p>To a solution of <italic>rac</italic>-benzyl
4-hydroxy-2-(((3<italic>R</italic>,4<italic>S</italic>,5<italic>R</italic>)-5-hydroxy-4-methoxy-1,4-dimethyl-2-oxo-7-oxabicyclo[4.1.0]heptan-3-yl)oxy)-3,6-dimethylbenzoate
(<bold>18</bold>) (0.3 g, 0.65 mol, 1 equiv) in EtOH (6 mL) was added
hydrazine hydrate (85% in water, 1.2 g, 20 mol, 0.38 mL, 30 equiv).
The mixture was stirred at 25 &#x000b0;C for 2 h. The reaction mixture
was quenched by the addition of HCl (2 M, 15 mL), and then extracted
with EtOAc (3 &#x000d7; 20 mL). The combined organic layers were washed
with brine (2 &#x000d7; 30 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated under reduced pressure to give a residue.
The residue was purified by flash chromatography (1&#x02013;50% EtOAc
in petroleum ether) to afford <italic>rac</italic>-benzyl 2-(((1<italic>R</italic>,2<italic>S</italic>,3<italic>R</italic>)-3,4-dihydroxy-2-methoxy-2,5-dimethyl-6-oxocyclohexyl)oxy)-4-hydroxy-3,6-dimethylbenzoate
(<bold>19</bold>) (0.2 g, 66% yield) as a white solid. LC&#x02013;MS <italic>m</italic>/<italic>z</italic> = 459.2 [M + H]<sup>+</sup>.</p></sec><sec id="sec4.3.3.10"><title><italic>rac</italic>-Benzyl 4-Hydroxy-2-(((1<italic>S</italic>,6<italic>R</italic>)-2-hydroxy-6-methoxy-3,6-dimethyl-4,5-dioxocyclohex-2-en-1-yl)oxy)-3,6-dimethylbenzoate
(<bold>20</bold>)</title><p>To a solution of <italic>rac</italic>-benzyl
2-(((1<italic>R</italic>,2<italic>S</italic>,3<italic>R</italic>)-3,4-dihydroxy-2-methoxy-2,5-dimethyl-6-oxocyclohexyl)oxy)-4-hydroxy-3,6-dimethylbenzoate
(<bold>19</bold>) (200 mg, 436 &#x003bc;mol, 1 equiv) in acetone (25
mL) was added Jones reagent (2.5 M, 349 &#x003bc;L, 2 equiv) at 0 &#x000b0;C.
The mixture was stirred at 0 &#x000b0;C for 0.2 h. The residue was diluted
with H<sub>2</sub>O (20 mL) and extracted with EtOAc (3 &#x000d7; 30
mL). The combined organic layers were washed with brine (2 &#x000d7;
20 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated
under reduced pressure to give a residue. The residue was purified
by prep-TLC (50% EtOAc in petroleum ether) to afford <italic>rac</italic>-benzyl 4-hydroxy-2-(((1<italic>S</italic>,6<italic>R</italic>)-2-hydroxy-6-methoxy-3,6-dimethyl-4,5-dioxocyclohex-2-en-1-yl)oxy)-3,6-dimethylbenzoate
(<bold>20</bold>) (40 mg, 20% yield) as a white solid. LC&#x02013;MS <italic>m</italic>/<italic>z</italic> = 455.1 [M + H]<sup>+</sup>.</p></sec><sec id="sec4.3.3.11"><title><italic>rac</italic>-Benzyl 2-(((1<italic>S</italic>,5<italic>R</italic>,6<italic>S</italic>)-2,5-Dihydroxy-6-methoxy-3,6-dimethyl-4-oxocyclohex-2-en-1-yl)oxy)-4-hydroxy-3,6-dimethylbenzoate
(<bold>21</bold>)</title><p>To a solution of <italic>rac</italic>-benzyl
4-hydroxy-2-(((1<italic>S</italic>,6<italic>R</italic>)-2-hydroxy-6-methoxy-3,6-dimethyl-4,5-dioxocyclohex-2-en-1-yl)oxy)-3,6-dimethylbenzoate
(<bold>20</bold>) (150 mg, 330 &#x003bc;mol, 1 equiv) in THF (9 mL)
was added Zn (432 mg, 6.6 mmol, 20 equiv) and saturated aqueous NH<sub>4</sub>Cl (9 mL, 30 equiv). The mixture was stirred at 0 &#x000b0;C
for 15 min. The reaction mixture was quenched by the addition of HCl
(2 M, 5 mL), and then diluted with H<sub>2</sub>O (15 mL) and extracted
with EtOAc (3 &#x000d7; 20 mL). The combined organic layers were washed
with brine (2 &#x000d7; 30 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated under reduced pressure to give a residue.
The residue was purified by prep-TLC (1&#x02013;25% EtOAc in petroleum
ether) to afford <italic>rac</italic>-benzyl 2-(((1<italic>S</italic>,5<italic>R</italic>,6<italic>S</italic>)-2,5-dihydroxy-6-methoxy-3,6-dimethyl-4-oxocyclohex-2-en-1-yl)oxy)-4-hydroxy-3,6-dimethylbenzoate
(<bold>21</bold>) (65 mg, 43% yield) as a white solid. LC&#x02013;MS <italic>m</italic>/<italic>z</italic> = 457.1 [M + H]<sup>+</sup>.</p></sec><sec id="sec4.3.3.12"><title><italic>rac</italic>-2-(((1<italic>S</italic>,5<italic>R</italic>,6<italic>S</italic>)-2,5-Dihydroxy-6-methoxy-3,6-dimethyl-4-oxocyclohex-2-en-1-yl)oxy)-4-hydroxy-3,6-dimethylbenzoic
Acid (<bold>22</bold>)</title><p>To a solution of <italic>rac</italic>-benzyl 2-(((1<italic>S</italic>,5<italic>R</italic>,6<italic>S</italic>)-2,5-dihydroxy-6-methoxy-3,6-dimethyl-4-oxocyclohex-2-en-1-yl)oxy)-4-hydroxy-3,6-dimethylbenzoate
(<bold>21</bold>) (65 mg, 0.14 mmol, 1 equiv) in THF (3 mL) was added
Pd/C (10 wt %, 25 mg). The suspension was degassed under vacuum and
purged with H<sub>2</sub>. The mixture was stirred under H<sub>2</sub> (15 psi) at 25 &#x000b0;C for 1 h. The reaction mixture was concentrated
under reduced pressure to afford <italic>rac</italic>-2-(((1<italic>S</italic>,5<italic>R</italic>,6<italic>S</italic>)-2,5-dihydroxy-6-methoxy-3,6-dimethyl-4-oxocyclohex-2-en-1-yl)oxy)-4-hydroxy-3,6-dimethylbenzoic
acid (<bold>22</bold>) (45 mg, 86% yield) was obtained as a white
solid which was used into the next step without further purification.
LC&#x02013;MS <italic>m</italic>/<italic>z</italic> = 366.9 [M + H]<sup>+</sup>.</p></sec><sec id="sec4.3.3.13"><title><italic>rac</italic>-(5a<italic>S</italic>,6<italic>S</italic>,7<italic>R</italic>)-3,7-Dihydroxy-6-methoxy-1,4,6,9-tetramethyl-6,7-dihydro-11<italic>H</italic>-dibenzo[<italic>b</italic>,<italic>e</italic>][1,4]dioxepine-8,11(5aH)-dione
(<bold>23</bold>)</title><p>To a solution of 4-hydroxy-2-(((1<italic>S</italic>,2<italic>R</italic>,3<italic>R</italic>)-3-hydroxy-2-methoxy-2,5-dimethyl-4,6-dioxocyclohexyl)oxy)-3,6-dimethylbenzoic
acid (<bold>22</bold>) (45 mg, 1 equiv, 0.12 mmol) in DCM (5 mL) was
added TFAA (0.10 g, 69 &#x003bc;L, 4 equiv, 0.49 mmol) at 25 &#x000b0;C.
The mixture was stirred at 25 &#x000b0;C for 30 min. The reaction was
diluted with H<sub>2</sub>O (25 mL), and then extracted with EtOAc
(3 &#x000d7; 15 mL). The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated under reduced pressure
to give a residue. The residue was purified by prep-TLC (25% EtOAc
in petroleum ether) to afford <italic>rac</italic>-(5a<italic>S</italic>,6<italic>S</italic>,7<italic>R</italic>)-3,7-dihydroxy-6-methoxy-1,4,6,9-tetramethyl-6,7-dihydro-11<italic>H</italic>-dibenzo[<italic>b</italic>,<italic>e</italic>][1,4]dioxepine-8,11(5aH)-dione
(18 mg, 42% yield) as a white solid. LC&#x02013;MS <italic>m</italic>/<italic>z</italic> = 349.0 [M + H]<sup>+</sup>. <sup>1</sup>H NMR
(400 MHz, THF-<italic>d</italic><sub>8</sub>) &#x003b4; 9.12 (s, 1H),
6.33 (s, 1H), 4.79 (s, 1H), 4.30 (d, <italic>J</italic> = 4.0 Hz,
1H), 4.25 (d, <italic>J</italic> = 4.1 Hz, 1H), 3.22 (s, 3H), 2.25
(s, 3H), 1.97 (s, 3H), 1.55 (s, 3H).</p></sec><sec id="sec4.3.3.14"><title>(5a<italic>S</italic>,6<italic>S</italic>,7<italic>R</italic>)-3,7-Dihydroxy-6-methoxy-1,4,6,9-tetramethyl-6,7-dihydro-11<italic>H</italic>-dibenzo[<italic>b</italic>,<italic>e</italic>][1,4]dioxepine-8,11(5aH)-dione
(<bold>1</bold>)</title><p>The racemate (<bold>23</bold>) (18 mg) was
purified by chiral SFC chromatography (Chiralpak AS (250 mm &#x000d7;
30 mm, 10 &#x003bc;m); 25% EtOH in CO<sub>2</sub>) to afford the title
compound (<bold>1</bold>) (5.46 mg, 30% yield) as a white solid. LC&#x02013;MS <italic>m</italic>/<italic>z</italic> = 349.2 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, THF-<italic>d</italic><sub>8</sub>) &#x003b4; 9.11
(s, 1H), 6.42 (s, 1H), 4.89 (s, 1H), 4.36 (s, 1H), 3.33 (s, 3H), 2.36
(s, 3H), 2.08 (s, 3H), 1.66 (s, 3H).</p></sec><sec id="sec4.3.3.15"><title>(5a<italic>R</italic>,6<italic>R</italic>,7<italic>S</italic>)-3,7-Dihydroxy-6-methoxy-1,4,6,9-tetramethyl-6,7-dihydro-11<italic>H</italic>-dibenzo[<italic>b</italic>,<italic>e</italic>][1,4]dioxepine-8,11(5aH)-dione
(<bold>24</bold>)</title><p>Also isolated from the above resolution
was the title compound (<bold>24</bold>) (5.57 mg, 31% yield) as a
white solid. LC&#x02013;MS <italic>m</italic>/<italic>z</italic> =
349.2 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, THF-<italic>d</italic><sub>8</sub>) &#x003b4; 9.11 (s, 1H), 6.42 (s, 1H), 4.89
(s, 1H), 4.36 (s, 1H), 3.33 (s, 3H), 2.36 (s, 3H), 2.08 (s, 3H), 1.66
(s, 3H).</p></sec><sec id="sec4.3.3.16"><title>(5a<italic>S</italic>,6<italic>S</italic>,7<italic>S</italic>)-3,7-Dihydroxy-6-methoxy-1,4,6,9-tetramethyl-6,7-dihydro-11<italic>H</italic>-dibenzo[<italic>b</italic>,<italic>e</italic>][1,4]dioxepine-8,11(5aH)-dione
(<bold>2</bold>)</title><p>Using the general procedure for the epimerization
(0.46 mg, 1.3 &#x003bc;mol, 11%) as a white solid. LC&#x02013;MS <italic>m</italic>/<italic>z</italic> = 346.8 [M &#x02013; H]<sup>&#x02212;</sup>. <sup>1</sup>H NMR (500 MHz, THF-<italic>d</italic><sub>8</sub>)
&#x003b4; 9.24 (s, 1H), 6.50 (s, 1H), 5.04 (q, <italic>J</italic> =
2.0 Hz, 1H), 4.54 (d, <italic>J</italic> = 3.2 Hz, 1H), 4.23 (d, <italic>J</italic> = 2.9 Hz, 1H), 3.44 (s, 3H), 2.44 (s, 3H), 2.18 (s, 3H),
1.86 (d, <italic>J</italic> = 1.9 Hz, 3H), 1.15 (s, 3H).</p></sec><sec id="sec4.3.3.17"><title><italic>rac</italic>-(5a<italic>S</italic>,6<italic>R</italic>,7<italic>S</italic>)-3,7-Dihydroxy-6-methoxy-1,4,6,9-tetramethyl-6,7-dihydro-11<italic>H</italic>-dibenzo[<italic>b</italic>,<italic>e</italic>][1,4]dioxepine-8,11(5aH)-dione
(<bold>26</bold>)</title><p>To a solution of <italic>rac</italic>-benzyl
2-(((6<italic>S</italic>,7<italic>R</italic>)-6-hydroxy-6,9-dimethyl-8-oxo-1,4-dioxaspiro[4.5]dec-9-en-7-yl)oxy)-4-((4-methoxybenzyl)oxy)-3,6-dimethylbenzoate
(<bold>15c</bold> and <bold>15d</bold>) (1 g, 1 equiv, 2 mmol) and
MeI (5 g, 2 mL, 20 equiv, 0.03 mol) in THF (40 mL) was added NaH (60%
dispersion in mineral oil, 0.3 g, 3 equiv, 8 mmol) at 0 &#x000b0;C. The
mixture was stirred at 0 &#x000b0;C for 1 h. The mixture was diluted
with H<sub>2</sub>O (20 mL) and extracted with EtOAc (3 &#x000d7; 40
mL). The combined organic layers were washed with brine (50 mL), dried
over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated under
reduced pressure to give a residue. The residue was purified by flash
chromatography (25% EtOAc in petroleum ether) to afford <italic>rac</italic>-benzyl 2-(((6<italic>S</italic>,7<italic>R</italic>)-6-methoxy-6,9-dimethyl-8-oxo-1,4-dioxaspiro[4.5]dec-9-en-7-yl)oxy)-4-((4-methoxybenzyl)oxy)-3,6-dimethylbenzoate
(600 mg, 60% yield) was obtained as yellow oil. LC&#x02013;MS <italic>m</italic>/<italic>z</italic> = 603.3 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) &#x003b4; 7.46 (br d, <italic>J</italic> = 7.0 Hz, 2H), 7.38&#x02013;7.30 (m, 5H), 6.92 (br d, <italic>J</italic> = 8.3 Hz, 2H), 6.89&#x02013;6.89 (m, 1H), 6.48 (s, 1H), 6.26 (s,
1H), 5.31 (s, 2H), 5.12 (s, 1H), 4.97 (s, 2H), 4.19&#x02013;4.04 (m,
4H), 3.83 (s, 3H), 3.41 (s, 3H), 2.24&#x02013;2.19 (m, 3H), 2.18 (s,
3H), 1.85&#x02013;1.75 (m, 3H), 1.39 (s, 3H).</p><p>To a solution of <italic>rac</italic>-benzyl 2-(((6<italic>S</italic>,7<italic>R</italic>)-6-methoxy-6,9-dimethyl-8-oxo-1,4-dioxaspiro[4.5]dec-9-en-7-yl)oxy)-4-((4-methoxybenzyl)oxy)-3,6-dimethylbenzoate
(6.4 g, 1 equiv, 11 mmol) in 1,3-dimethoxybenzene (29 g, 20 equiv,
0.21 mol) was added formic acid (20 g, 40 equiv, 0.42 mol). The mixture
was stirred at 50 &#x000b0;C for 16 h. The mixture was diluted with H<sub>2</sub>O (20 mL) and extracted with EtOAc (3 &#x000d7; 40 mL). The combined
organic layers were washed with brine (50 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated under reduced pressure
to give a residue. The residue was purified by flash chromatography
(25% EtOAc in petroleum ether) to afford <italic>rac</italic>-benzyl
4-hydroxy-2-(((1<italic>R</italic>,6<italic>S</italic>)-6-methoxy-3,6-dimethyl-2,5-dioxocyclohex-3-en-1-yl)oxy)-3,6-dimethylbenzoate
(3.4 g, 73% yield) as brown oil. LC&#x02013;MS <italic>m</italic>/<italic>z</italic> = 439.3 [M + H]<sup>+</sup>.</p><p>To a solution of <italic>rac</italic>-benzyl 4-hydroxy-2-(((1<italic>R</italic>,6<italic>S</italic>)-6-methoxy-3,6-dimethyl-2,5-dioxocyclohex-3-en-1-yl)oxy)-3,6-dimethylbenzoate
(1.2 g, 1 equiv, 2.7 mmol) and H<sub>2</sub>O<sub>2</sub> (30% w/w,
0.34 g, 0.31 mL, 1.1 equiv, 3.0 mmol) in MeOH (30 mL)was added Na<sub>2</sub>CO<sub>3</sub> (0.87 g, 8.2 mL, 1 M, 3 equiv, 8.2 mmol) at
0 &#x000b0;C. The mixture was stirred at 25 &#x000b0;C for 16 h. The mixture
was quenched with saturated aqueous NaS<sub>2</sub>O<sub>3</sub> and
adjusted to pH 6&#x02013;7 (1 N HCl<sub>(aq)</sub>). The mixture was
diluted with H<sub>2</sub>O (5 mL), extracted with EtOAc (3 &#x000d7;
20 mL). The combined organic layers were washed with brine (20 mL),
dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated
under reduced pressure to give a residue. The residue was purified
by flash chromatography (0&#x02013;30% EtOAc in petroleum ether, 40
g column) to give <italic>rac</italic>-benzyl 4-hydroxy-2-(((3<italic>R</italic>,4<italic>S</italic>)-4-methoxy-1,4-dimethyl-2,5-dioxo-7-oxabicyclo[4.1.0]heptan-3-yl)oxy)-3,6-dimethylbenzoate
(980 mg, 79% yield) as yellow oil. LC&#x02013;MS <italic>m</italic>/<italic>z</italic> = 455.1 [M + H]<sup>+</sup>.</p><p>To a solution
of <italic>rac</italic>-benzyl 4-hydroxy-2-(((3<italic>R</italic>,4<italic>S</italic>)-4-methoxy-1,4-dimethyl-2,5-dioxo-7-oxabicyclo[4.1.0]heptan-3-yl)oxy)-3,6-dimethylbenzoate
(4.6 g, 1 equiv, 10 mmol) in toluene (140 mL) were added titanium(IV)
isopropoxide (8.6 g, 9.2 mL, 3 equiv, 30 mmol) and 2-(trimethylsilyl)ethan-1-ol
(4.8 g, 4 equiv, 40 mmol). The mixture was stirred at 110 &#x000b0;C
for 10 h. The mixture was quenched with H<sub>2</sub>O (100 mL) and
extracted with EtOAc (3 &#x000d7; 200 mL). The combined organic layers
were washed with brine (200 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated under reduced pressure to give a residue.
The residue was purified by flash chromatography (0&#x02013;20% EtOAc
in petroleum ether, 80 g column) to afford <italic>rac</italic>-benzyl
4-hydroxy-2-(((3<italic>R</italic>,4<italic>R</italic>,5<italic>R</italic>)-5-hydroxy-4-methoxy-1,4-dimethyl-2-oxo-7-oxabicyclo[4.1.0]heptan-3-yl)oxy)-3,6-dimethylbenzoate
(2.6 g, 5.7 mmol, 56%) as yellow oil. LC&#x02013;MS <italic>m</italic>/<italic>z</italic> = 457.2 [M + H]<sup>+</sup>. <sup>1</sup>H NMR
(400 MHz, CDCl<sub>3</sub>) &#x003b4; 7.49 (s, 2H), 7.43&#x02013;7.33
(m, 3H), 6.35 (s, 1H), 5.32 (d, <italic>J</italic> = 17.1 Hz, 2H),
5.24 (br s, 1H), 5.19 (s, 1H), 3.78&#x02013;3.70 (m, 1H), 3.50 (s,
3H), 3.31 (s, 1H), 2.93 (d, <italic>J</italic> = 11.5 Hz, 1H), 2.25
(s, 3H), 2.14 (s, 3H), 1.49 (s, 3H), 1.39 (s, 3H).</p><p>To a solution
of <italic>rac</italic>-benzyl 4-hydroxy-2-(((3<italic>R</italic>,4<italic>R</italic>,5<italic>R</italic>)-5-hydroxy-4-methoxy-1,4-dimethyl-2-oxo-7-oxabicyclo[4.1.0]heptan-3-yl)oxy)-3,6-dimethylbenzoate
(700 mg, 1 equiv, 1.53 mmol) in EtOH (4.2 mL) was added hydrazine
hydrate (85% solution in water, 4.33 g, 4.20 mL, 48 equiv, 73.6 mmol).
The mixture was stirred at 25 &#x000b0;C for 16 h. The mixture was diluted
with H<sub>2</sub>O (20 mL), extracted with EA (3 &#x000d7; 20 mL). The
combined organic layers were washed with brine (20 mL), dried over
Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated under reduced
pressure to give a residue. The mixtures were purified by flash chromatography
(0&#x02013;100% EtOAc in petroleum ether, 20 g column) to give <italic>rac</italic>-benzyl 2-(((1<italic>R</italic>,2<italic>R</italic>,3<italic>R</italic>)-3,4-dihydroxy-2-methoxy-2,5-dimethyl-6-oxocyclohexyl)oxy)-4-hydroxy-3,6-dimethylbenzoate
(350 mg, 763 &#x003bc;mol, 50%) as a yellow solid. LC&#x02013;MS <italic>m</italic>/<italic>z</italic> = 459.3 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) &#x003b4; 7.52&#x02013;7.46 (m, 2
H), 7.45&#x02013;7.35 (m, 3 H), 6.37 (s, 1 H), 5.44 (d, <italic>J</italic> = 12.0 Hz, 1 H), 5.34&#x02013;5.26 (m, 1 H), 5.19 (d, <italic>J</italic> = 12.0 Hz, 1 H), 4.60 (d, <italic>J</italic> = 1.0 Hz, 1 H), 3.52&#x02013;3.49
(m, 3 H), 3.44&#x02013;3.35 (m, 1 H), 3.04 (br d, <italic>J</italic> = 8.9 Hz, 1 H), 2.28 (s, 3 H), 2.18&#x02013;2.13 (m, 3 H), 1.53&#x02013;1.49
(m, 3 H), 1.08 (d, <italic>J</italic> = 6.4 Hz, 3 H).</p><p>To a solution
of <italic>rac</italic>-benzyl 2-(((1<italic>R</italic>,2<italic>R</italic>,3<italic>R</italic>)-3,4-dihydroxy-2-methoxy-2,5-dimethyl-6-oxocyclohexyl)oxy)-4-hydroxy-3,6-dimethylbenzoate
(980 mg, 1 equiv, 2.14 mmol) in acetone (64 mL) was added Jones reagent
(847 mg, 0.65 mL, 2 equiv, 4.27 mmol) at &#x02212;10 &#x000b0;C. The mixture
was stirred at 25 &#x000b0;C for 1 h. The mixture was quenched with H<sub>2</sub>O (30 mL), extracted with DCM (3 &#x000d7; 60 mL). The combined
organic layers were washed with brine (50 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated under reduced pressure
to give a residue. The residue was purified by reverse phase HPLC
(36&#x02013;76% acetonitrile in water, 0.1% HCl) to afford <italic>rac</italic>-benzyl 4-hydroxy-2-(((1<italic>S</italic>,6<italic>S</italic>)-2-hydroxy-6-methoxy-3,6-dimethyl-4,5-dioxocyclohex-2-en-1-yl)oxy)-3,6-dimethylbenzoate
(190 mg, 418 &#x003bc;mol, 20%) as yellow solid. LC&#x02013;MS <italic>m</italic>/<italic>z</italic> = 455.1 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) &#x003b4; 7.42&#x02013;7.37 (m, 3
H), 7.34&#x02013;7.30 (m, 2 H), 6.83 (s, 1 H), 6.40 (s, 1 H), 5.31
(d, <italic>J</italic> = 12.0 Hz, 1 H), 5.23&#x02013;5.16 (m, 1 H),
5.05&#x02013;4.88 (m, 1 H), 4.69 (s, 1 H), 3.30 (s, 3 H), 2.18 (s,
3 H), 2.15 (s, 3 H), 1.91 (s, 3 H), 1.44 (s, 3 H).</p><p>To a solution
of <italic>rac</italic>-benzyl 4-hydroxy-2-(((1<italic>S</italic>,6<italic>S</italic>)-2-hydroxy-6-methoxy-3,6-dimethyl-4,5-dioxocyclohex-2-en-1-yl)oxy)-3,6-dimethylbenzoate
(170 mg, 1 equiv, 0.37 mmol) in THF (20 mL) and saturated aqueous
NH<sub>4</sub>Cl (4 mL) was added zinc (489 mg, 20 equiv, 7.48 mmol)
at 0 &#x000b0;C. The mixture was stirred at 0 &#x000b0;C for 10 min, then
filtered. The filtrate was concentrated under reduced pressure to
give a residue. The residue was purified by prep-TLC (50% EtOAc in
petroleum ether) to give <italic>rac</italic>-benzyl 2-(((1<italic>S</italic>,5<italic>S</italic>,6<italic>R</italic>)-2,5-dihydroxy-6-methoxy-3,6-dimethyl-4-oxocyclohex-2-en-1-yl)oxy)-4-hydroxy-3,6-dimethylbenzoate
(100 mg, 0.22 mmol, 59%) as yellow oil. LC&#x02013;MS <italic>m</italic>/<italic>z</italic> = 457.0 [M + H]<sup>+</sup>. <sup>1</sup>H NMR
(400 MHz, CDCl<sub>3</sub>) &#x003b4; 7.65 (s, 1 H), 7.51 (br d, <italic>J</italic> = 6.5 Hz, 1 H), 7.44 (br d, <italic>J</italic> = 6.5 Hz,
2 H), 7.41&#x02013;7.35 (m, 2 H), 6.48 (s, 1 H), 5.68 (d, <italic>J</italic> = 11.4 Hz, 1 H), 5.23&#x02013;4.91 (m, 3 H), 3.91 (d, <italic>J</italic> = 1.7 Hz, 1 H), 3.37&#x02013;3.34 (m, 3 H), 3.23 (br d, <italic>J</italic> = 11.7 Hz, 1 H), 2.36 (s, 3 H), 2.22 (s, 3 H), 1.84 (d, <italic>J</italic> = 1.3 Hz, 3 H), 1.08 (s, 3 H).</p><p>To a solution of <italic>rac</italic>-benzyl 2-(((1<italic>S</italic>,5<italic>S</italic>,6<italic>R</italic>)-2,5-dihydroxy-6-methoxy-3,6-dimethyl-4-oxocyclohex-2-en-1-yl)oxy)-4-hydroxy-3,6-dimethylbenzoate
(50 mg, 1 equiv, 0.11 mmol) in THF (1 mL) was added Pd/C (10 wt %,
12 mg). The mixture was degassed under vacuum and purged with H<sub>2</sub>. The mixture was stirred under H<sub>2</sub> (15 psi) at
25 &#x000b0;C for 2 h. The mixture was filtered and the filtrate was
concentrated under reduced pressure to afford <italic>rac</italic>-2-(((1<italic>S</italic>,5<italic>S</italic>,6<italic>R</italic>)-2,5-dihydroxy-6-methoxy-3,6-dimethyl-4-oxocyclohex-2-en-1-yl)oxy)-4-hydroxy-3,6-dimethylbenzoic
acid (30 mg, 75% yield) as yellow oil which was used without purification.
LC&#x02013;MS <italic>m</italic>/<italic>z</italic> = 389.0 [M + Na]<sup>+</sup>.</p><p>Two batches of the following reaction were conducted.
To a solution
of <italic>rac</italic>-2-(((1<italic>S</italic>,5<italic>S</italic>,6<italic>R</italic>)-2,5-dihydroxy-6-methoxy-3,6-dimethyl-4-oxocyclohex-2-en-1-yl)oxy)-4-hydroxy-3,6-dimethylbenzoic
acid (35 mg, 1 equiv, 96 &#x003bc;mol) in DCM (7 mL) was added TFAA
(80 mg, 4 equiv, 0.38 mmol). The mixture was stirred at 25 &#x000b0;C
for 30 min. The combined reaction mixtures were diluted with H<sub>2</sub>O (10 mL) and extracted with DCM (3 &#x000d7; 10 mL). The combined
organic layers were washed with brine (10 mL), dried with anhydrous
Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated under reduced
pressure to give a residue. The residue was purified by prep-TLC (33%
EtOAc in petroleum ether) to afford <italic>rac</italic>-(5a<italic>S</italic>,6<italic>R</italic>,7<italic>R</italic>)-3,7-dihydroxy-6-methoxy-1,4,6,9-tetramethyl-6,7-dihydro-11<italic>H</italic>-dibenzo[<italic>b</italic>,<italic>e</italic>][1,4]dioxepine-8,11(5aH)-dione
(<bold>26</bold>) (26 mg, 39% yield) as a yellow solid. LC&#x02013;MS <italic>m</italic>/<italic>z</italic> = 349.2 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, THF-<italic>d</italic><sub>8</sub>) &#x003b4; 9.05
(br s, 1 H), 6.40 (s, 1 H), 5.20 (d, <italic>J</italic> = 2.3 Hz,
1 H), 4.64 (br s, 1 H), 4.12 (s, 1 H), 3.16 (s, 3 H), 2.30 (s, 3 H),
2.11 (s, 3 H), 1.78 (d, <italic>J</italic> = 2.1 Hz, 3 H), 1.76 (s,
3 H).</p></sec><sec id="sec4.3.3.18"><title>(5a<italic>S</italic>,6<italic>R</italic>,7<italic>S</italic>)-3,7-Dihydroxy-6-methoxy-1,4,6,9-tetramethyl-6,7-dihydro-11<italic>H</italic>-dibenzo[<italic>b</italic>,<italic>e</italic>][1,4]dioxepine-8,11(5aH)-dione
(<bold>27</bold>)</title><p>The racemate (<bold>26</bold>) (24 mg)
was purified by chiral SFC chromatography (Chiralcel OJ, 250 mm &#x000d7;
30 mm, 10 &#x003bc;m, 20% EtOH in CO<sub>2</sub>) to afford the title
compound (<bold>27</bold>) (10.8 mg, 31.0 &#x003bc;mol, 32%) as a white
solid. LC&#x02013;MS <italic>m</italic>/<italic>z</italic> = 349.0
[M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, THF-<italic>d</italic><sub>8</sub>) &#x003b4; 8.94 (s, 1H), 6.38 (s, 1H), 5.20 (q, <italic>J</italic> = 2.1 Hz, 1H), 4.62 (s, 1H), 4.11 (br s, 1H), 3.16 (s,
3H), 2.30 (s, 3H), 2.11 (s, 3H), 1.78 (d, <italic>J</italic> = 2.1
Hz, 3H), 1.76 (s, 3H).</p></sec><sec id="sec4.3.3.19"><title>(5a<italic>R</italic>,6<italic>S</italic>,7<italic>R</italic>)-3,7-Dihydroxy-6-methoxy-1,4,6,9-tetramethyl-6,7-dihydro-11<italic>H</italic>-dibenzo[<italic>b</italic>,<italic>e</italic>][1,4]dioxepine-8,11(5aH)-dione
(<bold>29</bold>)</title><p>Also isolated from the above resolution
was the title compound (<bold>29</bold>) (10.6 mg, 30.4 &#x003bc;mol,
32%) as a white solid. LC&#x02013;MS <italic>m</italic>/<italic>z</italic> = 349.0 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, THF-<italic>d</italic><sub>8</sub>) &#x003b4; 8.94 (s, 1H), 6.38 (s, 1H), 5.20
(q, <italic>J</italic> = 2.2 Hz, 1H), 4.62 (br s, 1H), 4.11 (s, 1H),
3.16 (s, 3H), 2.30 (s, 3H), 2.11 (s, 3H), 1.78 (d, <italic>J</italic> = 2.2 Hz, 3H), 1.76 (s, 3H).</p></sec><sec id="sec4.3.3.20"><title>(5a<italic>S</italic>,6<italic>R</italic>,7<italic>R</italic>)-3,7-Dihydroxy-6-methoxy-1,4,6,9-tetramethyl-6,7-dihydro-11<italic>H</italic>-dibenzo[<italic>b</italic>,<italic>e</italic>][1,4]dioxepine-8,11(5aH)-dione
(<bold>28</bold>)</title><p>Using the general procedure for the epimerization,
(0.62 mg, 1.8 &#x003bc;mol, 6%) as a white solid. LC&#x02013;MS <italic>m</italic>/<italic>z</italic> = 346.8 [M &#x02013; H]<sup>&#x02212;</sup>. <sup>1</sup>H NMR (500 MHz, THF-<italic>d</italic><sub>8</sub>)
&#x003b4; 9.02 (s, 1H), 6.41 (s, 1H), 5.12 (t, <italic>J</italic> =
1.3 Hz, 1H), 4.85 (s, 1H), 4.25 (s, 1H), 3.29 (s, 3H), 2.35 (s, 3H),
2.13 (s, 3H), 1.38 (s, 3H), 1.30 (s, 3H).</p></sec><sec id="sec4.3.3.21"><title>2-Methyl-3-oxocyclohex-1-en-1-yl benzoate (<bold>32a</bold>)</title><p>2-Methyl-1,3-cyclohexadione (2.5 g, 1 equiv, 20 mmol), DMAP (300
mg, 0.12 equiv, 2.5 mmol) and triethylamine (3.5 mL, 1.25 equiv, 25
mmol) were placed in a vial with DCM (15 mL). Benzoyl chloride (3
mL, 1.25 equiv, 25 mmol) was added portion wise. The reaction was
stirred at room temperature overnight. The reaction was then quenched
with saturated aqueous sodium bicarbonate solution. The organics were
washed with brine and concentrated. The residue was purified by flash
chromatography (0&#x02013;20% EtOAc in hexanes) to afford 2-methyl-3-oxocyclohex-1-en-1-yl
benzoate (<bold>32a</bold>) (4.1 g, 17.8 mmol, 90%). LC&#x02013;MS <italic>m</italic>/<italic>z</italic> = 230.8 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) &#x003b4; 8.14&#x02013;8.08 (m, 2H),
7.64 (td, <italic>J</italic> = 7.3, 1.4 Hz, 1H), 7.50 (t, <italic>J</italic> = 7.8 Hz, 2H), 2.67 (tq, <italic>J</italic> = 6.1, 1.9
Hz, 2H), 2.50 (dd, <italic>J</italic> = 7.5, 6.0 Hz, 2H), 2.08 (p, <italic>J</italic> = 6.4 Hz, 2H), 1.72 (t, <italic>J</italic> = 1.9 Hz, 3H).</p></sec><sec id="sec4.3.3.22"><title>4-Bromo-2-methyl-3-oxocyclohex-1-en-1-yl benzoate (<bold>33a</bold>)</title><p>A mixture of 4-methylbenzenesulfonic acid (149.5 mg, 0.86
mmol, 0.1 equiv), NBS (1.93 g, 10.86 mmol, 1.25 equiv) in DCM (10
mL), and then 2-methyl-3-oxocyclohex-1-en-1-yl benzoate (<bold>32a</bold>) (2 g, 8.69 mmol, 1 equiv) was added. The mixture was stirred at
55 &#x000b0;C for 2 h under microwave tube. The mixture was quenched
with H<sub>2</sub>O (50 mL) and extracted with DCM (3 &#x000d7; 100 mL).
The combined organic layers were washed with brine (100 mL) dried
over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated under
reduced pressure. The residue was purified by flash chromatography
(0&#x02013;1% EtOAc in petroleum ether, 40 g column) to afford 4-bromo-2-methyl-3-oxocyclohex-1-en-1-yl
benzoate (<bold>33a</bold>) (10 g, 32.4 mmol, 74% yield) as yellow
oil. LC&#x02013;MS <italic>m</italic>/<italic>z</italic> = 308.8 [M
+ H]<sup>+</sup>.</p></sec><sec id="sec4.3.3.23"><title>Methyl 4-(Benzyloxy)-2-hydroxy-3,6-dimethylbenzoate (<bold>34</bold>)</title><p>To a solution of methyl 2,4-dihydroxy-3,6-dimethylbenzoate
(25 g, 127.42 mmol, 1 equiv) in MeCN (30 mL) was added K<sub>2</sub>CO<sub>3</sub> (35.22 g, 254.8 mmol, 2 equiv) and BnBr (26.15 g,
152.9 mmol, 18.16 mL, 1.2 equiv) at 0 &#x000b0;C. The mixture was stirred
at 25 &#x000b0;C for 16 h. The liquor was quenched with H<sub>2</sub>O (400 mL) and extracted with EtOAc (3 &#x000d7; 500 mL). The combined
organic layers were washed with brine (400 mL) dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated under reduced pressure.
The crude product was triturated with petroleum ether in MTBE (1:1,
100 mL) and filtered to give methyl methyl 4-(benzyloxy)-2-hydroxy-3,6-dimethylbenzoate
(<bold>34</bold>) (114 g, 78% yield) as a yellow solid. <sup>1</sup>H NMR (400 MHz, DMSO-<italic>d</italic><sub>6</sub>) &#x003b4; 11.28
(s, 1H), 7.49&#x02013;7.43 (m, 2H), 7.43&#x02013;7.37 (m, 2H), 7.36&#x02013;7.30
(m, 1H), 6.59 (s, 1H), 5.17 (s, 2H), 3.86 (s, 3H), 2.43 (s, 3H), 2.02
(s, 3H).</p></sec><sec id="sec4.3.3.24"><title><italic>rac</italic>-4-Benzyloxy-3,6-dimethyl-2-(3-methyl-2,4-dioxo-cyclohexoxy)benzoic
Acid (<bold>35a</bold>)</title><p>To a solution of methyl 4-(benzyloxy)-2-hydroxy-3,6-dimethylbenzoate
(<bold>34</bold>) (10.19 g, 35.58 mmol, 1.1 equiv) in THF (50 mL)
was added NaH (60% dispersion in mineral oil, 2.20 g, 55.0 mmol, 1.7
equiv) at 25 &#x000b0;C. The mixture was stirred at 25 &#x000b0;C for 30
min. The mixture was added (4-bromo-2-methyl-3-oxo-cyclohexen-1-yl)
benzoate (10 g, 32.35 mmol, 1 equiv) in THF (20 mL) at 25 &#x000b0;C.
The mixture was stirred at 25 &#x000b0;C for 4 h. The mixture was quenched
with H<sub>2</sub>O (40 mL), and HCl (2 N, 15 mL) added to give pH
&#x0223c; 2, the mixture was extracted with EtOAc (3 &#x000d7; 100 mL).
The combined organic layers were washed with brine (100 mL) dried
over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated under
reduced pressure. The crude product was triturated with EtOAc (15
mL) and filtered to afford <italic>rac</italic>-methyl 4-(benzyloxy)-3,6-dimethyl-2-((3-methyl-2,4-dioxocyclohexyl)oxy)benzoate
(5.6 g, 13.6 mmol, 42% yield) as a white solid. LC&#x02013;MS <italic>m</italic>/<italic>z</italic> = 411.0 [M + H]<sup>+</sup>.</p><p>To a solution of <italic>rac</italic>-methyl 4-(benzyloxy)-3,6-dimethyl-2-((3-methyl-2,4-dioxocyclohexyl)oxy)benzoate
(7 g, 17.05 mmol, 1 equiv) in EtOH (140 mL) was added KOH (31.58 g,
563 mmol, 33 equiv). The mixture was stirred at 80 &#x000b0;C for 4 h.
The mixture was quenched with H<sub>2</sub>O (20 mL), and HCl (2 N)
was added to give pH &#x0223c; 2, the mixture quenched with H<sub>2</sub>O (20 mL), and extracted with EA (3 &#x000d7; 300 mL). The combined
organic layers was washed with brine (10 mL) dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated under reduced pressure
to afford crude <italic>rac</italic>-4-(benzyloxy)-2-((2-hydroxy-3-methyl-4-oxocyclohex-2-en-1-yl)oxy)-3,6-dimethylbenzoic
acid (<bold>35a</bold>) (7 g, crude) as a brown solid. LC&#x02013;MS <italic>m</italic>/<italic>z</italic> = 397.0 [M + H]<sup>+</sup>.</p></sec><sec id="sec4.3.3.25"><title><italic>rac</italic>-3-(Benzyloxy)-1,4,9-trimethyl-6,7-dihydro-11<italic>H</italic>-dibenzo[<italic>b</italic>,<italic>e</italic>][1,4]dioxepine-8,11(5aH)-dione
(<bold>36a</bold>)</title><p>To a solution of <italic>rac</italic>-4-(benzyloxy)-2-((2-hydroxy-3-methyl-4-oxocyclohex-2-en-1-yl)oxy)-3,6-dimethylbenzoic
acid (<bold>35a</bold>) (7 g, 17.7 mmol, 1 equiv) in DCM (70 mL) was
added TFAA (122.38 g, 582.70 mmol, 81.05 mL, 33 equiv). The mixture
was stirred at 46 &#x000b0;C for 1 h. The mixture was filtered and concentrated
under reduced pressure. The mixture was quenched with H<sub>2</sub>O (20 mL) and extracted with EtOAc (3 &#x000d7; 50 mL). The combined
organic layers were washed with brine (50 mL) dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated under reduced pressure.
The crude product was triturated with a mixture of petroleum ether
and EtOAc (20:1, 20 mL) and filtered to give a solid. The filtrate
was concentrated and the residue was purified by flash chromatography
(0&#x02013;20% EtOAc in petroleum ether, 20 g column), and combined
with the solid above to afford <italic>rac</italic>-3-(benzyloxy)-1,4,9-trimethyl-6,7-dihydro-11<italic>H</italic>-dibenzo[<italic>b</italic>,<italic>e</italic>][1,4]dioxepine-8,11(5aH)-dione
(<bold>36a</bold>). (5.7 g, 84% yield) as a white solid. LC&#x02013;MS <italic>m</italic>/<italic>z</italic> = 379.1 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<italic>d</italic><sub>6</sub>) &#x003b4; 7.30&#x02013;7.48
(m, 5H), 6.95 (s, 1H), 5.56 (ddd, <italic>J</italic> = 10.76, 5.00,
2.13 Hz, 1H), 5.17 (s, 2H), 2.52&#x02013;2.57 (m, 1H), 2.37&#x02013;2.43
(m, 2H), 2.35 (s, 3H), 2.05 (s, 3H), 1.71&#x02013;1.83 (m, 1H), 1.62
(d, <italic>J</italic> = 2.00 Hz, 3H).</p></sec><sec id="sec4.3.3.26"><title>(<italic>R</italic>)-3-(Benzyloxy)-1,4,9-trimethyl-6,7-dihydro-11<italic>H</italic>-dibenzo[<italic>b</italic>,<italic>e</italic>][1,4]dioxepine-8,11(5aH)-dione
(<bold>37</bold>)</title><p><italic>rac</italic>-3-(Benzyloxy)-1,4,9-trimethyl-6,7-dihydro-11<italic>H</italic>-dibenzo[<italic>b</italic>,<italic>e</italic>][1,4]dioxepine-8,11(5aH)-dione
(<bold>36a</bold>) (5 g, 13.2 mmol, 1 equiv) was purified by chiral
SFC (Daicel Chiralpak IC 250 &#x000d7; 50 mm<sup>2</sup>, 10 &#x003bc;m,
40% EtOH in water, 0.1% NH<sub>3</sub>) to afford (<italic>R</italic>)-3-(benzyloxy)-1,4,9-trimethyl-6,7-dihydro-11<italic>H</italic>-dibenzo[<italic>b</italic>,<italic>e</italic>][1,4]dioxepine-8,11(5aH)-dione (<bold>37</bold>) (2.3 g, 45% yield) as a white solid. LC&#x02013;MS <italic>m</italic>/<italic>z</italic> = 379.1 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<italic>d</italic><sub>6</sub>) &#x003b4; 7.47&#x02013;7.33
(m, 5H), 6.95 (s, 1H), 5.56 (ddd, <italic>J</italic> = 2.1, 5.0, 10.7
Hz, 1H), 5.17 (s, 2H), 2.56&#x02013;2.51 (m, 1H), 2.42&#x02013;2.36
(m, 2H), 2.35 (s, 3H), 2.05 (s, 3H), 1.85&#x02013;1.70 (m, 1H), 1.62
(d, <italic>J</italic> = 2.0 Hz, 3H).</p></sec><sec id="sec4.3.3.27"><title>(<italic>R</italic>)-3-Hydroxy-1,4,9-trimethyl-6,7-dihydro-11<italic>H</italic>-dibenzo[<italic>b</italic>,<italic>e</italic>][1,4]dioxepine-8,11(5aH)-dione
(<bold>38</bold>)</title><p>To a solution of (<italic>R</italic>)-3-(benzyloxy)-1,4,9-trimethyl-6,7-dihydro-11<italic>H</italic>-dibenzo[<italic>b</italic>,<italic>e</italic>][1,4]dioxepine-8,11(5aH)-dione
(<bold>37</bold>) (100.0 mg, 0.26 mmol, 1 equiv) in THF (6 mL) was
added Pd/C (10 wt %, 12 mg). The mixture was stirred at 25 &#x000b0;C
for 4 h under H<sub>2</sub>. The reaction mixture was filtered and
the filtrate was concentrated. The residue was purified by flash chromatography
(0&#x02013;20% EtOAc in petroleum ether, 12 g column), then purified
by reverse phase HPLC (Welch Xtimate C18 100 &#x000d7; 40 mm<sup>2</sup> &#x000d7; 3 &#x003bc;m, 30&#x02013;60% acetonitrile in water, 0.1% HCl)
to afford (<italic>R</italic>)-3-hydroxy-1,4,9-trimethyl-6,7-dihydro-11<italic>H</italic>-dibenzo[<italic>b</italic>,<italic>e</italic>][1,4]dioxepine-8,11(5aH)-dione
(<bold>38</bold>) (15.6 mg, 31% yield) as a gray solid. LC&#x02013;MS <italic>m</italic>/<italic>z</italic> = 289.1 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) &#x003b4; 6.49 (s, 1H), 5.47 (s,
1H), 5.35&#x02013;5.26 (m, 1H), 2.63&#x02013;2.52 (m, 1H), 2.47&#x02013;2.37
(m, 2H), 2.35 (s, 3H), 2.09 (s, 3H), 2.03&#x02013;1.88 (m, 1H), 1.74
(d, <italic>J</italic> = 2.0 Hz, 3H).</p></sec><sec id="sec4.3.3.28"><title>2,5-Dimethylcyclohexane-1,3-dione (<bold>31b</bold>)</title><p>To a solution of 5-methylcyclohexane-1,3-dione (100 g, 1 equiv, 793
mmol) and NaOH (29 g, 0.91 equiv, 721 mmol) in H<sub>2</sub>O (250
mL) was added MeI (225 g, 99.1 mL, 2 equiv, 1.59 mol) at 0 &#x000b0;C.
The mixture was stirred at 100 &#x000b0;C for 16 h. Additional MeI (225
g, 99.1 mL, 2 equiv, 1.59 mol) was added at 0 &#x000b0;C and the mixture
was stirred at 100 &#x000b0;C for 16 h. Additional MeI (113 g, 49.6 mL,
1 equiv, 793 mmol) was added at 0 &#x000b0;C and the mixture was stirred
at 100 &#x000b0;C for 16 h. The mixture was cooled to 0 &#x000b0;C and stirred
for 30 min. The mixture was filtrated and afforded crude compound
2,5-dimethylcyclohexane-1,3-dione (<bold>31b</bold>) (76 g, 0.54 mol,
68% yield) as a brown solid which was used without purification.</p></sec><sec id="sec4.3.3.29"><title>2,5-Dimethyl-3-oxocyclohex-1-en-1-yl Benzoate (<bold>32b</bold>)</title><p>To a solution of 2,5-dimethylcyclohexane-1,3-dione (<bold>31b</bold>) (99 g, 1 equiv, 0.71 mol) in DCM (990 mL) was added TEA
(140 g, 0.20 L, 2 equiv, 1.4 mol) and DMAP (8.6 g, 0.1 equiv, 71 mmol).
Then the mixture was added benzoyl chloride (120 g, 98 mL, 1.2 equiv,
0.85 mol) at 0 &#x000b0;C. The mixture was stirred at 0 &#x000b0;C for 2
h. The mixture was quenched with H<sub>2</sub>O (100 mL) and extracted
with DCM (3 &#x000d7; 300 mL). The combined organic layers were washed
with brine (100 mL) dried over Na<sub>2</sub>SO<sub>4</sub>, filtered
and concentrated under reduced pressure. The residue was purified
by flash chromatography (0&#x02013;3% EtOAc in petroleum ether, 220
g column) to give 2,5-dimethyl-3-oxocyclohex-1-en-1-yl benzoate (<bold>32b</bold>) (85 g, 49% yield, 93% purity) as an oil. LC&#x02013;MS <italic>m</italic>/<italic>z</italic> = 245.1 [M + H]<sup>+</sup>.</p></sec><sec id="sec4.3.3.30"><title>4-Bromo-2,5-dimethyl-3-oxocyclohex-1-en-1-yl benzoate (<bold>33b</bold>)</title><p>Twenty batches of the following reaction were
conducted. A mixture of NBS (1.6 g, 1.1 equiv, 9.00 mmol), 4-methylbenzenesulfonic
acid (0.14 g, 0.1 equiv, 0.82 mmol) in DCE (10 mL), and then 2,5-dimethyl-3-oxocyclohex-1-en-1-yl
benzoate (<bold>32b</bold>) (2.0 g, 1 equiv, 8.2 mmol) was added.
The mixture was stirred at 100 &#x000b0;C for 5 min under microwave tube.
The batches were combined and the mixture was quenched with H<sub>2</sub>O (100 mL) and extracted with EtOAc (3 &#x000d7; 200 mL). The
combined organic layers were washed with brine (200 mL) dried over
Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated under reduced
pressure. The residue was purified by flash chromatography (0&#x02013;1%
EtOAc in petroleum ether, 220 g column) to give 4-bromo-2,5-dimethyl-3-oxocyclohex-1-en-1-yl
benzoate (<bold>33b</bold>) (37 g, 70% yield, 92% purity) as yellow
oil. LC&#x02013;MS <italic>m</italic>/<italic>z</italic> = 325.0 [M
+ H]<sup>+</sup>.</p></sec><sec id="sec4.3.3.31"><title><italic>rac</italic>-4-(Benzyloxy)-2-(((1<italic>R</italic>,6<italic>S</italic>)-2-hydroxy-3,6-dimethyl-4-oxocyclohex-2-en-1-yl)oxy)-3,6-dimethylbenzoic
Acid (<bold>35b</bold>)</title><p>To a solution of methyl 4-(benzyloxy)-2-hydroxy-3,6-dimethylbenzoate
(<bold>34</bold>) (29 g, 1.1 equiv, 0.10 mol) in THF (300 mL) was
added NaH (60% dispersion in mineral oil, 6.3 g, 1.7 equiv, 0.16 mol)
at 25 &#x000b0;C for 30 min. To the mixture was added a solution of 4-bromo-2,5-dimethyl-3-oxocyclohex-1-en-1-yl
benzoate (<bold>33b</bold>) (30 g, 1 equiv, 93 mmol) in THF (120 mL)
at 25 &#x000b0;C. The mixture was stirred at 25 &#x000b0;C for 4 h. The
mixture was quenched with H<sub>2</sub>O (100 mL) and extracted with
EtOAc (3 &#x000d7; 200 mL). The combined organic layers were washed with
brine (100 mL) dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and
concentrated under reduced pressure. The crude product was triturated
with EtOAc (50 mL) and filtered to give <italic>rac</italic>-methyl
4-(benzyloxy)-2-(((1<italic>R</italic>,6<italic>S</italic>)-3,6-dimethyl-2,4-dioxocyclohexyl)oxy)-3,6-dimethylbenzoate
(10.4 g, 26% yield) as a white solid. LC&#x02013;MS <italic>m</italic>/<italic>z</italic> = 425.2[M + H]<sup>+</sup>. <sup>1</sup>H NMR
(400 MHz, CDCl<sub>3</sub>) &#x003b4; 7.66 (s, 1H), 7.45&#x02013;7.34
(m, 5H), 6.59 (s, 1H), 5.10 (d, <italic>J</italic> = 1.5 Hz, 2H),
4.37 (dt, <italic>J</italic> = 6.9, 1.4 Hz, 1H), 3.93 (s, 3H), 2.63
(dd, <italic>J</italic> = 16.4, 4.7 Hz, 1H), 2.45 (dtd, <italic>J</italic> = 9.3, 6.7, 4.7 Hz, 1H), 2.38 (s, 3H), 2.21 (s, 3H), 2.11 (dd, <italic>J</italic> = 16.5, 9.3 Hz, 1H), 1.80 (d, <italic>J</italic> = 1.3
Hz, 3H), 0.84 (d, <italic>J</italic> = 6.7 Hz, 3H).</p><p>Three batches
of the following reaction were conducted. To a solution of <italic>rac</italic>-methyl 4-(benzyloxy)-2-(((1<italic>R</italic>,6<italic>S</italic>)-3,6-dimethyl-2,4-dioxocyclohexyl)oxy)-3,6-dimethylbenzoate
(17 g, 1 equiv, 40 mmol) in EtOH (500 mL) was added KOH (74 g, 33
equiv, 1.3 mol). The mixture was stirred at 80 &#x000b0;C for 4 h. The
mixture was acidified with HCl (2 N) to give pH &#x0223c; 2. The batches
were combined and the mixture was filtered and the filtrate was concentrated
to give crude compound <italic>rac</italic>-4-(benzyloxy)-2-(((1<italic>R</italic>,6<italic>S</italic>)-3,6-dimethyl-2,4-dioxocyclohexyl)oxy)-3,6-dimethylbenzoic
acid (<bold>35b</bold>) (45.4 g, 93% yield) as a brown solid. LC&#x02013;MS <italic>m</italic>/<italic>z</italic> = 411.0 [M + H]<sup>+</sup>.</p></sec><sec id="sec4.3.3.32"><title><italic>rac</italic>-(5a<italic>R</italic>,6<italic>S</italic>)-3-(Benzyloxy)-1,4,6,9-tetramethyl-6,7-dihydro-11<italic>H</italic>-dibenzo[<italic>b</italic>,<italic>e</italic>][1,4]dioxepine-8,11(5aH)-dione
(<bold>36b</bold>)</title><p>Two batches of the following reaction
were conducted. To solution of <italic>rac</italic>-4-(benzyloxy)-2-(((1<italic>R</italic>,6<italic>S</italic>)-3,6-dimethyl-2,4-dioxocyclohexyl)oxy)-3,6-dimethylbenzoic
acid (<bold>35b</bold>) (22.7 g, 1 equiv, 55.3 mmol) in DCM (227 mL)
was added TFAA (383 g, 258 mL, 33 equiv, 1.82 mol). The mixture was
stirred at 46 &#x000b0;C for 1 h. The mixture was concentrated under
reduced pressure and quenched with H<sub>2</sub>O (100 mL) and extracted
with EA (3 &#x000d7; 200 mL). The combined organic layers were washed
with brine (100 mL) dried over Na<sub>2</sub>SO<sub>4</sub>, filtered
and concentrated under reduced pressure. The batches were combined
and the residue was purified by flash chromatography (0&#x02013;20%
EtOAc in petroleum ether, 120 g column) to afford <italic>rac</italic>-(5a<italic>R</italic>,6<italic>S</italic>)-3-(benzyloxy)-1,4,6,9-tetramethyl-6,7-dihydro-11<italic>H</italic>-dibenzo[<italic>b</italic>,<italic>e</italic>][1,4]dioxepine-8,11(5a<italic>H</italic>)-dione (<bold>36b</bold>) (23.3 g, 53% yield, 88% purity)
as a white solid. LC&#x02013;MS <italic>m</italic>/<italic>z</italic> = 393.2 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) &#x003b4; 7.46&#x02013;7.33 (m, 5H), 6.63 (s, 1H), 5.10 (d, <italic>J</italic> = 1.8 Hz, 2H), 4.93 (dd, <italic>J</italic> = 1.8, 8.8
Hz, 1H), 2.59&#x02013;2.51 (m, 1H), 2.42 (s, 3H), 2.31&#x02013;2.19
(m, 2H), 2.18 (s, 3H), 1.75 (d, <italic>J</italic> = 2.0 Hz, 3H),
1.40 (d, <italic>J</italic> = 6.0 Hz, 3H).</p></sec><sec id="sec4.3.3.33"><title>(5a<italic>R</italic>,6<italic>S</italic>,7<italic>R</italic>)-3,7-Dihydroxy-1,4,6,9-tetramethyl-6,7-dihydro-11<italic>H</italic>-dibenzo[<italic>b</italic>,<italic>e</italic>][1,4]dioxepine-8,11(5aH)-dione
(<bold>39</bold>)</title><p>To a solution of <italic>rac</italic>-(5a<italic>R</italic>,6<italic>S</italic>)-3-(benzyloxy)-1,4,6,9-tetramethyl-6,7-dihydro-11<italic>H</italic>-dibenzo[<italic>b</italic>,<italic>e</italic>][1,4]dioxepine-8,11(5aH)-dione
(<bold>36b</bold>) (4.2 g, 1 equiv, 11 mmol) in THF (42 mL) was added
LiHMDS (2.1 g, 13 mL, 1 M, 1.2 equiv, 13 mmol) at &#x02212;78 &#x000b0;C
for 0.5 h. Then the mixture was added 3-phenyl-2-(phenylsulfonyl)-1,2-oxaziridine
(4.2 g, 1.5 equiv, 16 mmol) in THF (10.5 mL) at &#x02212;78 &#x000b0;C.
The mixture was stirred at &#x02212;78 &#x000b0;C for 1 h. The mixture
was quenched with saturated aqueous NH<sub>4</sub>Cl (50 mL), then
the mixture was concentrated under reduced pressure. The mixture was
extracted with EtOAc (3 &#x000d7; 100 mL). The combined organic layers
were washed with brine (100 mL) dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated under reduced pressure. The residue was
purified by flash chromatography (0&#x02013;20% EtOAc in petroleum
ether, 40 g column) to afford <italic>rac</italic>-(5a<italic>R</italic>,6<italic>S</italic>,7<italic>R</italic>)-3-(benzyloxy)-7-hydroxy-1,4,6,9-tetramethyl-6,7-dihydro-11<italic>H</italic>-dibenzo[<italic>b</italic>,<italic>e</italic>][1,4]dioxepine-8,11(5aH)-dione
(1.65 g, 38% yield) as a white solid. LC&#x02013;MS <italic>m</italic>/<italic>z</italic> = 409.0 [M + H]<sup>+</sup>.</p><p>To a solution
of <italic>rac</italic>-(5a<italic>R</italic>,6<italic>S</italic>,7<italic>R</italic>)-3-(benzyloxy)-7-hydroxy-1,4,6,9-tetramethyl-6,7-dihydro-11<italic>H</italic>-dibenzo[<italic>b</italic>,<italic>e</italic>][1,4]dioxepine-8,11(5aH)-dione
(2 g, 1 equiv, 5 mmol) in THF (120 mL) was added Pd/C (10 wt %, 480
mg) under N<sub>2</sub> atmosphere. The suspension was degassed and
purged with H<sub>2</sub> 3 times. The mixture was stirred under H<sub>2</sub> (15 Psi) at 25 &#x000b0;C for 1 h. The mixture was filtered
and the filtrate was concentrated. The residue was purified by flash
chromatography (0&#x02013;10% EtOAc in petroleum ether, 12 g column)
to afford <italic>rac</italic>-(5a<italic>R</italic>,6<italic>S</italic>,7<italic>R</italic>)-3,7-dihydroxy-1,4,6,9-tetramethyl-6,7-dihydro-11<italic>H</italic>-dibenzo[<italic>b</italic>,<italic>e</italic>][1,4]dioxepine-8,11(5aH)-dione
(1.3 g, 80% yield) as a white solid. LC&#x02013;MS <italic>m</italic>/<italic>z</italic> = 319.0 [M + H]<sup>+</sup>. <sup>1</sup>H NMR
(500 MHz, THF-<italic>d</italic><sub>8</sub>) &#x003b4; 9.11 (s, 1H),
6.43 (s, 1H), 4.99 (dd, <italic>J</italic> = 6.2, 1.6 Hz, 1H), 4.92
(d, <italic>J</italic> = 3.6 Hz, 1H), 4.06 (t, <italic>J</italic> =
3.6 Hz, 1H), 2.40&#x02013;2.34 (m, 1H), 2.32 (s, 3H), 2.10 (s, 3H),
1.69 (d, <italic>J</italic> = 1.5 Hz, 3H), 1.28 (d, <italic>J</italic> = 6.9 Hz, 3H).</p><p><italic>rac</italic>-(5a<italic>R</italic>,6<italic>S</italic>,7<italic>R</italic>)-3,7-dihydroxy-1,4,6,9-tetramethyl-6,7-dihydro-11<italic>H</italic>-dibenzo[<italic>b</italic>,<italic>e</italic>][1,4]dioxepine-8,11(5aH)-dione
(1.3 g) was resolved by reverse phase chiral HPLC (Daicel Chiralpak
AD, 250 &#x000d7; 50 mm<sup>2</sup>,10 &#x003bc;m, EtOH in water, 0.1%
NH<sub>3</sub>) to afford (5a<italic>R</italic>,6<italic>S</italic>,7<italic>R</italic>)-3,7-dihydroxy-1,4,6,9-tetramethyl-6,7-dihydro-11<italic>H</italic>-dibenzo[<italic>b</italic>,<italic>e</italic>][1,4]dioxepine-8,11(5aH)-dione
(<bold>39</bold>) (571 mg, 44% yield) as a white solid. LC&#x02013;MS <italic>m</italic>/<italic>z</italic> = 319.2 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, THF-<italic>d</italic><sub>8</sub>) &#x003b4; 8.98
(br s, 1H), 6.32 (s, 1H), 4.96&#x02013;4.64 (m, 2H), 3.95 (t, <italic>J</italic> = 3.4 Hz, 1H), 2.26 (ddd, <italic>J</italic> = 3.3, 6.6,
9.8 Hz, 1H), 2.21 (s, 3H), 1.99 (s, 3H), 1.58 (d, <italic>J</italic> = 1.4 Hz, 3H), 1.17 (d, <italic>J</italic> = 6.9 Hz, 3H).</p></sec><sec id="s0069"><title>(5a<italic>R</italic>,6<italic>S</italic>,7<italic>S</italic>)-3,7-Dihydroxy-1,4,6,9-tetramethyl-6,7-dihydro-11<italic>H</italic>-dibenzo[<italic>b</italic>,<italic>e</italic>][1,4]dioxepine-8,11(5aH)-dione
(<bold>40</bold>)</title><p>Using the general procedure for the epimerization,
(27.0 mg, 84.8 &#x003bc;mol, 54%) as a white solid. LC&#x02013;MS <italic>m</italic>/<italic>z</italic> = 316.8 [M &#x02013; H]<sup>&#x02212;</sup>. <sup>1</sup>H NMR (500 MHz, THF-<italic>d</italic><sub>8</sub>)
&#x003b4; 9.07 (s, 1H), 6.44 (s, 1H), 4.99 (dd, <italic>J</italic> =
9.5, 2.1 Hz, 1H), 4.40 (s, 1H), 3.78 (d, <italic>J</italic> = 11.9
Hz, 1H), 2.30 (s, 3H), 2.08 (s, 3H), 1.85 (ddq, <italic>J</italic> = 12.2, 9.5, 6.2 Hz, 1H), 1.71 (d, <italic>J</italic> = 2.0 Hz,
3H), 1.53 (d, <italic>J</italic> = 6.2 Hz, 3H).</p></sec><sec id="sec4.3.3.34"><title>(5a<italic>S</italic>,6<italic>S</italic>,7<italic>S</italic>)-2-Fluoro-3,7-dihydroxy-6-methoxy-1,4,6,9-tetramethyl-6,7-dihydro-11<italic>H</italic>-dibenzo[<italic>b</italic>,<italic>e</italic>][1,4]dioxepine-8,11(5aH)-dione
(<bold>41</bold>)</title><p>(5a<italic>S</italic>,6<italic>S</italic>,7<italic>S</italic>)-3,7-Dihydroxy-6-methoxy-1,4,6,9-tetramethyl-6,7-dihydro-11<italic>H</italic>-dibenzo[<italic>b</italic>,<italic>e</italic>][1,4]dioxepine-8,11(5aH)-dione
(<bold>2</bold>) (50 mg, 1 equiv, 0.14 mmol) and selectfluor (61 mg,
1.2 equiv, 0.17 mmol) were added to a vial under air. Acetonitrile
(1.4 mL) was added and the reaction was stirred at room temperature
for 18 h. The reaction mixture was concentrated and purified by reverse
phase HPLC (ISCO, Sunfire column, 10&#x02013;100% acetonitrile in water
with 0.1% formic acid) to give (5a<italic>S</italic>,6<italic>S</italic>,7<italic>S</italic>)-2-fluoro-3,7-dihydroxy-6-methoxy-1,4,6,9-tetramethyl-6,7-dihydro-11<italic>H</italic>-dibenzo[<italic>b</italic>,<italic>e</italic>][1,4]dioxepine-8,11(5aH)-dione
(<bold>41</bold>) (2.1 mg, 5.8 &#x003bc;mol, 4%) as a yellow solid.
LC&#x02013;MS <italic>m</italic>/<italic>z</italic> = 364.8 [M &#x02013;
H]<sup>&#x02212;</sup>. <sup>1</sup>H NMR (400 MHz, THF-<italic>d</italic><sub>8</sub>) &#x003b4; 5.76 (s, 1H), 5.09 (q, <italic>J</italic> =
2.0 Hz, 1H), 4.62 (d, <italic>J</italic> = 3.3 Hz, 1H), 4.23 (d, <italic>J</italic> = 2.8 Hz, 1H), 3.44 (s, 3H), 2.38 (d, <italic>J</italic> = 2.9 Hz, 3H), 2.24 (s, 3H), 1.86 (d, <italic>J</italic> = 2.0 Hz,
3H), 1.10 (s, 3H). <sup>19</sup>F NMR (376 MHz, THF-<italic>d</italic><sub>8</sub>) &#x003b4; &#x02212;146.64 (q, <italic>J</italic> = 2.9
Hz).</p></sec><sec id="sec4.3.3.35"><title>(5a<italic>S</italic>,6<italic>S</italic>,7<italic>S</italic>)-3,7-Dihydroxy-6-methoxy-1,2,4,6,9-pentamethyl-6,7-dihydro-11<italic>H</italic>-dibenzo[<italic>b</italic>,<italic>e</italic>][1,4]dioxepine-8,11(5aH)-dione
(<bold>42</bold>)</title><p>(5a<italic>S</italic>,6<italic>S</italic>,7<italic>S</italic>)-2-bromo-3,7-dihydroxy-6-methoxy-1,4,6,9-tetramethyl-6,7-dihydro-11<italic>H</italic>-dibenzo[<italic>b</italic>,<italic>e</italic>][1,4]dioxepine-8,11(5aH)-dione
(<bold>44</bold>) (90 mg, 1 equiv, 0.21 mmol) and 1H-imidazole (22
mg, 1.5 equiv, 0.32 mmol) were added to a vial under air. Chloroform
(2 mL) was added, followed by chlorotrimethylsilane (27 mg, 32 &#x003bc;L,
1.2 equiv, 0.25 mmol), and the mixture was heated to 50 &#x000b0;C and
stirred overnight. Additional portions of chlorotrimethylsilane (27
mg, 32 &#x003bc;L, 1.2 equiv, 0.25 mmol) and 1H-imidazole (22 mg, 1.5
equiv, 0.32 mmol) were added, and the mixture was stirred at 50 &#x000b0;C
for an additional 6 h. The mixture was quenched with saturated aqueous
NH<sub>4</sub>Cl and extracted with DCM, and the organic layer was
dried over MgSO<sub>4</sub> and concentrated. Purification over silica
gel (0&#x02013;25% EtOAc in hexanes) afforded (5a<italic>S</italic>,6<italic>S</italic>,7<italic>S</italic>)-2-bromo-7-hydroxy-6-methoxy-1,4,6,9-tetramethyl-3-((trimethylsilyl)oxy)-6,7-dihydro-11<italic>H</italic>-dibenzo[<italic>b</italic>,<italic>e</italic>][1,4]dioxepine-8,11(5aH)-dione
(52 mg, 0.10 mmol, 49% yield) as a light yellow solid. LC&#x02013;MS <italic>m</italic>/<italic>z</italic> = 500.0 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) &#x003b4; 6.19 (s, 1H), 4.97 (q, <italic>J</italic> = 1.9 Hz, 1H), 4.09 (s, 1H), 3.45 (s, 3H), 2.54 (d, <italic>J</italic> = 0.7 Hz, 3H), 2.28 (d, <italic>J</italic> = 0.7 Hz, 3H),
1.88 (d, <italic>J</italic> = 2.0 Hz, 3H), 1.26 (s, 3H), 0.13 (s,
9H).</p><p>(5a<italic>S</italic>,6<italic>S</italic>,7<italic>S</italic>)-2-Bromo-7-hydroxy-6-methoxy-1,4,6,9-tetramethyl-3-((trimethylsilyl)oxy)-6,7-dihydro-11<italic>H</italic>-dibenzo[<italic>b</italic>,<italic>e</italic>][1,4]dioxepine-8,11(5aH)-dione
(25 mg, 1 equiv, 50 &#x003bc;mol), potassium ethyltrifluoroborate (18
mg, 3 equiv, 0.15 mmol), potassium phosphate (32 mg, 3 equiv, 0.15
mmol), and P(<italic>t</italic>-Bu)<sub>3</sub> Pd G4 (2.9 mg, 0.1
equiv, 5.0 &#x003bc;mol) were added to a microwave vial, and the vial
was evacuated and refilled with N<sub>2</sub> 3 times. Toluene (1
mL) and water (0.1 mL) that had been degassed were added, and the
mixture was heated to 120 &#x000b0;C in a microwave reactor for 4 h.
The mixture was diluted in DCM and washed with saturated aqueous NH<sub>4</sub>Cl, and the organic layer was dried over MgSO<sub>4</sub> and
concentrated. The residue was purified by flash chromatography (20&#x02013;50%
EtOAc in hexanes) afforded (5a<italic>S</italic>,6<italic>S</italic>,7<italic>S</italic>)-7-hydroxy-6-methoxy-1,2,4,6,9-pentamethyl-3-((trimethylsilyl)oxy)-6,7-dihydro-11<italic>H</italic>-dibenzo[<italic>b</italic>,<italic>e</italic>][1,4]dioxepine-8,11(5aH)-dione
(7 mg, 0.02 mmol, 30% yield) as a yellow oil. LC&#x02013;MS <italic>m</italic>/<italic>z</italic> = 435.0 [M + H]<sup>+</sup>.</p><p>(5a<italic>S</italic>,6<italic>S</italic>,7<italic>S</italic>)-7-hydroxy-6-methoxy-1,2,4,6,9-pentamethyl-3-((trimethylsilyl)oxy)-6,7-dihydro-11<italic>H</italic>-dibenzo[<italic>b</italic>,<italic>e</italic>][1,4]dioxepine-8,11(5aH)-dione
(7 mg, 1 equiv, 0.02 mmol) was dissolved in THF (1 mL) in a vial under
air. Pyridine hydrofluoride (4 mg, 3 &#x003bc;L, 2 equiv, 0.04 mmol)
was added, and the mixture was stirred at room temperature for 4 h.
Additional portions of pyridine hydrofluoride (8 mg, 6 &#x003bc;L, 4
equiv, 0.08 mmol) were added, and the mixture was stirred at room
temperature overnight. The mixture was concentrated and the residue
was purified by reverse phase HPLC (10&#x02013;70% acetonitrile in
water, 0.1% formic acid) afforded (5a<italic>S</italic>,6<italic>S</italic>,7<italic>S</italic>)-3,7-dihydroxy-6-methoxy-1,2,4,6,9-pentamethyl-6,7-dihydro-11<italic>H</italic>-dibenzo[<italic>b</italic>,<italic>e</italic>][1,4]dioxepine-8,11(5aH)-dione
(<bold>42</bold>) (1.2 mg, 3.3 &#x003bc;mol, 20% yield) as a white solid.
LC&#x02013;MS <italic>m</italic>/<italic>z</italic> = 363.0 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, THF-<italic>d</italic><sub>8</sub>) &#x003b4; 8.25 (s, 1H), 5.17 (q, <italic>J</italic> = 2.1 Hz, 1H),
4.57 (d, <italic>J</italic> = 3.3 Hz, 1H), 4.25 (d, <italic>J</italic> = 3.4 Hz, 1H), 3.45 (s, 3H), 2.33 (s, 3H), 2.25 (s, 3H), 2.15 (s,
3H), 1.84 (d, <italic>J</italic> = 2.1 Hz, 3H), 1.00 (s, 3H).</p></sec><sec id="sec4.3.3.36"><title>(5a<italic>S</italic>,6<italic>S</italic>,7<italic>S</italic>)-2-Chloro-3,7-dihydroxy-6-methoxy-1,4,6,9-tetramethyl-6,7-dihydro-11<italic>H</italic>-dibenzo[<italic>b</italic>,<italic>e</italic>][1,4]dioxepine-8,11(5aH)-dione
(<bold>43</bold>)</title><p>(5a<italic>S</italic>,6<italic>S</italic>,7<italic>S</italic>)-3,7-Dihydroxy-6-methoxy-1,4,6,9-tetramethyl-6,7-dihydro-11<italic>H</italic>-dibenzo[<italic>b</italic>,<italic>e</italic>][1,4]dioxepine-8,11(5aH)-dione
(<bold>2</bold>) (1 g, 1 equiv, 3 mmol) was dissolved in THF (60 mL)
and transferred to an oven-dried, 2-neck round-bottom flask under
N<sub>2</sub>, and the solution was cooled to 0 &#x000b0;C in an ice
bath. Sulfuryl dichloride (1 M in DCM, 0.9 g, 6 mL, 2.2 equiv, 6 mmol)
was added dropwise via addition funnel. The mixture immediately turned
a pale yellow. The mixture was diluted in DCM and washed with saturated
NH<sub>4</sub>Cl, and the organic layer was dried over MgSO<sub>4</sub> and concentrated. The residue was purified by flash chromatography
(20&#x02013;50% EtOAc in hexanes) to afford (5a<italic>S</italic>,6<italic>S</italic>,7<italic>S</italic>)-2-chloro-3,7-dihydroxy-6-methoxy-1,4,6,9-tetramethyl-6,7-dihydro-11<italic>H</italic>-dibenzo[<italic>b</italic>,<italic>e</italic>][1,4]dioxepine-8,11(5aH)-dione
(<bold>43</bold>) (837 mg, 2.19 mmol, 76% yield) as a yellow solid.
LC&#x02013;MS <italic>m</italic>/<italic>z</italic> = 383.8 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, THF-<italic>d</italic><sub>8</sub>) &#x003b4; 9.11 (s, 1H), 5.21 (q, <italic>J</italic> = 2.1 Hz, 1H),
4.66 (dd, <italic>J</italic> = 3.4, 0.8 Hz, 1H), 4.29&#x02013;4.21
(m, 1H), 3.46 (s, 3H), 2.28 (s, 3H), 1.85 (d, <italic>J</italic> =
2.1 Hz, 3H), 1.04 (s, 3H).</p></sec><sec id="sec4.3.3.37"><title>(5a<italic>S</italic>,6<italic>S</italic>,7<italic>S</italic>)-2-Bromo-3,7-dihydroxy-6-methoxy-1,4,6,9-tetramethyl-6,7-dihydro-11<italic>H</italic>-dibenzo[<italic>b</italic>,<italic>e</italic>][1,4]dioxepine-8,11(5aH)-dione
(<bold>44</bold>)</title><p>(5a<italic>S</italic>,6<italic>S</italic>,7<italic>S</italic>)-3,7-dihydroxy-6-methoxy-1,4,6,9-tetramethyl-6,7-dihydro-11<italic>H</italic>-dibenzo[<italic>b</italic>,<italic>e</italic>][1,4]dioxepine-8,11(5aH)-dione
(<bold>2</bold>) (100 mg, 1 equiv, 287 &#x003bc;mol) was dissolved in
ACN (3 mL) in a vial under air. NBS (56.2 mg, 1.1 equiv, 316 &#x003bc;mol)
was added, and the mixture was stirred at room temperature for 1 h.
The mixture was concentrated without workup. The residue was purified
by flash chromatography (20&#x02013;50% EtOAc in hexanes) to afford
(5a<italic>S</italic>,6<italic>S</italic>,7<italic>S</italic>)-2-bromo-3,7-dihydroxy-6-methoxy-1,4,6,9-tetramethyl-6,7-dihydro-11<italic>H</italic>-dibenzo[<italic>b</italic>,<italic>e</italic>][1,4]dioxepine-8,11(5aH)-dione
(<bold>44</bold>) (87 mg, 0.20 mmol, 71% yield) as a yellow solid.
LC&#x02013;MS <italic>m</italic>/<italic>z</italic> = 428.8 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, THF-<italic>d</italic><sub>8</sub>) &#x003b4; 8.80 (s, 1H), 5.23 (q, <italic>J</italic> = 2.1 Hz, 1H),
4.66 (d, <italic>J</italic> = 3.4 Hz, 1H), 4.25 (d, <italic>J</italic> = 3.5 Hz, 1H), 3.46 (s, 3H), 2.52 (s, 3H), 2.30 (s, 3H), 1.85 (d, <italic>J</italic> = 2.1 Hz, 3H), 1.02 (s, 3H).</p></sec><sec id="sec4.3.3.38"><title>(5a<italic>S</italic>,6<italic>S</italic>,7<italic>S</italic>)-2-Ethyl-3,7-dihydroxy-6-methoxy-1,4,6,9-tetramethyl-6,7-dihydro-11<italic>H</italic>-dibenzo[<italic>b</italic>,<italic>e</italic>][1,4]dioxepine-8,11(5aH)-dione
(<bold>45</bold>)</title><p>(5a<italic>S</italic>,6<italic>S</italic>,7<italic>S</italic>)-2-Bromo-7-hydroxy-6-methoxy-1,4,6,9-tetramethyl-3-((trimethylsilyl)oxy)-6,7-dihydro-11<italic>H</italic>-dibenzo[<italic>b</italic>,<italic>e</italic>][1,4]dioxepine-8,11(5aH)-dione
(50 mg, 1 equiv, 0.10 mmol), potassium ethyltrifluoroborate (41 mg,
3 equiv, 0.30 mmol), potassium phosphate (64 mg, 3 equiv, 0.30 mmol),
and P(<italic>t</italic>-Bu)<sub>3</sub> Pd G4 (5.9 mg, 0.1 equiv,
10 &#x003bc;mol) were added to a microwave vial under air. The vial
was sealed, then evacuated and refilled with N<sub>2</sub> 3 times.
Degassed toluene (1 mL) and water (0.1 mL) were added, and the mixture
was heated to 120 &#x000b0;C in a microwave vial for 4 h. The mixture
was diluted in DCM (10 mL) and washed with NH<sub>4</sub>Cl (2 &#x000d7;
10 mL). The organic layer was dried over MgSO<sub>4</sub> and concentrated.
The residue was purified by flash chromatography (0&#x02013;100% EtOAc
in hexanes) to afford (5a<italic>S</italic>,6<italic>S</italic>,7<italic>S</italic>)-2-ethyl-7-hydroxy-6-methoxy-1,4,6,9-tetramethyl-3-((trimethylsilyl)oxy)-6,7-dihydro-11<italic>H</italic>-dibenzo[<italic>b</italic>,<italic>e</italic>][1,4]dioxepine-8,11(5aH)-dione
(14.4 mg, 32.1 &#x003bc;mol, 32%) as a yellow oil. LC&#x02013;MS <italic>m</italic>/<italic>z</italic> = 449.0 [M + H]<sup>+</sup>.</p><p>(5a<italic>S</italic>,6<italic>S</italic>,7<italic>S</italic>)-2-Ethyl-7-hydroxy-6-methoxy-1,4,6,9-tetramethyl-3-((trimethylsilyl)oxy)-6,7-dihydro-11<italic>H</italic>-dibenzo[<italic>b</italic>,<italic>e</italic>][1,4]dioxepine-8,11(5aH)-dione
(14.4 mg, 1 equiv, 32.1 &#x003bc;mol) was dissolved in THF (1 mL), pyridine
hydrofluoride (6.36 mg, 5.8 &#x003bc;L, 2 equiv, 64.2 &#x003bc;mol) was
added, then the mixture was stirred at room temperature for 30 min.
At this time, additional pyridine hydrofluoride (6.36 mg, 5.8 &#x003bc;L,
2 equiv, 64.2 &#x003bc;mol) was added, and the mixture was stirred at
room temperature for 18 h. The mixture was concentrated and the residue
was purified by reverse phase HPLC (10&#x02013;100% acetonitrile in
water, 0.1% formic acid) to afford (5a<italic>S</italic>,6<italic>S</italic>,7<italic>S</italic>)-2-ethyl-3,7-dihydroxy-6-methoxy-1,4,6,9-tetramethyl-6,7-dihydro-11<italic>H</italic>-dibenzo[<italic>b</italic>,<italic>e</italic>][1,4]dioxepine-8,11(5aH)-dione
(<bold>45</bold>) (4.8 mg, 13 &#x003bc;mol, 40%) as a white solid. LC&#x02013;MS <italic>m</italic>/<italic>z</italic> = 377.0 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, THF-<italic>d</italic><sub>8</sub>) &#x003b4; 8.28
(s, 1H), 5.16 (d, <italic>J</italic> = 2.2 Hz, 1H), 4.58 (d, <italic>J</italic> = 3.2 Hz, 1H), 4.24 (d, <italic>J</italic> = 3.2 Hz, 1H),
3.46 (s, 3H), 2.70 (qd, <italic>J</italic> = 7.5, 5.7 Hz, 2H), 2.37
(s, 3H), 2.25 (s, 3H), 1.85 (d, <italic>J</italic> = 2.2 Hz, 3H),
1.08 (t, <italic>J</italic> = 7.5 Hz, 3H), 1.01 (s, 3H).</p></sec><sec id="sec4.3.3.39"><title>(5a<italic>S</italic>,6<italic>S</italic>,7<italic>S</italic>)-7-Hydroxy-6-methoxy-1,4,6,9-tetramethyl-3-((triisopropylsilyl)oxy)-6,7-dihydro-11<italic>H</italic>-dibenzo[<italic>b</italic>,<italic>e</italic>][1,4]dioxepine-8,11(5aH)-dione
(<bold>46</bold>)</title><p>A vial was charged sequentially with (5a<italic>S</italic>,6<italic>S</italic>,7<italic>S</italic>)-3,7-dihydroxy-6-methoxy-1,4,6,9-tetramethyl-6,7-dihydro-11<italic>H</italic>-dibenzo[<italic>b</italic>,<italic>e</italic>][1,4]dioxepine-8,11(5aH)-dione
(<bold>2</bold>) (200 mg, 1 equiv, 574 &#x003bc;mol), THF (5 mL), followed
by 1H-imidazole (46.9 mg, 1.2 equiv, 689 &#x003bc;mol). Finally, chlorotriisopropylsilane
(133 mg, 147 &#x003bc;L, 1.2 equiv, 689 &#x003bc;mol) was added, and the
mixture was stirred at room temperature overnight. Additional portions
of chlorotriisopropylsilane (133 mg, 147 &#x003bc;L, 1.2 equiv, 689
&#x003bc;mol) and 1H-imidazole (46.9 mg, 1.2 equiv, 689 &#x003bc;mol)
were added, and the reaction was stirred an additional 6 h. The mixture
was diluted in DCM and washed with saturated aqueous NH<sub>4</sub>Cl, and the organic layer was dried over MgSO<sub>4</sub> and concentrated.
The residue was purified by flash chromatography (0&#x02013;25% EtOAc
in hexanes) to afford (5a<italic>S</italic>,6<italic>S</italic>,7<italic>S</italic>)-7-hydroxy-6-methoxy-1,4,6,9-tetramethyl-3-((triisopropylsilyl)oxy)-6,7-dihydro-11<italic>H</italic>-dibenzo[<italic>b</italic>,<italic>e</italic>][1,4]dioxepine-8,11(5aH)-dione
(<bold>46</bold>) (196 mg, 388 &#x003bc;mol, 68% yield) as a colorless
oil. LC&#x02013;MS <italic>m</italic>/<italic>z</italic> = 505.2 [M
+ H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, THF-d<sub>8</sub>) &#x003b4;
6.61 (s, 1H), 5.12 (q, <italic>J</italic> = 2.0 Hz, 1H), 4.60 (d, <italic>J</italic> = 3.3 Hz, 1H), 4.28&#x02013;4.19 (m, 1H), 3.44 (s, 3H),
2.45 (s, 3H), 2.26 (s, 3H), 1.86 (d, <italic>J</italic> = 2.0 Hz,
3H), 1.45&#x02013;1.30 (m, 3H), 1.15 (dd, <italic>J</italic> = 7.5,
3.5 Hz, 18H), 1.12 (s, 3H).</p></sec><sec id="sec4.3.3.40"><title>(5a<italic>S</italic>,6<italic>R</italic>,7<italic>S</italic>)-6-Methoxy-1,4,6,9-tetramethyl-8,11-dioxo-3-((triisopropylsilyl)oxy)-5a,6,7,8-tetrahydro-11<italic>H</italic>-dibenzo[<italic>b</italic>,<italic>e</italic>][1,4]dioxepin-7-yl
Acetate (<bold>47</bold>)</title><p>(5a<italic>S</italic>,6<italic>S</italic>,7<italic>S</italic>)-7-Hydroxy-6-methoxy-1,4,6,9-tetramethyl-3-((triisopropylsilyl)oxy)-6,7-dihydro-11<italic>H</italic>-dibenzo[<italic>b</italic>,<italic>e</italic>][1,4]dioxepine-8,11(5aH)-dione
(<bold>46</bold>) (50 mg, 1 equiv, 99 &#x003bc;mol) was dissolved in
DCM (2.0 mL). Pyridine (78 mg, 90 &#x003bc;L, 10 equiv, 0.99 mmol) was
added, followed by acetic anhydride (0.10 g, 94 &#x003bc;L, 10 equiv,
0.99 mmol), and the mixture was stirred at room temperature for 1
h, then the mixture was heated to 45 &#x000b0;C and stirred overnight.
An additional portion of acetic anhydride (0.10 g, 94 &#x003bc;L, 10
equiv, 0.99 mmol) was added, and the mixture was stirred overnight
at room temperature. The mixture was diluted in DCM and washed with
saturated aqueous NH<sub>4</sub>Cl, and the organic layer was dried
over MgSO<sub>4</sub> and concentrated. The residue was purified by
flash chromatography (0&#x02013;25% EtOAc in hexanes) to afford (5a<italic>S</italic>,6<italic>R</italic>,7<italic>S</italic>)-6-methoxy-1,4,6,9-tetramethyl-8,11-dioxo-3-((triisopropylsilyl)oxy)-5a,6,7,8-tetrahydro-11<italic>H</italic>-dibenzo[<italic>b</italic>,<italic>e</italic>][1,4]dioxepin-7-yl
acetate (46 mg, 99 &#x003bc;mol, 85% yield) as a colorless oil. LC&#x02013;MS <italic>m</italic>/<italic>z</italic> = 547.2 [M + H]<sup>+</sup>.</p><p>(5a<italic>S</italic>,6<italic>R</italic>,7<italic>S</italic>)-6-methoxy-1,4,6,9-tetramethyl-8,11-dioxo-3-((triisopropylsilyl)oxy)-5a,6,7,8-tetrahydro-11<italic>H</italic>-dibenzo[<italic>b</italic>,<italic>e</italic>][1,4]dioxepin-7-yl
acetate (46 mg, 1 equiv, 84 &#x003bc;mol) was dissolved in THF (3 mL)
and transferred to a vial under air. Pyridine hydrofluoride (17 mg,
15 &#x003bc;L, 2 equiv, 0.17 mmol) was added, and the mixture was stirred
at room temperature for 1 h. The mixture was concentrated without
workup. The residue was purified by flash chromatography (0&#x02013;40%
EtOAc in hexanes) to afford (5a<italic>S</italic>,6<italic>R</italic>,7<italic>S</italic>)-6-methoxy-1,4,6,9-tetramethyl-8,11-dioxo-3-((triisopropylsilyl)oxy)-5a,6,7,8-tetrahydro-11<italic>H</italic>-dibenzo[<italic>b</italic>,<italic>e</italic>][1,4]dioxepin-7-yl
acetate (<bold>47</bold>) (24 mg, 61 &#x003bc;mol, 73% yield) as a white
solid. LC&#x02013;MS <italic>m</italic>/<italic>z</italic> = 391.0
[M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, THF-<italic>d</italic><sub>8</sub>) &#x003b4; 9.31 (s, 1H), 6.52 (s, 1H), 5.61 (s, 1H), 5.33
(q, <italic>J</italic> = 2.0 Hz, 1H), 3.27 (s, 3H), 2.45 (s, 3H),
2.18 (s, 3H), 2.14 (s, 3H), 1.84 (d, <italic>J</italic> = 1.9 Hz,
3H), 1.27 (s, 3H).</p></sec><sec id="sec4.3.3.41"><title>(5a<italic>S</italic>,6<italic>R</italic>,7<italic>S</italic>)-3-Hydroxy-6-methoxy-1,4,6,9-tetramethyl-8,11-dioxo-5a,6,7,8-tetrahydro-11<italic>H</italic>-dibenzo[<italic>b</italic>,<italic>e</italic>][1,4]dioxepin-7-yl
methyl Carbonate (<bold>48</bold>)</title><p>(5a<italic>S</italic>,6<italic>S</italic>,7<italic>S</italic>)-7-Hydroxy-6-methoxy-1,4,6,9-tetramethyl-3-((triisopropylsilyl)oxy)-6,7-dihydro-11<italic>H</italic>-dibenzo[<italic>b</italic>,<italic>e</italic>][1,4]dioxepine-8,11(5aH)-dione
(<bold>46</bold>) (20 mg, 1 equiv, 40 &#x003bc;mol) was dissolved in
THF (1 mL). Dry sodium hydride (95%, 1.9 mg, 2 equiv, 79 &#x003bc;mol)
was added, and the mixture was stirred at 25 &#x000b0;C for 3 min. Then,
methyl chloroformate (7.5 mg, 6.1 &#x003bc;L, 2 equiv, 79 &#x003bc;mol)
was added, and the mixture was allowed to stir at 25 &#x000b0;C for 16
h. The mixture was then diluted with EtOAc (20 mL), washed with saturated
aqueous NH<sub>4</sub>Cl (2 &#x000d7; 20 mL), and the organic layer was
dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated. The residue
was purified by flash chromatography (0&#x02013;100% EtOAc in hexanes)
to afford (5a<italic>S</italic>,6<italic>R</italic>,7<italic>S</italic>)-6-methoxy-1,4,6,9-tetramethyl-8,11-dioxo-3-((triisopropylsilyl)oxy)-5a,6,7,8-tetrahydro-11<italic>H</italic>-dibenzo[<italic>b</italic>,<italic>e</italic>][1,4]dioxepin-7-yl
methyl carbonate (5.0 mg, 8.9 &#x003bc;mol, 22% yield) as a yellow oil.
LC&#x02013;MS <italic>m</italic>/<italic>z</italic> = 563.2 [M + H]<sup>+</sup>.</p><p>To a stirred solution of (5a<italic>S</italic>,6<italic>R</italic>,7<italic>S</italic>)-6-methoxy-1,4,6,9-tetramethyl-8,11-dioxo-3-((triisopropylsilyl)oxy)-5a,6,7,8-tetrahydro-11<italic>H</italic>-dibenzo[<italic>b</italic>,<italic>e</italic>][1,4]dioxepin-7-yl
methyl carbonate (5.0 mg, 1 equiv, 8.9 &#x003bc;mol) in THF (1 mL) was
added pyridine hydrofluoride (2.6 mg, 2.4 &#x003bc;L, 3 equiv, 27 &#x003bc;mol).
The mixture was allowed to stir at 25 &#x000b0;C for 1 h then concentrated
and the residue was purified by reverse phase HPLC (10&#x02013;100%
acetonitrile in water, 0.1% formic acid) to afford (5a<italic>S</italic>,6<italic>R</italic>,7<italic>S</italic>)-3-hydroxy-6-methoxy-1,4,6,9-tetramethyl-8,11-dioxo-5a,6,7,8-tetrahydro-11<italic>H</italic>-dibenzo[<italic>b</italic>,<italic>e</italic>][1,4]dioxepin-7-yl
methyl carbonate (<bold>48</bold>) (0.60 mg, 1.5 &#x003bc;mol, 17% yield)
as a white solid. LC&#x02013;MS <italic>m</italic>/<italic>z</italic> = 404.8 [M &#x02013; H]<sup>&#x02212;</sup>. <sup>1</sup>H NMR (400
MHz, THF-<italic>d</italic><sub>8</sub>) &#x003b4; 9.37 (s, 1H), 6.53
(s, 1H), 5.41 (s, 1H), 5.31 (q, <italic>J</italic> = 1.9 Hz, 1H),
3.78 (s, 3H), 3.31 (s, 3H), 2.45 (s, 3H), 2.18 (s, 3H), 1.85 (d, <italic>J</italic> = 1.9 Hz, 3H), 1.26 (s, 3H).</p></sec><sec id="sec4.3.3.42"><title>(5a<italic>S</italic>,6<italic>R</italic>,7<italic>S</italic>)-3-Hydroxy-6-methoxy-1,4,6,9-tetramethyl-8,11-dioxo-5a,6,7,8-tetrahydro-11<italic>H</italic>-dibenzo[<italic>b</italic>,<italic>e</italic>][1,4]dioxepin-7-yl
Glycinate (<bold>49</bold>)</title><p>(5a<italic>S</italic>,6<italic>S</italic>,7<italic>S</italic>)-7-Hydroxy-6-methoxy-1,4,6,9-tetramethyl-3-((triisopropylsilyl)oxy)-6,7-dihydro-11<italic>H</italic>-dibenzo[<italic>b</italic>,<italic>e</italic>][1,4]dioxepine-8,11(5aH)-dione
(<bold>46</bold>) (35 mg, 1 equiv, 69 &#x003bc;mol) was dissolved in
THF (2 mL). Sodium hydride (3.3 mg, 2 equiv, 0.14 mmol) was added,
and the mixture was stirred at 25 &#x000b0;C for 3 min. Then, Boc-Gly-OSu
(38 mg, 2 equiv, 0.14 mmol) was added, and the mixture was allowed
to stir at 25 &#x000b0;C for 16 h. The mixture was diluted in DCM and
quenched with saturated aqueous NH<sub>4</sub>Cl, and the organic
layer was dried over MgSO<sub>4</sub> and concentrated. The residue
was purified by flash chromatography (0&#x02013;50% EtOAc in hexanes)
afforded (5a<italic>S</italic>,6<italic>R</italic>,7<italic>S</italic>)-6-methoxy-1,4,6,9-tetramethyl-8,11-dioxo-3-((triisopropylsilyl)oxy)-5a,6,7,8-tetrahydro-11<italic>H</italic>-dibenzo[<italic>b</italic>,<italic>e</italic>][1,4]dioxepin-7-yl
(tert-butoxycarbonyl)glycinate (18 mg, 27 &#x003bc;mol, 39% yield) as
a colorless oil. LC&#x02013;MS <italic>m</italic>/<italic>z</italic> = 662.2 [M + H]<sup>+</sup>.</p><p>(5a<italic>S</italic>,6<italic>R</italic>,7<italic>S</italic>)-6-Methoxy-1,4,6,9-tetramethyl-8,11-dioxo-3-((triisopropylsilyl)oxy)-5a,6,7,8-tetrahydro-11<italic>H</italic>-dibenzo[<italic>b</italic>,<italic>e</italic>][1,4]dioxepin-7-yl
(tert-butoxycarbonyl)glycinate (18 mg, 1 equiv, 27 &#x003bc;mol) was
dissolved in THF (2 mL) in a vial under air. Pyridine hydrofluoride
(13 mg, 12 &#x003bc;L, 5 equiv, 0.14 mmol) was added, and the mixture
was stirred at 25 &#x000b0;C for 1 h. The mixture was washed with NH<sub>4</sub>Cl and extracted with DCM and the organic layer was dried
over MgSO<sub>4</sub> and concentrated. The residue was purified by
flash chromatography (0&#x02013;60% EtOAc in hexanes) to afford (5a<italic>S</italic>,6<italic>R</italic>,7<italic>S</italic>)-3-hydroxy-6-methoxy-1,4,6,9-tetramethyl-8,11-dioxo-5a,6,7,8-tetrahydro-11<italic>H</italic>-dibenzo[<italic>b</italic>,<italic>e</italic>][1,4]dioxepin-7-yl
(tert-butoxycarbonyl)glycinate (8 mg, 0.02 mmol, 60% yield) as a colorless
oil. LC&#x02013;MS <italic>m</italic>/<italic>z</italic> = 504.0 [M
&#x02013; H]<sup>&#x02212;</sup>.</p><p>(5a<italic>S</italic>,6<italic>R</italic>,7<italic>S</italic>)-3-Hydroxy-6-methoxy-1,4,6,9-tetramethyl-8,11-dioxo-5a,6,7,8-tetrahydro-11<italic>H</italic>-dibenzo[<italic>b</italic>,<italic>e</italic>][1,4]dioxepin-7-yl
(tert-butoxycarbonyl)glycinate (8 mg, 1 equiv, 0.02 mmol) was dissolved
in DCM (1 mL) and transferred to a vial under air. 2,2,2-trifluoroacetic
acid (10 &#x003bc;L, 10 equiv, 0.2 mmol) was added, and the mixture
was stirred at 25 &#x000b0;C for 1 h. The mixture was concentrated to
an oil and then lyophilized to afford (5a<italic>S</italic>,6<italic>R</italic>,7<italic>S</italic>)-3-hydroxy-6-methoxy-1,4,6,9-tetramethyl-8,11-dioxo-5a,6,7,8-tetrahydro-11<italic>H</italic>-dibenzo[<italic>b</italic>,<italic>e</italic>][1,4]dioxepin-7-yl
glycinate (<bold>49</bold>) (6 mg, 0.01 mmol, 90%) as a white solid.
LC&#x02013;MS <italic>m</italic>/<italic>z</italic> = 406.0 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, THF-<italic>d</italic><sub>8</sub>) &#x003b4; 6.54 (s, 1H), 5.72 (s, 1H), 5.31 (q, <italic>J</italic> = 2.0 Hz, 1H), 4.16 (d, <italic>J</italic> = 17.7 Hz, 1H), 4.05
(d, <italic>J</italic> = 17.6 Hz, 1H), 3.32 (s, 3H), 2.46 (s, 3H),
2.18 (s, 3H), 1.85 (d, <italic>J</italic> = 1.9 Hz, 3H), 1.32 (s,
3H).</p></sec><sec id="sec4.3.3.43"><title>(5a<italic>S</italic>,6<italic>R</italic>,7<italic>S</italic>)-3-Hydroxy-6-methoxy-1,4,6,9-tetramethyl-8,11-dioxo-5a,6,7,8-tetrahydro-11<italic>H</italic>-dibenzo[<italic>b</italic>,<italic>e</italic>][1,4]dioxepin-7-yl
17-oxo-21-((3a<italic>S</italic>,4<italic>S</italic>,6a<italic>R</italic>)-2-oxohexahydro-1<italic>H</italic>-thieno[3,4-<italic>d</italic>]imidazol-4-yl)-4,7,10,13-tetraoxa-16-azahenicosanoate (<bold>50</bold>)</title><p>To a vial under nitrogen containing (5a<italic>S</italic>,6<italic>S</italic>,7<italic>S</italic>)-7-hydroxy-6-methoxy-1,4,6,9-tetramethyl-3-((triisopropylsilyl)oxy)-6,7-dihydro-11<italic>H</italic>-dibenzo[<italic>b</italic>,<italic>e</italic>][1,4]dioxepine-8,11(5aH)-dione
(<bold>46</bold>) (47.4 mg, 1 equiv, 93.9 &#x003bc;mol) and dry sodium
hydride (95%, 6.8 mg, 3 equiv, 282 &#x003bc;mol) was added anhydrous
THF (1 mL). The mixture was stirred at room temperature for 5 min.
NHS-PEG4-biotin (175 mg, 3 equiv, 282 &#x003bc;mol) and DMF (0.2 mL)
were added, and the mixture was stirred for 3 h. An additional portion
of dry sodium hydride (95%, 4.5 mg, 2 equiv, 188 &#x003bc;mol) and DMF
(0.2 mL) were added, and the mixture was stirred overnight at room
temperature. The mixture was diluted in EtOAc and washed with saturated
aqueous NH<sub>4</sub>Cl, and the aqueous layer was extracted with
EtOAc. The combined organic layer was dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated. The residue was purified by reverse phase
chromatography (RediSep C18 column, 10&#x02013;100% acetonitrile in
water with 0.1% formic acid) to afford (5a<italic>S</italic>,6<italic>R</italic>,7<italic>S</italic>)-6-methoxy-1,4,6,9-tetramethyl-8,11-dioxo-3-((triisopropylsilyl)oxy)-5a,6,7,8-tetrahydro-11<italic>H</italic>-dibenzo[<italic>b</italic>,<italic>e</italic>][1,4]dioxepin-7-yl
17-oxo-21-((3a<italic>S</italic>,4<italic>S</italic>,6a<italic>R</italic>)-2-oxohexahydro-1<italic>H</italic>-thieno[3,4-<italic>d</italic>]imidazol-4-yl)-4,7,10,13-tetraoxa-16-azahenicosanoate (24 mg, 24
&#x003bc;mol, 26% yield) as a white solid. LC&#x02013;MS <italic>m</italic>/<italic>z</italic> = 979.4 [M + H]<sup>+</sup>. <sup>1</sup>H NMR
(400 MHz, THF-<italic>d</italic><sub>8</sub>) &#x003b4; 7.05 (s, 1H),
6.63 (s, 1H), 5.80 (s, 1H), 5.67 (s, 1H), 5.58 (s, 1H), 5.43 (d, <italic>J</italic> = 2.1 Hz, 1H), 4.35 (t, <italic>J</italic> = 6.5 Hz, 1H),
4.19 (t, <italic>J</italic> = 6.3 Hz, 1H), 3.77 (t, <italic>J</italic> = 6.5 Hz, 2H), 3.56 (s, 3H), 3.55&#x02013;3.50 (m, 1H), 3.45 (t, <italic>J</italic> = 5.5 Hz, 2H), 3.30 (s, 3H), 3.28 (d, <italic>J</italic> = 5.2 Hz, 2H), 3.16&#x02013;3.09 (m, 1H), 2.85 (dd, <italic>J</italic> = 12.3, 5.1 Hz, 1H), 2.71 (t, <italic>J</italic> = 6.4 Hz, 2H),
2.61 (d, <italic>J</italic> = 12.5 Hz, 1H), 2.48 (d, <italic>J</italic> = 10.8 Hz, 8H), 2.26 (s, 3H), 2.10 (t, <italic>J</italic> = 7.3
Hz, 2H), 1.85 (d, <italic>J</italic> = 2.0 Hz, 3H), 1.62 (q, <italic>J</italic> = 7.7 Hz, 2H), 1.47&#x02013;1.33 (m, 3H), 1.24 (s, 3H),
1.15 (dd, <italic>J</italic> = 7.5, 3.7 Hz, 18H).</p><p>To a vial
under nitrogen containing (5a<italic>S</italic>,6<italic>R</italic>,7<italic>S</italic>)-6-methoxy-1,4,6,9-tetramethyl-8,11-dioxo-3-((triisopropylsilyl)oxy)-5a,6,7,8-tetrahydro-11<italic>H</italic>-dibenzo[<italic>b</italic>,<italic>e</italic>][1,4]dioxepin-7-yl
17-oxo-21-((3aS,4S,6aR)-2-oxohexahydro-1<italic>H</italic>-thieno[3,4-<italic>d</italic>]imidazol-4-yl)-4,7,10,13-tetraoxa-16-azahenicosanoate
(9.4 mg, 1 equiv, 9.6 &#x003bc;mol) and TBAT (7.8 mg, 1.5 equiv, 14
&#x003bc;mol) was added anhydrous THF (0.4 mL). The mixture was stirred
at room temperature for 10 min then concentrated. The residue was
purified by reverse phase chromatography (RediSep C18 column, 10&#x02013;100%
acetonitrile in water with 0.1% formic acid) afforded (5a<italic>S</italic>,6<italic>R</italic>,7<italic>S</italic>)-3-hydroxy-6-methoxy-1,4,6,9-tetramethyl-8,11-dioxo-5a,6,7,8-tetrahydro-11<italic>H</italic>-dibenzo[<italic>b</italic>,<italic>e</italic>][1,4]dioxepin-7-yl
17-oxo-21-((3a<italic>S</italic>,4<italic>S</italic>,6a<italic>R</italic>)-2-oxohexahydro-1<italic>H</italic>-thieno[3,4-<italic>d</italic>]imidazol-4-yl)-4,7,10,13-tetraoxa-16-azahenicosanoate (<bold>50</bold>) (4.2 mg, 5.1 &#x003bc;mol, 53% yield) as a white solid. LC&#x02013;MS <italic>m</italic>/<italic>z</italic> = 822.2 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, THF-<italic>d</italic><sub>8</sub>) &#x003b4; 7.10
(s, 1H), 6.59 (s, 1H), 5.97 (s, 1H), 5.79 (s, 1H), 5.70 (s, 1H), 5.36
(d, <italic>J</italic> = 2.2 Hz, 1H), 4.42&#x02013;4.37 (m, 1H), 4.25&#x02013;4.19
(m, 1H), 3.77 (t, <italic>J</italic> = 6.2 Hz, 2H), 3.56&#x02013;3.50
(m, 6H), 3.44 (t, <italic>J</italic> = 5.4 Hz, 2H), 3.27 (d, <italic>J</italic> = 2.5 Hz, 5H), 3.16&#x02013;3.10 (m, 1H), 2.87 (dd, <italic>J</italic> = 12.5, 5.0 Hz, 1H), 2.70 (td, <italic>J</italic> = 6.3,
2.1 Hz, 2H), 2.64 (d, <italic>J</italic> = 12.5 Hz, 1H), 2.46 (s,
3H), 2.18 (s, 3H), 2.08 (t, <italic>J</italic> = 7.3 Hz, 2H), 1.84
(d, <italic>J</italic> = 1.9 Hz, 3H), 1.57 (h, <italic>J</italic> =
6.4 Hz, 3H), 1.41 (td, <italic>J</italic> = 14.4, 6.5 Hz, 2H), 1.29
(s, 3H).</p></sec><sec id="sec4.3.3.44"><title>(5a<italic>S</italic>,6<italic>S</italic>,7<italic>S</italic>)-3,7-Dihydroxy-6-methoxy-1,4,6,9-tetramethyl-6,7-dihydrodibenzo[<italic>b</italic>,<italic>f</italic>][1,4]oxazepine-8,11(5aH,10H)-dione
(<bold>51</bold>)</title><p>(5a<italic>S</italic>,6<italic>S</italic>,7<italic>S</italic>)-3,7-Dihydroxy-6-methoxy-1,4,6,9-tetramethyl-6,7-dihydro-11<italic>H</italic>-dibenzo[<italic>b</italic>,<italic>e</italic>][1,4]dioxepine-8,11(5aH)-dione
(60.0 mg, 1 equiv, 172 &#x003bc;mol), and DMF (0.3 mL) were added to
a microwave vial under air. Ammonia solution (0.4 M in THF, 2.15 mL,
5 equiv, 861 &#x003bc;mol) was added, then the mixture was stirred at
room temperature for 4 h. The reaction was concentrated then toluene
(5.0 mL) and PPTS (17.3 mg, 0.4 equiv, 68.9 &#x003bc;mol) were added
to the reaction mixture and the mixture was heated to 110 &#x000b0;C
for 1 h. Additional PPTS (17.3 mg, 0.4 equiv, 68.9 &#x003bc;mol) was
added and the reaction was heated to 115 &#x000b0;C in the microwave
reactor for 1 h. The reaction was heated to 120 &#x000b0;C in the microwave
reactor for 3 h. The reaction was concentrated and the residue was
purified by flash chromatography (0&#x02013;50% EtOAc in hexane, 10
g column) then further purified by reverse phase HPLC (10&#x02013;100%
acetonitrile in water, 0.1% formic acid) to give (5a<italic>S</italic>,6<italic>S</italic>,7<italic>S</italic>)-3,7-dihydroxy-6-methoxy-1,4,6,9-tetramethyl-6,7-dihydrodibenzo[<italic>b</italic>,<italic>f</italic>][1,4]oxazepine-8,11(5aH,10H)-dione
(<bold>51</bold>) (26 mg, 75 &#x003bc;mol, 43% yield) as a white solid.
LC&#x02013;MS <italic>m</italic>/<italic>z</italic> = 346.0 [M &#x02013;
H]<sup>&#x02212;</sup>. <sup>1</sup>H NMR (400 MHz, THF-<italic>d</italic><sub>8</sub>) &#x003b4; 8.96 (s, 1H), 8.44 (s, 1H), 6.48 (s, 1H), 4.77
(d, <italic>J</italic> = 1.9 Hz, 1H), 4.38 (d, <italic>J</italic> =
2.6 Hz, 1H), 4.15 (d, <italic>J</italic> = 2.5 Hz, 1H), 3.42 (s, 3H),
2.43 (s, 3H), 2.21 (s, 3H), 1.90 (d, <italic>J</italic> = 1.8 Hz,
3H), 1.22 (s, 3H).</p></sec></sec></sec></sec></body><back><notes id="notes-1" notes-type="si"><title>Supporting Information Available</title><p>The Supporting Information
is available free of charge at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.4c01095?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.4c01095</ext-link>.<list id="silist" list-type="simple"><list-item><p>Pho85:ETaG chimera activity; phylogenetic analysis of
production strain; transcriptional and metabolomic effects of BGC
gene KOs; in vitro assays with BGC enzymes, proposed biosynthesis
of known roseopurpurins and aculeatusquinones; intact MS and peptide
mapping of CDKs bound to <bold>2;</bold> chemoproteomics of <bold>2</bold> in human cell lysate; BGC function; NMR assignments; X-ray
crystallography; nucleic acids used; UniProt IDs for sequence data
used; MS and NMR spectra of compounds isolated from fungi; MS and
NMR spectra of synthetic compounds; X-ray crystallography reports
for compounds <bold>2</bold> and <bold>43</bold>; additional genomics
(ETaG search, resistance mutation analysis, phylogenetic reconstruction,
RNA sequencing and analysis); synthetic biology (filamentous fungal
engineering, heterologous expression and assay of RosA and RosD, fungal
Pho85 and human CDKs); microbiology (fungal fermentation and GEM extraction);
and biochemistry (protein intact mass spectrometry, X-ray crystallography,
chemoproteomics) methods (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.4c01095/suppl_file/jm4c01095_si_001.pdf">PDF</ext-link>)</p></list-item><list-item><p>SMILES strings for all compounds in this
study (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.4c01095/suppl_file/jm4c01095_si_002.csv">CSV</ext-link>)</p></list-item><list-item><p>Raw data for phylogenetic trees (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.4c01095/suppl_file/jm4c01095_si_003.zip">ZIP</ext-link>)</p></list-item></list></p></notes><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="sifile1"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jm4c01095_si_001.pdf"><caption><p>jm4c01095_si_001.pdf</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="sifile2"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jm4c01095_si_002.csv"><caption><p>jm4c01095_si_002.csv</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="sifile3"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jm4c01095_si_003.zip"><caption><p>jm4c01095_si_003.zip</p></caption></media></supplementary-material></sec><notes notes-type="" id="notes-2"><title>Author Present Address</title><p><sup>&#x000a7;</sup> Mount
Sinai South Nassau, One Healthy Way, Oceanside, New York
11572, United States</p></notes><notes notes-type="" id="notes-3"><title>Author Present Address</title><p><sup>&#x02225;</sup> Matchpoint
Therapeutics, 99 Coolidge Ave, Watertown, Massachusetts
02472, United States</p></notes><notes notes-type="" id="notes-4"><title>Author Present Address</title><p><sup>&#x022a5;</sup> Sail
Biomedicines, 140 First St, Suite 600, Cambridge, Massachusetts
02141, United States</p></notes><notes notes-type="" id="notes-5"><title>Author Present Address</title><p><sup>#</sup> Moderna Inc.,
1 Upland Rd, Norwood, Massachusetts 02062, United
States</p></notes><notes notes-type="" id="notes-6"><title>Author Present Address</title><p><sup>&#x02207;</sup> Bactobio
Ltd., 1&#x02013;45 Durham St, London SE11 5JH, U.K.</p></notes><notes notes-type="" id="notes-7"><title>Author Present Address</title><p><sup>&#x025cb;</sup> JN Analytical Solutions LLC, 2 Oneida Place, Hudson, Massachusetts
01749, United States</p></notes><notes notes-type="" id="notes-8"><title>Author Present Address</title><p><sup>&#x025c6;</sup> Sensorium
Therapeutics, 40 Guest Street, Boston, Massachusetts
02135, United States</p></notes><notes notes-type="" id="notes-9"><title>Author Present Address</title><p><sup>&#x000b6;</sup> Center
for Cystic Fibrosis and Airways Disease Research (CF-AIR),
Department of Pediatrics, Emory University School of Medicine, 2015
Uppergate Dr NE, Atlanta, Georgia 30322, United States</p></notes><notes notes-type="" id="notes-10"><title>Author Present Address</title><p><sup>&#x02020;&#x02020;</sup> University of Iowa. 230 N Madison St,
Iowa City, Iowa 52240, United States</p></notes><notes notes-type="" id="notes-11"><title>Author Present Address</title><p><sup>&#x02021;&#x02021;</sup> Atavistik Bio Inc., 101 Cambridgepark
Drive, Cambridge, Massachusetts 02140, United States</p></notes><notes notes-type="" id="notes-12"><title>Author Present Address</title><p><sup>&#x000a7;&#x000a7;</sup> Entact Bio, 65 Grove St, Watertown, Massachusetts
02472, United States</p></notes><notes notes-type="" id="notes-13"><title>Author Present Address</title><p><sup>&#x02225;&#x02225;</sup> Servier Pharmaceuticals, 200 Pier 4 Blvd.,
Boston, Massachusetts 02210, United States</p></notes><notes notes-type="" id="notes-14"><title>Author Present Address</title><p><sup>&#x022a5;&#x022a5;</sup> Empress Therapeutics, 99 Coolidge Ave,
Watertown, Massachusetts 02472, United States</p></notes><notes notes-type="" id="notes-15"><title>Author Present Address</title><p><sup>##</sup> Fungal Biotech Solutions, 20 fourth St, Medford, Massachusetts
02155, United States</p></notes><notes notes-type="" id="notes-16"><title>Author Present Address</title><p><sup>&#x02207;&#x02207;</sup> Revolution Medicines, Inc., 700 Saginaw
Dr., Redwood City, California 94063, United States</p></notes><notes notes-type="" id="notes-17"><title>Author Contributions</title><p><sup>&#x025cb;&#x025cb;</sup> J.D., M.H., S.P.R., and Y.J.C. contributed equally to this work.</p></notes><notes notes-type="COI-statement" id="notes-18"><p>The authors
declare the following competing financial interest(s): All authors
are current or former employees of LifeMine Therapeutics.</p></notes><ack><title>Acknowledgments</title><p>Thanks to John Bacsa and the Emory X-ray Crystallography Center
for single crystal X-ray crystallographic analysis, Eric Smith for
graphic design, and several contract research organizations for experimental
support&#x02014;WuXi AppTec (Shanghai, China), WuXi AppTec (New Jersey),
Viva Biotech (Shanghai, China), CreLux (Martinsried, Germany), Certis
Oncology Solutions, Inc. (San Diego, CA), Promega (Madison, WI), XenoBiotic
Laboratory (Cranbury, NJ).</p></ack><glossary id="dl1"><def-list><title>Abbreviations Used</title><def-item><term>CDK</term><def><p>cyclin-dependent kinase</p></def></def-item><def-item><term>GEM</term><def><p>genetically encoded small
molecule</p></def></def-item><def-item><term>ETaG</term><def><p>embedded
target gene</p></def></def-item><def-item><term>TD<sup>3</sup></term><def><p>top-down drug discovery</p></def></def-item><def-item><term>BGC</term><def><p>biosynthetic gene cluster</p></def></def-item><def-item><term>PDX</term><def><p>patient-derived xenotransplant</p></def></def-item></def-list></glossary><ref-list><title>References</title><ref id="ref1"><mixed-citation publication-type="journal" id="cit1"><name><surname>Tobert</surname><given-names>J. A.</given-names></name>
<article-title>Lovastatin
and beyond: The History of the HMG-CoA Reductase Inhibitors</article-title>. <source>Nat. Rev. Drug Discovery</source>
<year>2003</year>, <volume>2</volume> (<issue>7</issue>), <fpage>517</fpage>&#x02013;<lpage>526</lpage>. <pub-id pub-id-type="doi">10.1038/nrd1112</pub-id>.<pub-id pub-id-type="pmid">12815379</pub-id>
</mixed-citation></ref><ref id="ref2"><mixed-citation publication-type="journal" id="cit2"><name><surname>Matyori</surname><given-names>A.</given-names></name>; <name><surname>Brown</surname><given-names>C. P.</given-names></name>; <name><surname>Ali</surname><given-names>A.</given-names></name>; <name><surname>Sherbeny</surname><given-names>F.</given-names></name>
<article-title>Statins Utilization
Trends and Expenditures in the U.S. before and after the Implementation
of the 2013 ACC/AHA Guidelines</article-title>. <source>Saudi Pharm.
J.</source>
<year>2023</year>, <volume>31</volume> (<issue>6</issue>), <fpage>795</fpage>&#x02013;<lpage>800</lpage>. <pub-id pub-id-type="doi">10.1016/j.jsps.2023.04.002</pub-id>.<pub-id pub-id-type="pmid">37228328</pub-id>
</mixed-citation></ref><ref id="ref3"><mixed-citation publication-type="journal" id="cit3"><name><surname>Azzi</surname><given-names>J. R.</given-names></name>; <name><surname>Sayegh</surname><given-names>M. H.</given-names></name>; <name><surname>Mallat</surname><given-names>S. G.</given-names></name>
<article-title>Calcineurin Inhibitors:
40 Years
Later, Can&#x02019;t Live Without&#x000b7;&#x000b7;&#x000b7;</article-title>. <source>J. Immunol</source>
<year>2013</year>, <volume>191</volume> (<issue>12</issue>), <fpage>5785</fpage>&#x02013;<lpage>5791</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.1390055</pub-id>.<pub-id pub-id-type="pmid">24319282</pub-id>
</mixed-citation></ref><ref id="ref4"><mixed-citation publication-type="journal" id="cit4"><name><surname>Schreiber</surname><given-names>S. L.</given-names></name>
<article-title>The Rise
of Molecular Glues</article-title>. <source>Cell</source>
<year>2021</year>, <volume>184</volume> (<issue>1</issue>), <fpage>3</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2020.12.020</pub-id>.<pub-id pub-id-type="pmid">33417864</pub-id>
</mixed-citation></ref><ref id="ref5"><mixed-citation publication-type="journal" id="cit5"><name><surname>Newman</surname><given-names>D. J.</given-names></name>; <name><surname>Cragg</surname><given-names>G. M.</given-names></name>
<article-title>Natural Products
as Sources of New Drugs over the Nearly
Four Decades from 01/1981 to 09/2019</article-title>. <source>J. Nat.
Prod.</source>
<year>2020</year>, <volume>83</volume> (<issue>3</issue>), <fpage>770</fpage>&#x02013;<lpage>803</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jnatprod.9b01285</pub-id>.<pub-id pub-id-type="pmid">32162523</pub-id>
</mixed-citation></ref><ref id="ref6"><mixed-citation publication-type="journal" id="cit6"><name><surname>Rolinson</surname><given-names>G. N.</given-names></name>; <name><surname>Geddes</surname><given-names>A. M.</given-names></name>
<article-title>The 50th Anniversary of the Discovery
of 6-Aminopenicillanic
Acid (6-APA)</article-title>. <source>Int. J. Antimicrob. Agents</source>
<year>2007</year>, <volume>29</volume> (<issue>1</issue>), <fpage>3</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijantimicag.2006.09.003</pub-id>.<pub-id pub-id-type="pmid">17137753</pub-id>
</mixed-citation></ref><ref id="ref7"><mixed-citation publication-type="journal" id="cit7"><name><surname>Bentley</surname><given-names>R.</given-names></name>
<article-title>Mycophenolic
Acid: A One Hundred Year Odyssey from Antibiotic to Immunosuppressant</article-title>. <source>Chem. Rev.</source>
<year>2000</year>, <volume>100</volume> (<issue>10</issue>), <fpage>3801</fpage>&#x02013;<lpage>3826</lpage>. <pub-id pub-id-type="doi">10.1021/cr990097b</pub-id>.<pub-id pub-id-type="pmid">11749328</pub-id>
</mixed-citation></ref><ref id="ref8"><mixed-citation publication-type="journal" id="cit8"><name><surname>Beutler</surname><given-names>J. A.</given-names></name>
<article-title>Natural
Products as a Foundation for Drug Discovery</article-title>. <source>Curr. Protoc. Pharmacol.</source>
<year>2019</year>, <volume>86</volume> (<issue>1</issue>), <elocation-id>e67</elocation-id><pub-id pub-id-type="doi">10.1002/cpph.67</pub-id>.<pub-id pub-id-type="pmid">31539923</pub-id>
</mixed-citation></ref><ref id="ref9"><mixed-citation publication-type="journal" id="cit9"><name><surname>Atanasov</surname><given-names>A. G.</given-names></name>; <name><surname>Zotchev</surname><given-names>S. B.</given-names></name>; <name><surname>Dirsch</surname><given-names>V. M.</given-names></name>; <name><surname>Orhan</surname><given-names>I. E.</given-names></name>; <name><surname>Banach</surname><given-names>M.</given-names></name>; <name><surname>Rollinger</surname><given-names>J. M.</given-names></name>; <name><surname>Barreca</surname><given-names>D.</given-names></name>; <name><surname>Weckwerth</surname><given-names>W.</given-names></name>; <name><surname>Bauer</surname><given-names>R.</given-names></name>; <name><surname>Bayer</surname><given-names>E. A.</given-names></name>; <name><surname>Majeed</surname><given-names>M.</given-names></name>; <name><surname>Bishayee</surname><given-names>A.</given-names></name>; <name><surname>Bochkov</surname><given-names>V.</given-names></name>; <name><surname>Bonn</surname><given-names>G. K.</given-names></name>; <name><surname>Braidy</surname><given-names>N.</given-names></name>; <name><surname>Bucar</surname><given-names>F.</given-names></name>; <name><surname>Cifuentes</surname><given-names>A.</given-names></name>; <name><surname>D&#x02019;Onofrio</surname><given-names>G.</given-names></name>; <name><surname>Bodkin</surname><given-names>M.</given-names></name>; <name><surname>Diederich</surname><given-names>M.</given-names></name>; <name><surname>Dinkova-Kostova</surname><given-names>A. T.</given-names></name>; <name><surname>Efferth</surname><given-names>T.</given-names></name>; <name><surname>Bairi</surname><given-names>K. E.</given-names></name>; <name><surname>Arkells</surname><given-names>N.</given-names></name>; <name><surname>Fan</surname><given-names>T.-P.</given-names></name>; <name><surname>Fiebich</surname><given-names>B. L.</given-names></name>; <name><surname>Freissmuth</surname><given-names>M.</given-names></name>; <name><surname>Georgiev</surname><given-names>M. I.</given-names></name>; <name><surname>Gibbons</surname><given-names>S.</given-names></name>; <name><surname>Godfrey</surname><given-names>K. M.</given-names></name>; <name><surname>Gruber</surname><given-names>C. W.</given-names></name>; <name><surname>Heer</surname><given-names>J.</given-names></name>; <name><surname>Huber</surname><given-names>L. A.</given-names></name>; <name><surname>Ibanez</surname><given-names>E.</given-names></name>; <name><surname>Kijjoa</surname><given-names>A.</given-names></name>; <name><surname>Kiss</surname><given-names>A. K.</given-names></name>; <name><surname>Lu</surname><given-names>A.</given-names></name>; <name><surname>Macias</surname><given-names>F. A.</given-names></name>; <name><surname>Miller</surname><given-names>M. J. S.</given-names></name>; <name><surname>Mocan</surname><given-names>A.</given-names></name>; <name><surname>M&#x000fc;ller</surname><given-names>R.</given-names></name>; <name><surname>Nicoletti</surname><given-names>F.</given-names></name>; <name><surname>Perry</surname><given-names>G.</given-names></name>; <name><surname>Pittal&#x000e0;</surname><given-names>V.</given-names></name>; <name><surname>Rastrelli</surname><given-names>L.</given-names></name>; <name><surname>Ristow</surname><given-names>M.</given-names></name>; <name><surname>Russo</surname><given-names>G. L.</given-names></name>; <name><surname>Silva</surname><given-names>A. S.</given-names></name>; <name><surname>Schuster</surname><given-names>D.</given-names></name>; <name><surname>Sheridan</surname><given-names>H.</given-names></name>; <name><surname>Skalicka-Wo&#x0017a;niak</surname><given-names>K.</given-names></name>; <name><surname>Skaltsounis</surname><given-names>L.</given-names></name>; <name><surname>Sobarzo-S&#x000e1;nchez</surname><given-names>E.</given-names></name>; <name><surname>Bredt</surname><given-names>D. S.</given-names></name>; <name><surname>Stuppner</surname><given-names>H.</given-names></name>; <name><surname>Sureda</surname><given-names>A.</given-names></name>; <name><surname>Tzvetkov</surname><given-names>N. T.</given-names></name>; <name><surname>Vacca</surname><given-names>R. A.</given-names></name>; <name><surname>Aggarwal</surname><given-names>B. B.</given-names></name>; <name><surname>Battino</surname><given-names>M.</given-names></name>; <name><surname>Giampieri</surname><given-names>F.</given-names></name>; <name><surname>Wink</surname><given-names>M.</given-names></name>; <name><surname>Wolfender</surname><given-names>J.-L.</given-names></name>; <name><surname>Xiao</surname><given-names>J.</given-names></name>; <name><surname>Yeung</surname><given-names>A. W. K.</given-names></name>; <name><surname>Lizard</surname><given-names>G.</given-names></name>; <name><surname>Popp</surname><given-names>M. A.</given-names></name>; <name><surname>Heinrich</surname><given-names>M.</given-names></name>; <name><surname>Berindan-Neagoe</surname><given-names>I.</given-names></name>; <name><surname>Stadler</surname><given-names>M.</given-names></name>; <name><surname>Daglia</surname><given-names>M.</given-names></name>; <name><surname>Verpoorte</surname><given-names>R.</given-names></name>; <name><surname>Supuran</surname><given-names>C. T.</given-names></name>
<article-title>Natural Products in Drug Discovery:
Advances and Opportunities</article-title>. <source>Nat. Rev. Drug Discovery</source>
<year>2021</year>, <volume>20</volume>, <fpage>200</fpage>&#x02013;<lpage>216</lpage>. <pub-id pub-id-type="doi">10.1038/s41573-020-00114-z</pub-id>.<pub-id pub-id-type="pmid">33510482</pub-id>
</mixed-citation></ref><ref id="ref10"><mixed-citation publication-type="journal" id="cit10"><name><surname>Shigdel</surname><given-names>U. K.</given-names></name>; <name><surname>Lee</surname><given-names>S.-J.</given-names></name>; <name><surname>Sowa</surname><given-names>M. E.</given-names></name>; <name><surname>Bowman</surname><given-names>B. R.</given-names></name>; <name><surname>Robison</surname><given-names>K.</given-names></name>; <name><surname>Zhou</surname><given-names>M.</given-names></name>; <name><surname>Pua</surname><given-names>K. H.</given-names></name>; <name><surname>Stiles</surname><given-names>D. T.</given-names></name>; <name><surname>Blodgett</surname><given-names>J. A. V.</given-names></name>; <name><surname>Udwary</surname><given-names>D. W.</given-names></name>; <name><surname>Rajczewski</surname><given-names>A. T.</given-names></name>; <name><surname>Mann</surname><given-names>A. S.</given-names></name>; <name><surname>Mostafavi</surname><given-names>S.</given-names></name>; <name><surname>Hardy</surname><given-names>T.</given-names></name>; <name><surname>Arya</surname><given-names>S.</given-names></name>; <name><surname>Weng</surname><given-names>Z.</given-names></name>; <name><surname>Stewart</surname><given-names>M.</given-names></name>; <name><surname>Kenyon</surname><given-names>K.</given-names></name>; <name><surname>Morgenstern</surname><given-names>J. P.</given-names></name>; <name><surname>Pan</surname><given-names>E.</given-names></name>; <name><surname>Gray</surname><given-names>D. C.</given-names></name>; <name><surname>Pollock</surname><given-names>R. M.</given-names></name>; <name><surname>Fry</surname><given-names>A. M.</given-names></name>; <name><surname>Klausner</surname><given-names>R. D.</given-names></name>; <name><surname>Townson</surname><given-names>S. A.</given-names></name>; <name><surname>Verdine</surname><given-names>G. L.</given-names></name>
<article-title>Genomic Discovery of an Evolutionarily
Programmed Modality
for Small-Molecule Targeting of an Intractable Protein Surface</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source>
<year>2020</year>, <volume>117</volume> (<issue>29</issue>), <fpage>17195</fpage>&#x02013;<lpage>17203</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.2006560117</pub-id>.<pub-id pub-id-type="pmid">32606248</pub-id>
</mixed-citation></ref><ref id="ref11"><mixed-citation publication-type="journal" id="cit11"><name><surname>Osbourn</surname><given-names>A.</given-names></name>
<article-title>Secondary
Metabolic Gene Clusters: Evolutionary Toolkits for Chemical Innovation</article-title>. <source>Trends Genet.</source>
<year>2010</year>, <volume>26</volume> (<issue>10</issue>), <fpage>449</fpage>&#x02013;<lpage>457</lpage>. <pub-id pub-id-type="doi">10.1016/j.tig.2010.07.001</pub-id>.<pub-id pub-id-type="pmid">20739089</pub-id>
</mixed-citation></ref><ref id="ref12"><mixed-citation publication-type="journal" id="cit12"><name><surname>Cundliffe</surname><given-names>E.</given-names></name>; <name><surname>Demain</surname><given-names>A. L.</given-names></name>
<article-title>Avoidance of Suicide
in Antibiotic-Producing Microbes</article-title>. <source>J. Ind. Microbiol.
Biotechnol.</source>
<year>2010</year>, <volume>37</volume> (<issue>7</issue>), <fpage>643</fpage>&#x02013;<lpage>672</lpage>. <pub-id pub-id-type="doi">10.1007/s10295-010-0721-x</pub-id>.<pub-id pub-id-type="pmid">20446033</pub-id>
</mixed-citation></ref><ref id="ref13"><mixed-citation publication-type="journal" id="cit13"><name><surname>Almabruk</surname><given-names>K. H.</given-names></name>; <name><surname>Dinh</surname><given-names>L. K.</given-names></name>; <name><surname>Philmus</surname><given-names>B.</given-names></name>
<article-title>Self-Resistance of
Natural Product
Producers: Past, Present, and Future Focusing on Self-Resistant Protein
Variants</article-title>. <source>ACS Chem. Biol.</source>
<year>2018</year>, <volume>13</volume> (<issue>6</issue>), <fpage>1426</fpage>&#x02013;<lpage>1437</lpage>. <pub-id pub-id-type="doi">10.1021/acschembio.8b00173</pub-id>.<pub-id pub-id-type="pmid">29763292</pub-id>
</mixed-citation></ref><ref id="ref14"><mixed-citation publication-type="journal" id="cit14"><name><surname>Hutchinson</surname><given-names>C. R.</given-names></name>; <name><surname>Kennedy</surname><given-names>J.</given-names></name>; <name><surname>Park</surname><given-names>C.</given-names></name>; <name><surname>Kendrew</surname><given-names>S.</given-names></name>; <name><surname>Auclair</surname><given-names>K.</given-names></name>; <name><surname>Vederas</surname><given-names>J.</given-names></name>
<article-title>Aspects of the Biosynthesis
of Non-Aromatic Fungal
Polyketides by Iterative Polyketide Synthases</article-title>. <source>Antonie van Leeuwenhoek</source>
<year>2000</year>, <volume>78</volume> (<issue>3&#x02013;4</issue>), <fpage>287</fpage>&#x02013;<lpage>295</lpage>. <pub-id pub-id-type="doi">10.1023/A:1010294330190</pub-id>.<pub-id pub-id-type="pmid">11386351</pub-id>
</mixed-citation></ref><ref id="ref15"><mixed-citation publication-type="journal" id="cit15"><name><surname>Kachroo</surname><given-names>A. H.</given-names></name>; <name><surname>Laurent</surname><given-names>J. M.</given-names></name>; <name><surname>Yellman</surname><given-names>C. M.</given-names></name>; <name><surname>Meyer</surname><given-names>A. G.</given-names></name>; <name><surname>Wilke</surname><given-names>C. O.</given-names></name>; <name><surname>Marcotte</surname><given-names>E. M.</given-names></name>
<article-title>Systematic Humanization
of Yeast Genes Reveals Conserved
Functions and Genetic Modularity</article-title>. <source>Science</source>
<year>2015</year>, <volume>348</volume> (<issue>6237</issue>), <fpage>921</fpage>&#x02013;<lpage>925</lpage>. <pub-id pub-id-type="doi">10.1126/science.aaa0769</pub-id>.<pub-id pub-id-type="pmid">25999509</pub-id>
</mixed-citation></ref><ref id="ref16"><mixed-citation publication-type="journal" id="cit16"><name><surname>Bedoya-Cardona</surname><given-names>J. E.</given-names></name>; <name><surname>Rubio-Carrasquilla</surname><given-names>M.</given-names></name>; <name><surname>Ram&#x000ed;rez-Vel&#x000e1;squez</surname><given-names>I. M.</given-names></name>; <name><surname>Vald&#x000e9;s-Tresanco</surname><given-names>M. S.</given-names></name>; <name><surname>Moreno</surname><given-names>E.</given-names></name>
<article-title>Identifying Potential
Molecular Targets in Fungi Based on (Dis)Similarities in Binding Site
Architecture with Proteins of the Human Pharmacolome</article-title>. <source>Molecules</source>
<year>2023</year>, <volume>28</volume> (<issue>2</issue>), <elocation-id>692</elocation-id><pub-id pub-id-type="doi">10.3390/molecules28020692</pub-id>.<pub-id pub-id-type="pmid">36677748</pub-id>
</mixed-citation></ref><ref id="ref17"><mixed-citation publication-type="journal" id="cit17"><name><surname>Yan</surname><given-names>Y.</given-names></name>; <name><surname>Liu</surname><given-names>N.</given-names></name>; <name><surname>Tang</surname><given-names>Y.</given-names></name>
<article-title>Recent Developments in Self-Resistance
Gene Directed
Natural Product Discovery</article-title>. <source>Nat. Prod. Rep.</source>
<year>2020</year>, <volume>37</volume> (<issue>7</issue>), <fpage>879</fpage>&#x02013;<lpage>892</lpage>. <pub-id pub-id-type="doi">10.1039/C9NP00050J</pub-id>.<pub-id pub-id-type="pmid">31912842</pub-id>
</mixed-citation></ref><ref id="ref18"><mixed-citation publication-type="patent" id="cit18"><person-group person-group-type="allauthors"><name><surname>Hooda</surname><given-names>D. U.</given-names></name>; <name><surname>Haruyoshi</surname><given-names>S.</given-names></name>; <name><surname>Yuki</surname><given-names>T.</given-names></name>; <name><surname>Michael</surname><given-names>W. P.</given-names></name>; <name><surname>Nami</surname><given-names>Y.</given-names></name></person-group><article-title>Dibenzo-Oxazepine and -Dioxepine Derivatives
and Their Use as Anti-Tumor Agents</article-title>. WO Patent <patent>WO1997047611A1</patent>, <year>1997</year>.</mixed-citation></ref><ref id="ref19"><mixed-citation publication-type="journal" id="cit19"><name><surname>Chen</surname><given-names>L.</given-names></name>; <name><surname>Zhang</surname><given-names>W.</given-names></name>; <name><surname>Zheng</surname><given-names>Q.</given-names></name>; <name><surname>Liu</surname><given-names>Q.</given-names></name>; <name><surname>Zhong</surname><given-names>P.</given-names></name>; <name><surname>Hu</surname><given-names>X.</given-names></name>; <name><surname>Fang</surname><given-names>Z.</given-names></name>; <name><surname>Zhang</surname><given-names>Q.</given-names></name>
<article-title>Aculeatusquinones
A&#x02014;D, Novel
Metabolites from the Marine-Derived Fungus Aspergillus Aculeatus</article-title>. <source>Heterocycles</source>
<year>2013</year>, <volume>87</volume> (<issue>4</issue>), <fpage>861</fpage>&#x02013;<lpage>867</lpage>. <pub-id pub-id-type="doi">10.3987/COM-13-12667</pub-id>.</mixed-citation></ref><ref id="ref20"><mixed-citation publication-type="journal" id="cit20"><name><surname>Shang</surname><given-names>Z.</given-names></name>; <name><surname>Khalil</surname><given-names>Z.</given-names></name>; <name><surname>Li</surname><given-names>L.</given-names></name>; <name><surname>Salim</surname><given-names>A. A.</given-names></name>; <name><surname>Quezada</surname><given-names>M.</given-names></name>; <name><surname>Kalansuriya</surname><given-names>P.</given-names></name>; <name><surname>Capon</surname><given-names>R. J.</given-names></name>
<article-title>Roseopurpurins: Chemical Diversity
Enhanced by Convergent Biosynthesis and Forward and Reverse Michael
Additions</article-title>. <source>Org. Lett.</source>
<year>2016</year>, <volume>18</volume> (<issue>17</issue>), <fpage>4340</fpage>&#x02013;<lpage>4343</lpage>. <pub-id pub-id-type="doi">10.1021/acs.orglett.6b02099</pub-id>.<pub-id pub-id-type="pmid">27537356</pub-id>
</mixed-citation></ref><ref id="ref21"><mixed-citation publication-type="patent" id="cit21"><person-group person-group-type="allauthors"><name><surname>Verdine</surname><given-names>G. L.</given-names></name>; <name><surname>Cumming</surname><given-names>J. N.</given-names></name>; <name><surname>Saalau</surname><given-names>S. M.</given-names></name>; <name><surname>Castaldi</surname><given-names>P. M.</given-names></name>; <name><surname>Choi</surname><given-names>Y.</given-names></name></person-group><article-title>CDK Inhibitor
Compounds for Use in Methods of Treatment</article-title>. WO Patent <patent>WO2022187611A1</patent>, <year>2022</year>.</mixed-citation></ref><ref id="ref22"><mixed-citation publication-type="journal" id="cit22"><name><surname>Dunbar</surname><given-names>K.
L.</given-names></name>; <name><surname>Perlatti</surname><given-names>B.</given-names></name>; <name><surname>Liu</surname><given-names>N.</given-names></name>; <name><surname>Cornelius</surname><given-names>A.</given-names></name>; <name><surname>Mummau</surname><given-names>D.</given-names></name>; <name><surname>Chiang</surname><given-names>Y.-M.</given-names></name>; <name><surname>Hon</surname><given-names>L.</given-names></name>; <name><surname>Nimavat</surname><given-names>M.</given-names></name>; <name><surname>Pallas</surname><given-names>J.</given-names></name>; <name><surname>Kordes</surname><given-names>S.</given-names></name>; <name><surname>Ng</surname><given-names>H. L.</given-names></name>; <name><surname>Harvey</surname><given-names>C. J. B.</given-names></name>
<article-title>Resistance
Gene&#x02013;Guided Genome Mining Reveals the Roseopurpurins as Inhibitors
of Cyclin-Dependent Kinases</article-title>. <source>Proc. Natl. Acad.
Sci. U.S.A.</source>
<year>2023</year>, <volume>120</volume> (<issue>48</issue>), <elocation-id>e2310522120</elocation-id><pub-id pub-id-type="doi">10.1073/pnas.2310522120</pub-id>.<pub-id pub-id-type="pmid">37983497</pub-id>
</mixed-citation></ref><ref id="ref23"><mixed-citation publication-type="journal" id="cit23"><name><surname>Tadesse</surname><given-names>S.</given-names></name>; <name><surname>Anshabo</surname><given-names>A. T.</given-names></name>; <name><surname>Portman</surname><given-names>N.</given-names></name>; <name><surname>Lim</surname><given-names>E.</given-names></name>; <name><surname>Tilley</surname><given-names>W.</given-names></name>; <name><surname>Caldon</surname><given-names>C. E.</given-names></name>; <name><surname>Wang</surname><given-names>S.</given-names></name>
<article-title>Targeting CDK2 in Cancer: Challenges
and Opportunities for Therapy</article-title>. <source>Drug Discovery
Today</source>
<year>2020</year>, <volume>25</volume> (<issue>2</issue>), <fpage>406</fpage>&#x02013;<lpage>413</lpage>. <pub-id pub-id-type="doi">10.1016/j.drudis.2019.12.001</pub-id>.<pub-id pub-id-type="pmid">31839441</pub-id>
</mixed-citation></ref><ref id="ref24"><mixed-citation publication-type="journal" id="cit24"><name><surname>Zhang</surname><given-names>J.</given-names></name>; <name><surname>Yang</surname><given-names>P. L.</given-names></name>; <name><surname>Gray</surname><given-names>N. S.</given-names></name>
<article-title>Targeting Cancer
with Small Molecule
Kinase Inhibitors</article-title>. <source>Nat. Rev. Cancer</source>
<year>2009</year>, <volume>9</volume> (<issue>1</issue>), <fpage>28</fpage>&#x02013;<lpage>39</lpage>. <pub-id pub-id-type="doi">10.1038/nrc2559</pub-id>.<pub-id pub-id-type="pmid">19104514</pub-id>
</mixed-citation></ref><ref id="ref25"><mixed-citation publication-type="journal" id="cit25"><name><surname>Huang</surname><given-names>K.</given-names></name>; <name><surname>Ferrin-O&#x02019;Connell</surname><given-names>I.</given-names></name>; <name><surname>Zhang</surname><given-names>W.</given-names></name>; <name><surname>Leonard</surname><given-names>G. A.</given-names></name>; <name><surname>O&#x02019;Shea</surname><given-names>E. K.</given-names></name>; <name><surname>Quiocho</surname><given-names>F. A.</given-names></name>
<article-title>Structure of the Pho85-Pho80 CDK-Cyclin
Complex of the Phosphate-Responsive Signal Transduction Pathway</article-title>. <source>Mol. Cell</source>
<year>2007</year>, <volume>28</volume> (<issue>4</issue>), <fpage>614</fpage>&#x02013;<lpage>623</lpage>. <pub-id pub-id-type="doi">10.1016/j.molcel.2007.09.013</pub-id>.<pub-id pub-id-type="pmid">18042456</pub-id>
</mixed-citation></ref><ref id="ref26"><mixed-citation publication-type="journal" id="cit26"><name><surname>Visagie</surname><given-names>C. M.</given-names></name>; <name><surname>Seifert</surname><given-names>K. A.</given-names></name>; <name><surname>Houbraken</surname><given-names>J.</given-names></name>; <name><surname>Samson</surname><given-names>R. A.</given-names></name>; <name><surname>Jacobs</surname><given-names>K.</given-names></name>
<article-title>A Phylogenetic
Revision of Penicillium Sect. Exilicaulis, Including Nine New Species
from Fynbos in South Africa</article-title>. <source>IMA Fungus</source>
<year>2016</year>, <volume>7</volume> (<issue>1</issue>), <fpage>75</fpage>&#x02013;<lpage>117</lpage>. <pub-id pub-id-type="doi">10.5598/imafungus.2016.07.01.06</pub-id>.<pub-id pub-id-type="pmid">27433442</pub-id>
</mixed-citation></ref><ref id="ref27"><mixed-citation publication-type="journal" id="cit27"><name><surname>Zhao</surname><given-names>X.</given-names></name>; <name><surname>Chen</surname><given-names>Y.</given-names></name>; <name><surname>Long</surname><given-names>T.</given-names></name>; <name><surname>Liu</surname><given-names>Z.</given-names></name>; <name><surname>Zhang</surname><given-names>Q.</given-names></name>; <name><surname>Zhang</surname><given-names>H.</given-names></name>; <name><surname>Yan</surname><given-names>Y.</given-names></name>; <name><surname>Zhang</surname><given-names>C.</given-names></name>; <name><surname>Zhu</surname><given-names>Y.</given-names></name>
<article-title>Genome Mining
and Biosynthetic Reconstitution of Fungal Depsidone Mollicellins Reveal
a Dual Functional Cytochrome P450 for Ether Formation</article-title>. <source>J. Nat. Prod.</source>
<year>2023</year>, <volume>86</volume> (<issue>8</issue>), <fpage>2046</fpage>&#x02013;<lpage>2053</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jnatprod.3c00609</pub-id>.<pub-id pub-id-type="pmid">37566707</pub-id>
</mixed-citation></ref><ref id="ref28"><mixed-citation publication-type="journal" id="cit28"><name><surname>Armstrong</surname><given-names>R. N.</given-names></name>
<article-title>Mechanistic
Diversity in a Metalloenzyme Superfamily</article-title>. <source>Biochemistry</source>
<year>2000</year>, <volume>39</volume> (<issue>45</issue>), <fpage>13625</fpage>&#x02013;<lpage>13632</lpage>. <pub-id pub-id-type="doi">10.1021/bi001814v</pub-id>.<pub-id pub-id-type="pmid">11076500</pub-id>
</mixed-citation></ref><ref id="ref29"><mixed-citation publication-type="journal" id="cit29"><name><surname>Endicott</surname><given-names>J.
A.</given-names></name>; <name><surname>Noble</surname><given-names>M. E. M.</given-names></name>; <name><surname>Johnson</surname><given-names>L. N.</given-names></name>
<article-title>The Structural Basis for Control
of Eukaryotic Protein Kinases</article-title>. <source>Annu. Rev. Biochem.</source>
<year>2012</year>, <volume>81</volume> (<issue>1</issue>), <fpage>587</fpage>&#x02013;<lpage>613</lpage>. <pub-id pub-id-type="doi">10.1146/annurev-biochem-052410-090317</pub-id>.<pub-id pub-id-type="pmid">22482904</pub-id>
</mixed-citation></ref><ref id="ref30"><mixed-citation publication-type="journal" id="cit30"><name><surname>Copeland</surname><given-names>R. A.</given-names></name>; <name><surname>Luo</surname><given-names>L.</given-names></name>; <name><surname>Auger</surname><given-names>K. R.</given-names></name>; <name><surname>Huang</surname><given-names>P. S.</given-names></name>
<article-title>A Method for Determining Intracellular
Concentrations of Enzyme Substrates from a Combination of Competitive
Inhibition and Mutagenesis Studies</article-title>. <source>Anal. Biochem.</source>
<year>2005</year>, <volume>337</volume> (<issue>2</issue>), <fpage>351</fpage>&#x02013;<lpage>353</lpage>. <pub-id pub-id-type="doi">10.1016/j.ab.2004.10.010</pub-id>.<pub-id pub-id-type="pmid">15691518</pub-id>
</mixed-citation></ref><ref id="ref31"><mixed-citation publication-type="journal" id="cit31"><name><surname>Schwartz</surname><given-names>P. A.</given-names></name>; <name><surname>Kuzmic</surname><given-names>P.</given-names></name>; <name><surname>Solowiej</surname><given-names>J.</given-names></name>; <name><surname>Bergqvist</surname><given-names>S.</given-names></name>; <name><surname>Bolanos</surname><given-names>B.</given-names></name>; <name><surname>Almaden</surname><given-names>C.</given-names></name>; <name><surname>Nagata</surname><given-names>A.</given-names></name>; <name><surname>Ryan</surname><given-names>K.</given-names></name>; <name><surname>Feng</surname><given-names>J.</given-names></name>; <name><surname>Dalvie</surname><given-names>D.</given-names></name>; <name><surname>Kath</surname><given-names>J. C.</given-names></name>; <name><surname>Xu</surname><given-names>M.</given-names></name>; <name><surname>Wani</surname><given-names>R.</given-names></name>; <name><surname>Murray</surname><given-names>B. W.</given-names></name>
<article-title>Covalent EGFR Inhibitor Analysis
Reveals Importance of Reversible Interactions to Potency and Mechanisms
of Drug Resistance</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source>
<year>2014</year>, <volume>111</volume> (<issue>1</issue>), <fpage>173</fpage>&#x02013;<lpage>178</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1313733111</pub-id>.<pub-id pub-id-type="pmid">24347635</pub-id>
</mixed-citation></ref><ref id="ref32"><mixed-citation publication-type="journal" id="cit32"><name><surname>Tsherniak</surname><given-names>A.</given-names></name>; <name><surname>Vazquez</surname><given-names>F.</given-names></name>; <name><surname>Montgomery</surname><given-names>P. G.</given-names></name>; <name><surname>Weir</surname><given-names>B. A.</given-names></name>; <name><surname>Kryukov</surname><given-names>G.</given-names></name>; <name><surname>Cowley</surname><given-names>G. S.</given-names></name>; <name><surname>Gill</surname><given-names>S.</given-names></name>; <name><surname>Harrington</surname><given-names>W. F.</given-names></name>; <name><surname>Pantel</surname><given-names>S.</given-names></name>; <name><surname>Krill-Burger</surname><given-names>J. M.</given-names></name>; <name><surname>Meyers</surname><given-names>R. M.</given-names></name>; <name><surname>Ali</surname><given-names>L.</given-names></name>; <name><surname>Goodale</surname><given-names>A.</given-names></name>; <name><surname>Lee</surname><given-names>Y.</given-names></name>; <name><surname>Jiang</surname><given-names>G.</given-names></name>; <name><surname>Hsiao</surname><given-names>J.</given-names></name>; <name><surname>Gerath</surname><given-names>W. F. J.</given-names></name>; <name><surname>Howell</surname><given-names>S.</given-names></name>; <name><surname>Merkel</surname><given-names>E.</given-names></name>; <name><surname>Ghandi</surname><given-names>M.</given-names></name>; <name><surname>Garraway</surname><given-names>L. A.</given-names></name>; <name><surname>Root</surname><given-names>D. E.</given-names></name>; <name><surname>Golub</surname><given-names>T. R.</given-names></name>; <name><surname>Boehm</surname><given-names>J. S.</given-names></name>; <name><surname>Hahn</surname><given-names>W. C.</given-names></name>
<article-title>Defining a Cancer Dependency Map</article-title>. <source>Cell</source>
<year>2017</year>, <volume>170</volume> (<issue>3</issue>), <fpage>564</fpage>&#x02013;<lpage>576.e16</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2017.06.010</pub-id>.<pub-id pub-id-type="pmid">28753430</pub-id>
</mixed-citation></ref><ref id="ref33"><mixed-citation publication-type="journal" id="cit33"><name><surname>Zarkowska</surname><given-names>T.</given-names></name>; <name><surname>Mittnacht</surname><given-names>S.</given-names></name>
<article-title>Differential Phosphorylation of the Retinoblastoma
Protein by G1/S Cyclin-Dependent Kinases*</article-title>. <source>J.
Biol. Chem.</source>
<year>1997</year>, <volume>272</volume> (<issue>19</issue>), <fpage>12738</fpage>&#x02013;<lpage>12746</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.272.19.12738</pub-id>.<pub-id pub-id-type="pmid">9139732</pub-id>
</mixed-citation></ref><ref id="ref34"><mixed-citation publication-type="journal" id="cit34"><name><surname>Scheeff</surname><given-names>E. D.</given-names></name>; <name><surname>Bourne</surname><given-names>P. E.</given-names></name>
<article-title>Structural Evolution of the Protein
Kinase&#x02013;Like
Superfamily</article-title>. <source>PLoS Comput. Biol.</source>
<year>2005</year>, <volume>1</volume> (<issue>5</issue>), <elocation-id>e49</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pcbi.0010049</pub-id>.<pub-id pub-id-type="pmid">16244704</pub-id>
</mixed-citation></ref><ref id="ref35"><mixed-citation publication-type="journal" id="cit35"><name><surname>M&#x000e9;dard</surname><given-names>G.</given-names></name>; <name><surname>Pachl</surname><given-names>F.</given-names></name>; <name><surname>Ruprecht</surname><given-names>B.</given-names></name>; <name><surname>Klaeger</surname><given-names>S.</given-names></name>; <name><surname>Heinzlmeir</surname><given-names>S.</given-names></name>; <name><surname>Helm</surname><given-names>D.</given-names></name>; <name><surname>Qiao</surname><given-names>H.</given-names></name>; <name><surname>Ku</surname><given-names>X.</given-names></name>; <name><surname>Wilhelm</surname><given-names>M.</given-names></name>; <name><surname>Kuehne</surname><given-names>T.</given-names></name>; <name><surname>Wu</surname><given-names>Z.</given-names></name>; <name><surname>Dittmann</surname><given-names>A.</given-names></name>; <name><surname>Hopf</surname><given-names>C.</given-names></name>; <name><surname>Kramer</surname><given-names>K.</given-names></name>; <name><surname>Kuster</surname><given-names>B.</given-names></name>
<article-title>Optimized Chemical
Proteomics Assay
for Kinase Inhibitor Profiling</article-title>. <source>J. Proteome
Res.</source>
<year>2015</year>, <volume>14</volume> (<issue>3</issue>), <fpage>1574</fpage>&#x02013;<lpage>1586</lpage>. <pub-id pub-id-type="doi">10.1021/pr5012608</pub-id>.<pub-id pub-id-type="pmid">25660469</pub-id>
</mixed-citation></ref><ref id="ref36"><mixed-citation publication-type="journal" id="cit36"><name><surname>Malumbres</surname><given-names>M.</given-names></name>; <name><surname>Barbacid</surname><given-names>M.</given-names></name>
<article-title>Cell cycle, CDKs and cancer: a changing paradigm</article-title>. <source>Nat. Rev. Cancer</source>
<year>2009</year>, <volume>9</volume> (<issue>3</issue>), <fpage>153</fpage>&#x02013;<lpage>166</lpage>. <pub-id pub-id-type="doi">10.1038/nrc2602</pub-id>.<pub-id pub-id-type="pmid">19238148</pub-id>
</mixed-citation></ref><ref id="ref37"><mixed-citation publication-type="journal" id="cit37"><name><surname>Jiang</surname><given-names>S.</given-names></name>; <name><surname>Zhang</surname><given-names>M.</given-names></name>; <name><surname>Sun</surname><given-names>J.</given-names></name>; <name><surname>Yang</surname><given-names>X.</given-names></name>
<article-title>Casein kinase 1&#x003b1;:
biological mechanisms and theranostic potential</article-title>. <source>Cell Commun. Signaling</source>
<year>2018</year>, <volume>16</volume>, <elocation-id>23</elocation-id><pub-id pub-id-type="doi">10.1186/s12964-018-0236-z</pub-id>.</mixed-citation></ref><ref id="ref38"><mixed-citation publication-type="journal" id="cit38"><name><surname>Majumdar</surname><given-names>A.</given-names></name>; <name><surname>Burban</surname><given-names>D. J.</given-names></name>; <name><surname>Muretta</surname><given-names>J. M.</given-names></name>; <name><surname>Thompson</surname><given-names>A. R.</given-names></name>; <name><surname>Engel</surname><given-names>T. A.</given-names></name>; <name><surname>Rasmussen</surname><given-names>D. M.</given-names></name>; <name><surname>Subrahmanian</surname><given-names>M. V.</given-names></name>; <name><surname>Veglia</surname><given-names>G.</given-names></name>; <name><surname>Thomas</surname><given-names>D. D.</given-names></name>; <name><surname>Levinson</surname><given-names>N. M.</given-names></name>
<article-title>Allostery governs
Cdk2 activation and differential
recognition of CDK inhibitors</article-title>. <source>Nat. Chem. Biol.</source>
<year>2021</year>, <volume>17</volume>, <fpage>456</fpage>&#x02013;<lpage>464</lpage>. <pub-id pub-id-type="doi">10.1038/s41589-020-00725-y</pub-id>.<pub-id pub-id-type="pmid">33526892</pub-id>
</mixed-citation></ref><ref id="ref39"><mixed-citation publication-type="journal" id="cit39"><name><surname>Leeson</surname><given-names>P. D.</given-names></name>; <name><surname>Davis</surname><given-names>A. M.</given-names></name>
<article-title>Time-Related Differences
in the Physical Property Profiles
of Oral Drugs</article-title>. <source>J. Med. Chem.</source>
<year>2004</year>, <volume>47</volume> (<issue>25</issue>), <fpage>6338</fpage>&#x02013;<lpage>6348</lpage>. <pub-id pub-id-type="doi">10.1021/jm049717d</pub-id>.<pub-id pub-id-type="pmid">15566303</pub-id>
</mixed-citation></ref><ref id="ref40"><mixed-citation publication-type="journal" id="cit40"><name><surname>Lin</surname><given-names>N. U.</given-names></name>; <name><surname>Amiri-Kordestani</surname><given-names>L.</given-names></name>; <name><surname>Palmieri</surname><given-names>D.</given-names></name>; <name><surname>Liewehr</surname><given-names>D. J.</given-names></name>; <name><surname>Steeg</surname><given-names>P. S.</given-names></name>
<article-title>CNS Metastases
in Breast Cancer: Old Challenge, New Frontiers</article-title>. <source>Clin. Cancer Res.</source>
<year>2013</year>, <volume>19</volume> (<issue>23</issue>), <fpage>6404</fpage>&#x02013;<lpage>6418</lpage>. <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-13-0790</pub-id>.<pub-id pub-id-type="pmid">24298071</pub-id>
</mixed-citation></ref><ref id="ref41"><mixed-citation publication-type="journal" id="cit41"><name><surname>Cohen</surname><given-names>P.</given-names></name>; <name><surname>Cross</surname><given-names>D.</given-names></name>; <name><surname>J&#x000e4;nne</surname><given-names>P. A.</given-names></name>
<article-title>Kinase
Drug Discovery 20 Years after
Imatinib: Progress and Future Directions</article-title>. <source>Nat.
Rev. Drug Discovery</source>
<year>2021</year>, <volume>20</volume>, <fpage>551</fpage>&#x02013;<lpage>569</lpage>. <pub-id pub-id-type="doi">10.1038/s41573-021-00195-4</pub-id>.<pub-id pub-id-type="pmid">34002056</pub-id>
</mixed-citation></ref><ref id="ref42"><mixed-citation publication-type="journal" id="cit42"><name><surname>Shults</surname><given-names>M. D.</given-names></name>; <name><surname>Imperiali</surname><given-names>B.</given-names></name>
<article-title>Versatile
Fluorescence Probes of Protein Kinase Activity</article-title>. <source>J. Am. Chem. Soc.</source>
<year>2003</year>, <volume>125</volume> (<issue>47</issue>), <fpage>14248</fpage>&#x02013;<lpage>14249</lpage>. <pub-id pub-id-type="doi">10.1021/ja0380502</pub-id>.<pub-id pub-id-type="pmid">14624552</pub-id>
</mixed-citation></ref></ref-list></back></article>